Adenosine receptor antagonist compounds

JP2023505915A5Active Publication Date: 2024-12-04IL DONG PHARMACEUTICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2022554968
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-11-19
Filing Date
2020-11-19
Publication Date
2024-12-04
Estimated Expiration
2040-11-19

AI Technical Summary

Technical Problem

Current treatments for diseases such as cancer and neurodegenerative disorders, particularly Parkinson's disease, are limited by the immunosuppressive effects of adenosine, which inhibits T cell function and immune response, and immune checkpoint inhibitors only show efficacy in a fraction of patients.

Method used

Development of adenosine receptor antagonist compounds, specifically targeting A2A and/or A1 receptors, to modulate immune response and enhance anti-tumor immunity, combined with immune checkpoint inhibitors for cancer therapy, and treat neurodegenerative diseases like Parkinson's disease.

Benefits of technology

The compounds enhance anti-tumor immunity and improve treatment outcomes for cancers and neurodegenerative diseases by overcoming immunosuppression, potentially increasing the effectiveness of immune checkpoint inhibitors and providing therapeutic benefits.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2021099838000001
    Figure 2021099838000001
  • Figure 2021099838000002
    Figure 2021099838000002
  • Figure 2021099838000003
    Figure 2021099838000003
Patent Text Reader

Abstract

The present disclosure provides adenosine receptor (e.g., A2A and / or A1 receptor) antagonist compounds and compositions comprising the compounds. The present disclosure also provides methods of using the compounds and compositions to modulate (e.g., inhibit or antagonize) A2A and / or A1 receptors in biological systems. The compounds and compositions are used in a variety of therapeutic applications, including the treatment of cancer and immuno-oncology. The compounds and compositions are used in a variety of therapeutic applications, including the treatment of central nervous system or neurodegenerative disorders such as Parkinson's disease.
Need to check novelty before this filing date? Find Prior Art

Description

Technical field

[0001] Cross-references to related applications This application claims the priority benefit of Korean Application No. 10-2019-0149117 filed on November 19, 2019. This application is incorporated herein by reference in its entirety. [Background technology]

[0002] prologue Adenosine performs many biological functions through specific cell receptors and has been implicated in a variety of biological activities, including immune function and inflammation.

[0003] There are four types of adenosine receptors (A1, A2A, A2B, A3), which bind heteromeric G proteins. Each A2A and A2B receptor is connected to the Gs subtype of the Gα protein. When these receptors are stimulated, their format changes, and such changes induce shedding of Gs subunits activated by Gβρ dimers, leading to intracellular adenosine triphosphate ( ATP) is hydrolyzed to produce cyclic adenosine monophosphate (cAMP). cAMP synthesis activates phosphorylation of protein kinase A (PKA) and other proteins. In T cells, predominantly type I PKA isoforms are present around the T cell receptor (TCR), and increased activation of PKA by elevated cAMP levels inhibits the TCR signaling process, leading to a variety of diseases. contribute to development.

[0004] Cancer cells produce significantly more adenosine than normal cells. In cancer cells, high density adenosine induces A2A receptor activation, thereby inhibiting the immune system and protecting the cells. In the tumor microenvironment, the concentration of adenosine is 50 μM, increased over normal cells, and may lead to immunosuppression of T cell function and activation. A2A receptor antagonists can be used to modulate the inhibition of the immune system by cancer cells and induce anticancer effects.

[0005] A2A receptor antagonists are under development for immuno-oncology therapy. A2A receptor antagonists can enhance anti-tumor immunity. A2A receptors are widely produced on leukocytes. Activation of A2A receptors on T cells reduces TCR-mediated cytotoxicity and cytokine production, suppresses T cell proliferation, and induces Treg cell proliferation. In immuno-oncology, PD-1 or PD-L1 immune checkpoint inhibitors (eg, antibody inhibitors) are widely used. However, statistically only 20% to 30% of patients produce PD-1 / PD-L1, so there are many patients who do not benefit from the effectiveness of such inhibitors. Treatments involving immune checkpoint inhibitors in combination with A2A receptor antagonists are of interest.

[0006] Regulation of adenosine receptors is important for the treatment of various indications. Modulatory activity of adenosine A1 receptors is important in the treatment of nervous system disorders, asthma, heart failure, renal failure, etc.; antagonizing adenosine A2A receptors is important in the treatment of Parkinson's disease, etc.; adenosine A2B receptors Modulating body activity is important in the treatment of chronic lung disorders such as asthma, cancer, immuno-oncology, etc.; It is important in the treatment of cancer, brain apoplexy, and the like. [Outline of the Invention]

[0007] overview The present disclosure provides adenosine receptor (eg, A2A and / or A1 receptor) antagonist compounds and compositions comprising said compounds. The disclosure also provides methods of using the compounds and compositions to modulate (eg, inhibit or antagonize) A2A and / or A1 receptors in biological systems. The compounds and compositions are used in a variety of therapeutics, including cancer treatment, and immuno-oncology applications. The compounds and compositions are used in a variety of therapeutic applications, including treatment of central nervous system or neurodegenerative diseases such as Parkinson's disease.

[0008] In a first aspect, the present disclosure provides A2A and / or A1 antagonist compounds of formula (I), or solvates, hydrates, prodrugs and / or stereoisomers thereof, or pharmaceutical compounds thereof. Provides acceptable salts for: TIFF2023505915000001.tif2849(I) where Z 1 and Z 2 are independently selected from CR and N and Z 1 and Z 2 at least one of is N; R is H, (C 1 -C 3 ) alkyl, or substituted (C 1 -C 3 ) is an alkyl; Y 1 or Y 4 independently CR 10 and N, and at least two of Y1 through Y4 independently CR 10 is; R. 10 are independently H, (C 1 -C 8 ) alkyl, substituted (C 1 -C 8 ) alkyl, (C 2 -C 8 ) alkenyl, substituted (C 2 -C 8 ) alkenyl, (C 2 -C 8 )alkynyl, substituted (C 2 -C 8 ) alkynyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 8 )alkoxy, substituted (C 1 -C 8 )alkoxy, -CONH 2 , substituted amides, -NH 2 , substituted amino, -CO 2 H, cyano, halogen, hydroxyl, -NO 2 , -SO 3 H, -SO 2 NH 2 , substituted sulfonamides, and thiols; R. a and R b are independently H, F, (C 1 -C 3 ) alkyl, and substituted (C 1 -C 3 ) alkyl, or R a and R b are attached cyclically and together with the carbon atom to which they are attached form cyclopropyl, or substituted cyclopropyl; A is phenyl, substituted phenyl, pyridyl, or substituted pyridyl.

[0009] In a second aspect, the present disclosure provides compounds described herein, or pharmaceutically acceptable salts thereof (e.g., compounds of Formulas (I)-(XVIb)), and pharmaceutically acceptable excipients. A pharmaceutical composition is provided that includes a formulation.

[0010] In a third aspect, the present disclosure provides that a sample or cell or biological system is treated with an effective amount of a compound described herein (e.g., a compound of Formulas (I)-(XVIb) or a pharmaceutically acceptable compound thereof). A method of modulating (eg, inhibiting or antagonizing) adenosine A2A and / or A1 receptors is provided, comprising contacting with a salt).

[0011] Also provided are methods of treating cancer comprising administering to a subject with cancer a therapeutically effective amount of an A2A and / or A1 receptor antagonist compound (eg, as described herein). In some embodiments, the method further comprises co-administering to the subject an additional active agent, such as an immune checkpoint inhibitor. A therapeutically effective amount of an A2A and / or A1 receptor antagonist compound (e.g., of formulas (I)-(XVIb), as described herein, in a subject with or at risk of central nervous system or neurodegenerative disease) Also provided are methods of treating a central nervous system or neurodegenerative disease comprising administering the compound, or a pharmaceutically acceptable salt thereof.

[0012] detailed description Adenosine receptor antagonist compounds As summarized above, the present disclosure provides A2A and / or A1 receptor antagonist compounds and compositions. These compounds are capable of modulating adenosine A2A and / or A1 receptors in cells and biological systems of interest. These compounds are used in a variety of therapeutic applications, including the treatment of cancer, immuno-oncology, and the treatment of central nervous system and neurodegenerative diseases such as Parkinson's disease.

[0013] The compounds of the present disclosure can be described as cyano-substituted fused pyrimidine compounds that contain a core structure with a 2-amino-pyrimidine ring fused to a five-membered heterocyclic ring. The core structure itself can be further substituted with benzonitrile substituents (eg, 3-cyano-phenyl) or derivatives thereof (eg, cyano-pyridyl substituents). The fused 5-membered heterocycle can be further substituted with an optionally substituted benzyl group. Optionally, the compounds have a 9H-purin-2-amine or 1H-pyrazolo[3,4-d]pyrimidin-6-amine core structure that is further substituted as described herein.

[0014] In some embodiments, the compound is, for example, a benzonitrile-substituted fused pyrimidine compound of the formula: TIFF2023505915000002.tif2841 or a derivative thereof (eg, a derivative compound in which the 3-benzonitrile group is substituted with a cyano-pyridyl group). Here, Cy is a fused 5-membered heterocyclic ring (eg, heteroaryl or heterocycloalkyl ring) containing at least one heteroatom selected from nitrogen, oxygen and sulfur. R is an optionally substituted phenyl group. R. 10 is one or more optional substituents. In some embodiments, R is halogen, hydroxyl group, thiol group, carbonyl group, amido group, nitro group, amino group, substituted or unsubstituted (C 1 -C 5 ) alkyl group, substituted or unsubstituted (C 2 -C 5 ) alkenyl groups, substituted or unsubstituted (C 2 -C 5 ) alkynyl groups, substituted or unsubstituted (C 1 -C 3 ) haloalkyl groups, and substituted or unsubstituted (C 1 -C 3 ) aminoalkyl group or substituted or unsubstituted (C 1 -C 5 ) R each independently selected from an alkoxy group 11 , R 12 , and / or R 13 is phenyl substituted by a group, and R 10 is hydrogen, halogen, hydroxyl group, thiol group, substituted or unsubstituted (C 1 -C 5 ) alkyl group, substituted or unsubstituted (C 2 -C 5 ) alkenyl groups, substituted or unsubstituted (C 2 -C 5 ) alkynyl groups, substituted or unsubstituted (C 1 -C 3 ) haloalkyl groups, substituted or unsubstituted (C 1 -C 5 ) alkoxy groups, or one or more groups independently selected from cyano groups.

[0015] In some embodiments, the aforementioned R 11 and R 13 are each independently hydrogen, halogen, (C 1 -C 5 ) alkyl group, or (C 1 -C 3 ) is a haloalkyl group and R 12 is a hydrogen or amino group and each R 10 are independently hydrogen, halogen, (C 1 -C 5 ) an alkyl group or a cyano group. Further embodiments of the above formula are described herein.

[0016] Embodiments of the present disclosure include A2A and / or A1 antagonist compounds of formula (I), or solvates, hydrates, prodrugs, and / or stereoisomers thereof, or pharmaceutically acceptable compounds thereof. contains salts that: TIFF2023505915000003.tif2849(I) here, Z. 1 and Z 2 are independently selected from CR and N and Z 1 and Z 2 at least one of is N; R is H, (C 1 -C 3 ) alkyl, or substituted (C 1 -C 3 ) is an alkyl; Y 1 or Y 4 independently CR 10 and N, and Y 1 or Y 4 at least two independently CR 10 is; R. 10 are independently H, (C 1 -C 8 ) alkyl, substituted (C 1 -C 8 ) alkyl, (C 2 -C 8 ) alkenyl, substituted (C 2 -C 8 ) alkenyl, (C 2 -C 8 )alkynyl, substituted (C 2 -C 8 ) alkynyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 8 )alkoxy, substituted (C 1 -C 8 )alkoxy, -CONH 2 , substituted amides, -NH 2 , substituted amino, -CO 2 H, cyano, halogen, hydroxyl, -NO 2 , -SO 3 H, -SO 2 NH 2 , substituted sulfonamides, and thiols; R. a and R b are independently H, F, (C 1 -C 3 ) alkyl, and substituted (C 1 -C 3 ) alkyl, or R a and R b are attached cyclically and together with the carbon atom to which they are attached form cyclopropyl, or substituted cyclopropyl; A is phenyl, substituted phenyl, pyridyl, or substituted pyridyl.

[0017] In some embodiments of Formula (I), Y 1 or Y 4 is CR 10 and N, where Y 1 or Y 4 at least 3 of which independently CR 10 is.

[0018] In some embodiments of Formula (I), the compound is a compound of Formula (Ia), or a solvate, hydrate, prodrug, and / or stereoisomer thereof, or a pharmaceutically acceptable Z 1 is CR and Z 2 is N. TIFF2023505915000004.tif3351(Ia)

[0019] In some embodiments of Formula (Ia), R is (C 1 -C 3 ) alkyl. In some embodiments of Formula (Ia), R is H.

[0020] In some embodiments of Formula (I), the compound is a compound of Formula (Ib), or a solvate, hydrate, prodrug, and / or stereoisomer thereof, or a pharmaceutically acceptable Z 1 is CR and Z2 is N. TIFF2023505915000005.tif3354(Ib)

[0021] In some embodiments of Formula (Ib), R is (C 1 -C 3 ) alkyl. In some embodiments of Formula (Ib), R is H.

[0022] In some embodiments of Formulas (I)-(Ib), A is phenyl. In some embodiments of Formulas (I)-(Ib), A is substituted phenyl. In some embodiments of Formulas (I)-(Ib), A is phenyl, or 1, 2, or 3 R 20 is phenyl substituted with a group and each R 20 is (C 1 -C 8 ) alkyl, substituted (C 1 -C 8 ) alkyl, (C 2 -C 8 ) alkenyl, substituted (C 2 -C 8 ) alkenyl, (C 2 -C 8 )alkynyl, substituted (C 2 -C 8 ) alkynyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 8 )alkoxy, substituted (C 1 -C 8 )alkoxy, -CONH2 , substituted amides, -NH 2 , substituted amino, -CO 2 H, cyano, halogen, hydroxyl, -NO 2 , -SO 3 H, -SO 2 NH 2 , substituted sulfonamides, and thiols.

[0023] In some embodiments of Formulas (I)-(Ib), A is pyridyl. In some embodiments of Formulas (I)-(Ib), A is substituted pyridyl. A can be an optionally substituted pyridyl that is 2-pyridyl, 3-pyridyl or 4-pyridyl. In some embodiments of Formulas (I)-(Ib), A is pyridyl, or 1, 2, or 3 R 20 is pyridyl substituted with a group and each R 20 is (C 1 -C 8 ) alkyl, substituted (C 1 -C 8 ) alkyl, (C 2 -C 8 ) alkenyl, substituted (C 2 -C 8 ) alkenyl, (C 2 -C 8 )alkynyl, substituted (C 2 -C 8 ) alkynyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 8 )alkoxy, substituted (C 1 -C 8 )alkoxy, -CONH 2 , substituted amides, -NH 2 , substituted amino, -CO 2 H, cyano, halogen, hydroxyl, -NO 2 , -SO 3 H, -SO 2 NH 2 , substituted sulfonamides, and thiols.

[0024] In some embodiments of Formulas (I)-(Ib), R a and R b are H respectively.

[0025] In some embodiments of Formulas (Ia)-(Ib), Y 1 or Y 4 is CR 10 and N, where Y 1 or Y 4 at least 3 of which independently CR 10 is.

[0026] In some embodiments of Formulas (Ia)-(Ib), the compound is of Formula (IIa) or (IIb), or solvates, hydrates, prodrugs, and / or stereoisomers thereof, or Included are pharmaceutically acceptable salts thereof: TIFF2023505915000006.tif42170 where R 1 or R 9 are independently H, (C 1 -C 8 ) alkyl, substituted (C 1 -C 8 ) alkyl, (C 2 -C 8 ) alkenyl, substituted (C 2 -C 8 ) alkenyl, (C 2 -C 8 )alkynyl, substituted (C 2 -C 8 ) alkynyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 8 )alkoxy, substituted (C 1 -C 8 )alkoxy, -CONH 2 , substituted amides, -NH 2 , substituted amino, -CO 2 H, cyano, halogen, hydroxyl, -NO 2 , -SO 3 H, -SO 2 NH 2 , substituted sulfonamides, and thiols.

[0027] In some embodiments of Formulas (IIa)-(IIb), R. 1 or R 9 are independently H, (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 5 )alkoxy, substituted (C 1 -C 5 )alkoxy, -NH 2 , substituted amino, halogen, and hydroxyl. In some embodiments of Formulas (IIa)-(IIb), R 1 or R 9 are independently H, NH 2 , F, CH 3 , and CF 3 is selected from

[0028] In some embodiments of Formulas (IIa)-(IIb), the compound is of Formula (IIIa) or (IIIb), or a solvate, hydrate, prodrug, and / or stereoisomer thereof; or pharmaceutically acceptable salts thereof including: TIFF2023505915000007.tif46170 where R 21 and R 22 are independently H, (C 1 -C 8 ) alkyl, substituted (C 1 -C 8 ) alkyl, SO 2 R. 30 , and COR 30 is selected from R 30 is (C 1 -C 8 ) alkyl, or substituted (C 1 -C 8 ) alkyl.

[0029] In some embodiments of Formulas (IIIa)-(IIIb), R 21 and R 22 are H respectively.

[0030] In some embodiments of Formulas (IIIa)-(IIIb), R 5 , R 6 , R 8 and R 9 , H, (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 5 )alkoxy, substituted (C 1 -C 5 ) independently selected from alkoxy, halogen, and hydroxyl; In some embodiments of Formulas (IIIa)-(IIIb), R 5 , R 6 , R 8 and R 9 is H, F, CH 3 , and CF 3 is independently selected from In some embodiments of Formulas (IIIa)-(IIIb), R 5 , R 6 , R 8 and R 9 are H respectively.

[0031] In some embodiments of Formulas (IIIa)-(IIIb), R 2 or R 4 are each H; R 1 is H, (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 5 )alkoxy, substituted (C 1 -C 5 ) alkoxy, halogen, and hydroxyl. In some embodiments of Formulas (IIIa)-(IIIb), R 1 is H, F, CH 3 , and CF 3 is selected from

[0032] In some embodiments of Formulas (IIIa)-(IIIb), the compounds are: or solvates, hydrates, prodrugs, and / or stereoisomers thereof, or pharmaceutical are selected from salts that are acceptable to TIFF2023505915000008.tif106170

[0033] In some embodiments of Formulas (IIIa)-(IIIb), the compound is of Formula (IVa) or (IVb), or solvates, hydrates, prodrugs, and / or stereoisomers thereof. body, or a pharmaceutically acceptable salt thereof. TIFF2023505915000009.tif41170

[0034] In some embodiments of Formulas (IVa)-(IVb), R 6 is (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 5 )alkoxy, substituted (C 1 -C 5 ) alkoxy, halogen, and hydroxyl. In some embodiments of Formulas (IVa)-(IVb), R 6 but (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, and (C 1 -C 3 ) haloalkyl. In some embodiments of Formulas (IVa)-(IVb), R 6 is CH 3 or CF 3 is.

[0035] In some embodiments of Formulas (IVa)-(IVb), R 2 or R 4 are each H; R 1 is H, (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 5 )alkoxy, substituted (C 1 -C 5 ) alkoxy, halogen, and hydroxyl. In some embodiments of Formulas (IVa)-(IVb), R 1 is H, F, CH 3 , and CF 3 is selected from

[0036] In some embodiments of Formulas (IVa)-(IVb), the compound is or a solvate, hydrate, prodrug, and / or stereoisomer thereof, or a pharmaceutically Selected from acceptable salts. TIFF2023505915000010.tif143170

[0037] In some embodiments of Formulas (IIIa)-(IIIb), the compound is of Formula (Va) or (Vb), or solvates, hydrates, prodrugs, and / or stereoisomers thereof. compounds, or pharmaceutically acceptable salts thereof. TIFF2023505915000011.tif41170

[0038] In some embodiments of Formulas (Va)-(Vb), R 5 and R 9 , H, (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 5 )alkoxy, substituted (C 1 -C 5 ) independently selected from alkoxy, halogen, and hydroxyl; In some embodiments of Formulas (Va)-(Vb), R 5 and R 9 is independently selected from H and halogen. In some embodiments of Formulas (Va)-(Vb), R 5 is F. In some embodiments of Formulas (Va)-(Vb), R 9 is F. In some embodiments of Formulas (Va)-(Vb), R 5 and R 9 are respectively F. In some embodiments of Formulas (Va)-(Vb), R 5 is H and R 9 is F.

[0039] In some embodiments of Formulas (Va)-(Vb), the compound is or a solvate, hydrate, prodrug, and / or stereoisomer thereof, or a pharmaceutically Selected from acceptable salts. TIFF2023505915000012.tif144170

[0040] In some embodiments of Formulas (IIa)-(IIb), the compound is of Formula (VIa) or (VIb), or a solvate, hydrate, prodrug, and / or stereoisomer thereof. , or pharmaceutically acceptable salts thereof. TIFF2023505915000013.tif41170

[0041] In some embodiments of Formulas (VIa)-(VIb), R 5 , R 6 and R 9 , H, (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 5 )alkoxy, substituted (C 1 -C 5 )alkoxy, -NH 2 , substituted amino, halogen, and hydroxyl. In some embodiments of Formulas (VIa)-(VIb), R 6 is H, (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, and (C 1 -C 3 ) haloalkyl. In some embodiments of Formulas (VIa)-(VIb), R 6 is CH 3 or CF 3 is. In some embodiments of Formulas (VIa)-(VIb), R 6 is H.

[0042] In some embodiments of Formulas (VIa)-(VIb), R 5 and R 9 is independently selected from H and halogen. In some embodiments of Formulas (VIa)-(VIb), R 5 is F. In some embodiments of Formulas (VIa)-(VIb), R 9 is F. In some embodiments of Formulas (VIa)-(VIb), R 5 and R 9 are respectively F. In some embodiments of Formulas (VIa)-(VIb), R 5 is H and R 9 is F.

[0043] In some embodiments of Formulas (VIa)-(VIb), the compound is or a solvate, hydrate, prodrug, and / or stereoisomer thereof, or a pharmaceutically Selected from acceptable salts. TIFF2023505915000014.tif94170

[0044] In some embodiments of Formulas (IIa)-(VIb), R 1 or R 4 , H, (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 5 )alkoxy, substituted (C 1 -C 5 )alkoxy, -NH 2 , substituted amino, halogen, and hydroxyl. In some embodiments of Formulas (IIa)-(VIb), R 1 or R 4 , H, (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) independently selected from haloalkyl and halogen.

[0045] In some embodiments of Formulas (IIa)-(VIb), R 1 is H. In some embodiments of Formulas (IIa)-(VIb), R 1 is (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) selected from haloalkyl and halogen. In some embodiments of Formulas (IIa)-(VIb), R 1 is F, CH 3 or CF 3 is. In some embodiments of Formulas (IIa)-(VIb), R 2 , R 3 or R 4 is (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C1 -C 3 ) selected from haloalkyl and halogen. In some embodiments of Formulas (IIa)-(VIb), R 2 , R 3 and R 4 are H respectively.

[0046] In some embodiments of Formulas (Ia)-(Ib), the compound is of Formula (VIIa) or (VIIb), or a solvate, hydrate, prodrug, and / or stereoisomer thereof; or a pharmaceutically acceptable salt thereof. TIFF2023505915000015.tif42170 where Y 1 or Y 4 is CR 10 and N, and Y 1 or Y 4 at least three independently CR 10 is; R. 5 or R 9 and each R 10 is H, (C 1 -C 8 ) alkyl, substituted (C 1 -C 8 ) alkyl, (C 2 -C 8 ) alkenyl, substituted (C 2 -C 8 ) alkenyl, (C 2 -C 8 )alkynyl, substituted (C 2 -C 8 ) alkynyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 8 )alkoxy, substituted (C 1 -C 8 )alkoxy, -CONH 2 , substituted amides, -NH 2 , substituted amino, -CO 2 H, cyano, halogen, hydroxyl, -NO 2 , -SO 3 H, -SO 2 NH 2 , substituted sulfonamides, and thiols.

[0047] In some embodiments of Formulas (VIIa)-(VIIb), Y 1 or Y 4 one of which is N.

[0048] In some embodiments of Formulas (VIIa)-(VIIb), R 5 or R 9 and each R 10 , H, (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 5 )alkoxy, substituted (C 1 -C 5 )alkoxy, -NH 2 , substituted amino, halogen, and hydroxyl. In some embodiments of Formulas (VIIa)-(VIIb), R 5 or R 9 and each R 10 is H, NH 2 , F, CH 3 , and CF 3 is independently selected from

[0049] In some embodiments of Formulas (VIIa)-(VIIb), the compound is of Formula (VIIIa) or (VIIIb), or a solvate, hydrate, prodrug, and / or stereoisomer thereof , or a pharmaceutically acceptable salt thereof. TIFF2023505915000016.tif46170 where Y 1 or Y 4 one of is N; R. 21 and R 22 is H, (C 1 -C 8 ) alkyl, substituted (C 1 -C 8 ) alkyl, SO 2 R. 30 , and COR 30 is independently selected from and R 30 is (C 1 -C 8 ) alkyl, or substituted (C 1 -C 8 ) alkyl.

[0050] In some embodiments of Formulas (VIIIa)-(VIIIb), R 21 and R 22 are H respectively.

[0051] In some embodiments of Formulas (VIIIa)-(VIIIb), R 5 , R 6 , R 8 and R 9 , H, (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 5 )alkoxy, substituted (C 1 -C 5 ) independently selected from alkoxy, halogen, and hydroxyl; In some embodiments of Formulas (VIIIa)-(VIIIb), R 5 , R 6 , R 8 and R 9 is H, F, CH 3 , and CF 3 is independently selected from In some embodiments of Formulas (VIIIa)-(VIIIb), R 5 , R 6 , R 8 and R 9 are H respectively.

[0052] In some embodiments of Formulas (VIIIa)-(VIIIb), the compound is or a solvate, hydrate, prodrug, and / or stereoisomer thereof, or a pharmaceutically Selected from acceptable salts. TIFF2023505915000017.tif143170

[0053] In some embodiments of Formulas (VIIIa)-(VIIIb), the compound is of Formula (IXa) or (IXb), or a solvate, hydrate, prodrug, and / or stereoisomer thereof , or a pharmaceutically acceptable salt thereof. TIFF2023505915000018.tif41170

[0054] In some embodiments of Formulas (IXa)-(IXb), R 6 is (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 5 )alkoxy, substituted (C 1 -C 5 ) alkoxy, halogen, and hydroxyl. In some embodiments of Formulas (IXa)-(IXb), R 6 but (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, and (C 1 -C 3 ) haloalkyl. In some embodiments of Formulas (IXa)-(IXb), R 6 is CH 3 or CF 3 is.

[0055] In some embodiments of Formulas (IXa)-(IXb), the compound is or a solvate, hydrate, prodrug, and / or stereoisomer thereof, or a pharmaceutically acceptable selected from the salts TIFF2023505915000019.tif219170 TIFF2023505915000020.tif73170

[0056] In some embodiments of Formulas (VIIIa)-(VIIIb), those of Formula (Xa) or (Xb), or solvates, hydrates, prodrugs, and / or stereoisomers thereof, or is a pharmaceutically acceptable salt of TIFF2023505915000021.tif41170

[0057] In some embodiments of Formulas (Xa)-(Xb), R 5 and R 9 , H, (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 5 )alkoxy, substituted (C 1-C 5 ) independently selected from alkoxy, halogen, and hydroxyl; In some embodiments of Formulas (Xa)-(Xb), R 5 and R 9 is independently selected from H and halogen. In some embodiments of formulas (Xa)-(Xb), R 5 is F. In some embodiments of formulas (Xa)-(Xb), R 9 is F. In some embodiments of formulas (Xa)-(Xb), R 5 and R 9 are respectively F. In some embodiments of formulas (Xa)-(Xb), R 5 is H and R 9 is F.

[0058] In some embodiments of Formulas (Xa)-(Xb), the compound is or a solvate, hydrate, prodrug, and / or stereoisomer thereof, or a pharmaceutically acceptable selected from the salts TIFF2023505915000022.tif213170 TIFF2023505915000023.tif72170

[0059] In some embodiments of Formulas (VIIa)-(VIIb), the compound is of Formula (XIa) or (XIb), or a solvate, hydrate, prodrug, and / or stereoisomer thereof; or a pharmaceutically acceptable salt thereof. TIFF2023505915000024.tif41170

[0060] In some embodiments of Formulas (XIa)-(XIb), R 5 , R 6 and R 9 , H, (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 5 )alkoxy, substituted (C 1 -C 5 )alkoxy, -NH 2 , substituted amino, halogen, and hydroxyl. In some embodiments of Formulas (XIa)-(XIb), R 6 , H, (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, and (C 1 -C 3 ) haloalkyl. In some embodiments of formulas (XIa)-(XIb), R 6 is CH 3 or CF 3 is. In some embodiments of formulas (XIa)-(XIb), R 6 is H.

[0061] In some embodiments of Formulas (XIa)-(XIb), R 5 and R 9 is independently selected from H and halogen. In some embodiments of formulas (XIa)-(XIb), R 5 is F. In some embodiments of formulas (XIa)-(XIb), R 9 is F. In some embodiments of formulas (XIa)-(XIb), R 5 and R 9 are respectively F. In some embodiments of formulas (XIa)-(XIb), R 5 is F and R 9 is H.

[0062] In some embodiments of Formulas (XIa)-(XIb), the compound is or a solvate, hydrate, prodrug, and / or stereoisomer thereof, or a pharmaceutically acceptable selected from the salts TIFF2023505915000025.tif124170

[0063] In some embodiments of Formulas (VIIa)-(VIIb), the compound is of Formula (XIVa) or (XIVb), or a solvate, hydrate, prodrug, and / or stereoisomer thereof; or a pharmaceutically acceptable salt thereof. TIFF2023505915000026.tif46170 where Y 4 is CR 4 or N; R. 1 or R 4 is H, (C 1 -C 8 ) alkyl, substituted (C 1 -C 8 ) alkyl, (C 2 -C 8 ) alkenyl, substituted (C 2 -C 8 ) alkenyl, (C 2 -C 8 )alkynyl, substituted (C 2 -C 8 ) alkynyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 8 )alkoxy, substituted (C 1 -C 8 )alkoxy, -CONH 2 , substituted amides, -NH 2 , substituted amino, -CO 2 H, cyano, halogen, hydroxyl, -NO 2 , -SO 3 H, -SO 2 NH 2 , substituted sulfonamides, and thiols; R. 21 and R 22 is H, (C 1 -C 8 ) alkyl, substituted (C 1 -C 8 ) alkyl, SO 2 R. 30 , and COR 30 is independently selected from and R 30 is (C 1 -C 8 ) alkyl, and substituted (C 1 -C 8 ) alkyl.

[0064] In some embodiments of Formulas (XIVa)-(XIVb), R 5 , R 6 , R 8 and R 9 , H, (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 5 )alkoxy, substituted (C 1 -C 5 ) independently selected from alkoxy, halogen, and hydroxyl;

[0065] In some embodiments of formulas (XIVa)-(XIVb), R 21 and R 22 are H respectively.

[0066] In some embodiments of formulas (XIVa)-(XIVb), R 2 or R 4 are each H; R 1 is H, (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 5 )alkoxy, substituted (C 1 -C 5 ) alkoxy, halogen, and hydroxyl. In some embodiments of formulas (XIVa)-(XIVb), R 1 is H, F, CH 3 , and CF 3 is selected from

[0067] In some embodiments of Formulas (XIVa)-(XIVb), the compound is of Formula (XVa) or (XVb), or a solvate, hydrate, prodrug, and / or stereoisomer thereof , or a pharmaceutically acceptable salt thereof. TIFF2023505915000027.tif41170

[0068] In some embodiments of Formulas (XVa)-(XVb), R 5 and R 9 , H, (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 5 )alkoxy, substituted (C 1 -C 5 ) independently selected from alkoxy, halogen, and hydroxyl; In some embodiments of formulas (XVa)-(XVb), R 5 and R 9is independently selected from H and halogen. In some embodiments of formulas (XVa)-(XVb), R 5 is F. In some embodiments of formulas (XVa)-(XVb), R 9 is F. In some embodiments of formulas (XVa)-(XVb), R 5 and R 9 are respectively F. In some embodiments of formulas (XVa)-(XVb), R 5 is H and R 9 is F.

[0069] In some embodiments of Formulas (XVa)-(XVb), R 1 teeth, H, (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 5 )alkoxy, substituted (C 1 -C 5 ) alkoxy, halogen, and hydroxyl. In some embodiments of Formulas (XVa)-(XVb), R 1 is H, F, CH 3 , and CF 3 is selected from

[0070] In some embodiments of formulas (XVa)-(XVb), Y 4 is CH. In some embodiments of formulas (XVa)-(XVb), Y 4 is N.

[0071] In some embodiments of Formulas (XVIa)-(XVIb), the compound is or a solvate, hydrate, prodrug, and / or stereoisomer thereof, or a pharmaceutically acceptable selected from the salts TIFF2023505915000028.tif72170

[0072] In some embodiments of Formulas (XIVa)-(XIVb), the compound is of Formula (XVIa) or (XVIb), or solvates, hydrates, prodrugs, and / or stereoisomers thereof; or a pharmaceutically acceptable salt thereof. TIFF2023505915000029.tif41170

[0073] In some embodiments of Formulas (XVIa)-(XVIb), R 6 is (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 5 )alkoxy, substituted (C 1 -C 5 ) alkoxy, halogen, and hydroxyl. In some embodiments of Formulas (XVIa)-(XVIb), R 6 but (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, and (C 1 -C 3 ) haloalkyl. In some embodiments of formulas (XVIa)-(XVIb), R 6 is CH 3 or CF 3 It is.

[0074] In some embodiments of Formulas (XVIa)-(XVIb), R 1 is H, (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 5 )alkoxy, substituted (C 1 -C 5 ) alkoxy, halogen, and hydroxyl. In some embodiments of Formulas (XVIa)-(XVIb), R 1 is H, F, CH 3 , and CF 3 is selected from

[0075] In some embodiments of formulas (XVIa)-(XVIb), Y 4 is CH. In some embodiments of formulas (XVIa)-(XVIb), Y 4 is N.

[0076] In some embodiments of Formulas (XVIa)-(XVIb), the compound is or a solvate, hydrate, prodrug, and / or stereoisomer thereof, or a pharmaceutically acceptable Salts selected from: TIFF2023505915000030.tif75170

[0077] In some embodiments of Formulas (I)-(Ib), the compound is of Formula (XIIa) or (XIIb). TIFF2023505915000031.tif44170 where Y 5 or Y 7 are independently CR 20 or N and Y 5 or Y 7 is N; R 1 or R 4 , R 8 , R 9 and each R 20 is H, (C 1 -C 8 ) alkyl, substituted (C 1 -C 8 ) alkyl, (C 2 -C 8 ) alkenyl, substituted (C 2 -C 8 ) alkenyl, (C 2 -C 8 )alkynyl, substituted (C 2 -C 8 ) alkynyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 8 )alkoxy, substituted (C 1 -C 8 )alkoxy, -CONH 2 , substituted amides, -NH 2 , substituted amino, -CO 2 H, cyano, halogen, hydroxyl, -NO 2 , -SO 3 H, -SO 2 NH 2 , substituted sulfonamides, and thiols.

[0078] In some embodiments of Formulas (XIIa)-(XIIb), Y 5 is N. In some embodiments of Formulas (XIIa)-(XIIb), Y 6 is N. In some embodiments of Formulas (XIIa)-(XIIb), Y 7 is N.

[0079] In some embodiments of Formulas (XIIa)-(XIIb), R 8 , R 9 and each R 20 is H, (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 5 )alkoxy, substituted (C 1 -C 5 )alkoxy, -NH 2 , substituted amino, halogen, and hydroxyl.

[0080] In some embodiments of Formulas (XIIa)-(XIIb), R 8 , R 9 and each R 20 is H, NH 2 , F, CH 3 , and CF 3 is independently selected from

[0081] In some embodiments of Formulas (XIIa)-(XIIb), R 1 or R 4 is H, (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 5 )alkoxy, substituted (C 1 -C 5 )alkoxy, -NH 2 , substituted amino, halogen, and hydroxyl. In some embodiments of Formulas (XIIa)-(XIIb), R 1 or R 4 is H, (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3) haloalkyl, and halogen.

[0082] In some embodiments of Formulas (I)-(Ib), the compound is of Formula (XIIIa) or (XIIIb). TIFF2023505915000032.tif39170 where Y 5 to Y 7 are independently CR 20 or N and Y 5 to Y 7 one of is N; R. 8 , R 9 , each R 10 , and each R 20 is H, (C 1 -C 8 ) alkyl, substituted (C 1 -C 8 ) alkyl, (C 2 -C 8 ) alkenyl, substituted (C 2 -C 8 ) alkenyl, (C 2 -C 8 )alkynyl, substituted (C 2 -C 8 ) alkynyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 8 )alkoxy, substituted (C 1 -C 8 )alkoxy, -CONH 2 , substituted amides, -NH 2 , substituted amino, -CO 2 H, cyano, halogen, hydroxyl, -NO 2 , -SO 3 H, -SO 2 NH 2 , substituted sulfonamides, and thiols.

[0083] In some embodiments of Formulas (XIIIa)-(XIIIb), Y 5 is N. In some embodiments of Formulas (XIIIa)-(XIIIb), Y 6 is N. In some embodiments of Formulas (XIIIa)-(XIIIb), Y 7 is N.

[0084] In some embodiments of Formulas (XIIIa)-(XIIIb), R 8 , R 9 and each R 20 is H, (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 5 )alkoxy, substituted (C 1 -C 5 )alkoxy, -NH 2 , substituted amino, halogen, and hydroxyl. In some embodiments of Formulas (XIIIa)-(XIIIb), R 8 , R 9 and each R 20 is H, F, CH 3 , and CF 3 is independently selected from In some embodiments of Formulas (XIIIa)-(XIIIb), each R 10 is H, (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 5 )alkoxy, substituted (C 1 -C 5 )alkoxy, -NH 2 , substituted amino, halogen, and hydroxyl.

[0085] In some embodiments of Formulas (XIIIa)-(XIIIb), Y 1 is CR 10 is.

[0086] In some embodiments of Formulas (XIIIa)-(XIIIb), R 10 is H. In some embodiments of Formulas (XIIIa)-(XIIIb), R 10 is (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, and halogen. In some embodiments of Formulas (XIIIa)-(XIIIb), R 10 is H, F, CH 3 , and CF 3 is.

[0087] In some embodiments of Formulas (XIIIa)-(XIIIb), Y 1 or Y 4 are CR 10 is.

[0088] In some embodiments of Formulas (XIIIa)-(XIIIb), each R 10 is (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, and halogen.

[0089] In some embodiments of Formulas (XIIIa)-(XIIIb), Y 1 or Y 4 are each CH. In some embodiments of Formulas (XIIIa)-(XIIIb), Y 1 or Y 4 is N. In some embodiments of Formulas (XIIIa)-(XIIIb), Y 1 is N. In some embodiments of Formulas (XIIIa)-(XIIIb), Y 2 is N. In some embodiments of Formulas (XIIIa)-(XIIIb), Y 3 is N. In some embodiments of Formulas (XIIIa)-(XIIIb), Y 4 is N.

[0090] In some embodiments of the above embodiments, the compound is of Formulas (Ia) through (XVIa) (eg, purine compounds), or salts thereof (eg, pharmaceutically acceptable salts). In some of the above embodiments, the compound is of Formulas (Ib) through (XVIb) (eg, pyrazolopyrimidine compounds), or salts thereof (eg, pharmaceutically acceptable salts).

[0091] In some embodiments of Formula (I), compounds are selected from: 3-(6-amino-1-(4-aminobenzyl)-1H-pyrazolo-[3,4-d]-pyrimidin-4-yl)-benzonitrile; 3-(6-amino-1-(4-aminobenzyl)-1H-pyrazolo-[3,4-d]-pyrimidin-4-yl)-2-methylbenzonitrile; 3-(6-amino-1-(4-aminobenzyl)-1H-pyrazolo-[3,4-d]-pyrimidin-4-yl)-2-fluorobenzonitrile; 3-(2-amino-9-(4-aminobenzyl)-9H-purin-6-yl)-benzonitrile; 3-(2-amino-9-(4-aminobenzyl)-9H-purin-6-yl)-2-fluorobenzonitrile; 3-(2-amino-9-(4-aminobenzyl)-9H-purin-6-yl)-2-methylbenzonitrile; 3-(2-amino-9-(4-amino-2,6-difluorobenzyl)-9H-purin-6-yl)-benzonitrile; 3-(2-amino-9-(4-amino-2,6-difluorobenzyl)-9H-purin-6-yl)-2-fluorobenzonitrile; 3-(2-amino-9-(4-amino-2-fluorobenzyl)-9H-purin-6-yl)-benzonitrile; 3-(2-amino-9-(4-amino-2-fluorobenzyl)-9H-purin-6-yl)-2-fluorobenzonitrile; 3-(2-amino-9-(4-amino-3-methylbenzyl)-9H-purin-6-yl)-benzonitrile; 3-(2-amino-9-(4-amino-3-methylbenzyl)-9H-purin-6-yl)-2-fluorobenzonitrile; 3-(2-amino-9-(2,6-difluorobenzyl)-9H-purin-6-yl)benzonitrile; 3-(2-amino-9-(2,6-difluorobenzyl)-9H-purin-6-yl)-2-fluorobenzonitrile; and 3-(2-amino-9-(2,6-difluorobenzyl)-9H-purin-6-yl)-2-methylbenzonitrile.

[0092] Salts and / or solvates, hydrates, prodrugs and / or stereoisomers of compounds described herein, for example compounds of formulas (I)-(XVIb), or compounds shown in Table 1 All variations are included in the present disclosure. Accordingly, any of the compounds described herein may be compounds of formulas (I)-(XVIb) or solvates, hydrates, prodrugs and / or stereoisomers thereof, or pharmaceutically acceptable compounds thereof. It is sometimes called the salt that is used.

[0093] In some embodiments, the compound is a structure of one of the compounds of Table 1, or solvates, hydrates, prodrugs, and / or stereoisomers thereof, or salts thereof (e.g., pharmaceutically acceptable salts). In some embodiments, the compound is represented by the structure of one of the compounds of Table 1 of Formula (Ia) (eg, a purine compound) or a salt thereof (eg, a pharmaceutically acceptable salt). In some embodiments, the compound is represented by the structure of one of the compounds of Table 1 that is Formula (Ib) (e.g., a pyrazolo-pyrimidine compound) or a salt thereof (e.g., a pharmaceutically acceptable salt) . The present disclosure provides compounds of any one of Table 1, or salts thereof, and / or solvates, hydrates, prodrugs, single stereoisomers, mixtures of stereoisomers, and / or isotopes thereof. It is meant to include iso-labeled forms. For example, solvates, hydrates, prodrugs and / or stereoisomeric forms of any of the compounds described herein (e.g., of formulas (I)-(XVIb)) or shown in Table 1 are meant to be included in the disclosure herein. TIFF2023505915000033.tif250165 TIFF2023505915000034.tif251167 TIFF2023505915000035.tif245170 TIFF2023505915000036.tif244170 TIFF2023505915000037.tif225170 TIFF2023505915000038.tif81170 isotopically labeled analog

[0094] This disclosure also covers isotopes identical to the compounds described herein, except that one or more atoms are replaced by atoms having atomic weights or mass numbers different from those normally found in nature. including biolabeling compounds (“isotopologues”). The compounds of the present disclosure may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. Examples of isotopes that can be incorporated into the compounds described herein include: 2 H ("D"), 3 H. 13 C. 14 C. 15 N, 18 O 17 O 31 P. 32 P. 35 S, 18 F, and 36 Included are isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, respectively, such as Cl. For example, the compounds described herein can have one or more H atoms replaced with deuterium.

[0095] Generally, a reference or depiction of a particular element such as hydrogen or H is meant to include all isotopes of that element. For example, if the R group is defined to include hydrogen or H, then deuterium and tritium are also included. Therefore, tritium, 14 C. 32 P and 35 Compounds containing radioactive isotopes such as S are within the scope of the present technology. Procedures for inserting such labels into compounds of the present technology will be readily apparent to those skilled in the art based on the disclosure herein.

[0096] Unless otherwise stated, compounds described herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, replacement of hydrogen by deuterium or tritium, or 13 C or 14 Except for the replacement of carbons by C-rich carbons, compounds having the structures of this invention are within the scope of this disclosure.

[0097] In some embodiments, 3 H and 14 Certain isotopically-labeled compounds, such as those labeled with C, may be useful in compound and / or substrate tissue distribution assays. tritiated ( 3 H) and carbon-14 ( 14 C) Isotopes may be particularly preferred for their ease of preparation and detectability. Furthermore, substitution with heavier isotopes such as deuterium can provide certain therapeutic advantages resulting from greater metabolic stability, such as increased in vivo half-life or reduced dosage requirements, thus It may be preferable in some circumstances. Isotopically-labeled compounds can generally be prepared by procedures analogous to those disclosed herein, e.g., by substituting non-isotopically-labeled reagents for isotopically-labeled reagents in the Examples section.

[0098] In some embodiments, the compounds disclosed in this disclosure are deuterated analogs or salts thereof of any of the compounds described herein. Deuterated analogs of compounds of Formulas (I)-(XVIb) are compounds in which one or more hydrogen atoms have been replaced with deuterium. In some embodiments, the deuterated analog is deuterated R, R a , R b , or R 1 or R 20 A compound of formula (I) containing a group.

[0099] Deuterated compounds are synthesized using a variety of methods, such as those described in: Dean, Dennis C.; Editor. Recent Advances in the Synthesis and Applications of Radiolabeled Compounds for Drug Discovery and Development. Recent advances in the synthesis and application of radiolabeled compounds for drug discovery and development) [In: Curr. , Pharm. Des. 2000; 6(10)] 2000, 110 pp; George W.; Varma, Ragender S. Synthesis of radiolabeled compounds via organometallic intermediates, Tetrahedron, 1989, 45(21), 6601-21; Anthony. Synthesis of Radiolabeled Compounds, J. Radioanal. Chem., 1981, 64(1-2), 9-32.

[0100] Deuterated starting materials are readily available and provided by the synthetic methods described herein to provide synthesis of deuterium-containing compounds. Many deuterium-containing reagents and building blocks are commercially available from chemical vendors such as Aldrich Chemical Co. Fluorinated analogues

[0101] In some embodiments, the compounds disclosed in this disclosure are fluorinated analogs or salts thereof of any compound as described herein. Fluorinated analogs of compounds of formulas (I)-(XVIb) are compounds in which one or more hydrogen atoms or substituents have been replaced with fluorine atoms. In some embodiments, the fluorinated analogs are fluorinated R, R a , R b , or R 1 or R 20 A compound of formula (I) containing a group. In some embodiments of fluorinated analogs of compounds of formula (I), a hydrogen atom in an aliphatic or aromatic C-H bond is replaced by a fluorine atom. In some embodiments of fluorinated analogs of compounds of Formula (I), at least one hydrogen of an optionally substituted aryl (e.g., phenyl) or optionally substituted heteroaryl (e.g., pyridyl) is replaced by a fluorine atom. In some embodiments of fluorinated analogs of compounds of formula (I), the hydroxyl substituent (-OH) or amino substituent (-NH 2 ) is replaced by a fluorine atom. In some embodiments of the fluorinated analogue of the compound, the compound is -F, -CF 3 , -CF 2 CF 3 , -CHF 2 , -OCF 3 , -OCHF 2 , and -OCF 2 CF 3 contains one or more substituents independently selected from Isomer

[0102] The term "compound" as used herein is meant to include all stereoisomers, geometric isomers, tautomers and isotopes of the depicted structures.

[0103] The compounds described herein may have asymmetric centers, geometric centers (eg, double bonds), or both. All chiral, diastereomeric, racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated. In some embodiments, compounds described herein possess one or more chiral centers. It is understood that, unless absolute stereochemistry is explicitly indicated, each chiral center may independently be of the R or S configuration or mixtures thereof. Accordingly, the compounds described herein include optical isomers enriched or resolved at any or all asymmetric atoms as indicated by the depiction. Racemic mixtures of the R-enantiomer and the S-enantiomer, and enantiomerically-enriched stereoisomeric mixtures containing the R- and S-enantiomers, as well as individual optical isomers, are substantially free of their enantiomeric or diastereomeric partners. All these stereoisomers are within the scope of the present technology.

[0104] Compounds of the disclosure containing an asymmetrically substituted atom may be isolated in optically active or racemic forms. Methods for preparing optically active forms, such as by resolving racemic forms, synthesizing from optically active starting materials, or using chiral auxiliaries, are well known in the art.

[0105] Geometric isomers can also exist in the compounds of this disclosure, arising from the arrangement of substituents around a carbon-carbon double bond, or the arrangement of substituents around a cycloalkyl or heterocycle. Geometric isomers of olefins, C=N double bonds, or other types of double bonds may be present in the compounds described herein and all such stable isomers are included in the present disclosure. Specifically, cis and trans geometric isomers of the compounds of this disclosure may also exist and may be isolated as a mixture of isomers or as separated isomeric forms.

[0106] The compounds of this disclosure also include tautomeric forms. Tautomers arise when a single bond is exchanged for an adjacent double bond with concomitant proton migration. Tautomers include prototropic tautomers, which are isomeric protonation states with the same empirical formula and overall charge. Examples of protic tautomers include ketone-enol pairs, amide-imidic acid pairs, lactam-lactimum pairs, amide-imidic acid pairs, enamine-imine pairs, and protons occupying two or more positions in a heterocyclic ring system. cyclic forms such as 1H- and 3H-imidazole, 1H-, 2H- and 4H-1,2,4-triazole, 1H- and 2H-isoindole, and 1H- and 2H-pyrazole. Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution. salts and other forms

[0107] In some embodiments, the compounds described herein exist in salt form. In some embodiments, compounds are provided in the form of pharmaceutically acceptable salts.

[0108] Compounds included in the present compositions that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids. Acids that can be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds include, but are not limited to, non-toxic acid addition salts, i. It forms a salt containing an anion.

[0109] Compounds containing an amine functional group or a nitrogen-containing heteroaryl group can be basic in nature and can be reacted with various inorganic and organic acids to form the corresponding salts. The compounds can be used in the form of pharmaceutically acceptable salts derived from inorganic or organic acids. In some embodiments, a pharmaceutically acceptable salt can be a salt derived from hydrochloric acid (ie, hydrochloride salts of the compounds described herein), and the like.

[0110] A pharmaceutically acceptable salt of a compound of the present disclosure can be prepared by dissolving the compound in a water-miscible organic solvent such as acetone, methanol, ethanol, or acetonitrile, adding an excess amount of an organic acid or an aqueous inorganic acid, and It can be produced by precipitation or crystallization. Additional salts can then be obtained by evaporating the solvent or excess acid from this mixture and drying it, or by filtering the extracted salts. .

[0111] Other examples of salts include the anions of the compounds of this disclosure combined with suitable cations. For therapeutic use, salts of the compounds of the disclosure are pharmaceutically acceptable. However, salts of non-pharmaceutically acceptable acids and bases may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound.

[0112] Compounds included in the present compositions that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts include alkali metal or alkaline earth metal salts.

[0113] Compounds containing basic or acidic moieties can also form pharmaceutically acceptable salts with various amino acids. The compounds of this disclosure can contain both acidic and basic groups, eg, one amino group and one carboxylic acid group. In such cases, the compounds can exist as acid addition salts, zwitterions, or base salts.

[0114] The compounds described herein include crystalline, powder and amorphous forms of those compounds, including polymorphs, pseudopolymorphs, solvates, hydrates, unsolvated polymorphs (including anhydrates) of the compounds. , conformational polymorphs, and amorphous forms, and pharmaceutically acceptable salts, including mixtures thereof. It is understood that the salt forms of any one of the subject compounds can exist in crystalline, powder, or amorphous form.

[0115] The compounds described herein may exist as solvates, especially hydrates, and all such solvates and hydrates are intended unless otherwise specified. The term "solvate" can refer to compounds of the present disclosure that contain stoichiometric or non-stoichiometric solvents associated by non-covalent intermolecular forces or salts thereof. Hydrates may form during manufacture of the compounds or compositions containing such compounds, or hydrates may form over time due to the hygroscopic nature of the compounds. The compounds of the present technology can also exist as organic solvates, including dimethylformamide (DMF), ether, and alcohol solvates, among others. Identification and preparation of particular solvates is within the skill of those skilled in synthetic organic or medicinal chemistry.

[0116] In some embodiments, the compounds described herein exist in the form of solvates. In some embodiments, compounds described herein exist in the form of hydrates when the solvent component of the solvate is water. prodrug

[0117] In some embodiments, the compounds described herein exist in prodrug form. Any convenient prodrug form of the subject compounds can be prepared, for example, according to the strategies and methods described by Rauchio et al. ("Prodrugs: Design and Clinical Application," Nature Reviews Drug Discovery 7, 255-270 (February 2008)). compound synthesis

[0118] The compounds of the present disclosure can be synthesized according to standard methods known in the art [see, eg, Morrison and Boyd in Organic Chemistry, 6th ed., Prentice Hall (1992)]. Some compounds and / or intermediates of the disclosure are commercially available, known in the literature, or readily available to those skilled in the art using standard procedures. Certain compounds of the disclosure can be synthesized using the schemes, examples, or intermediates described herein. Where the synthesis of a compound, intermediate or variant thereof is not fully described, one skilled in the art can estimate reaction times, number of equivalents of reagents, and / or temperatures to prepare a given compound or intermediate. Any variations from the reactions described herein, or variants thereof, and different work-up and / or purification techniques may be necessary or desirable to prepare such compounds, intermediates, or variants. can recognize

[0119] Synthesized compounds can be verified for proper structure by methods known to those skilled in the art, for example, by nuclear magnetic resonance (NMR) spectroscopy and / or mass spectroscopy. Pharmaceutical composition

[0120] The compounds of the disclosure can be formulated into pharmaceutical compositions. A pharmaceutical composition comprises one or more example A2A and / or A1 receptor antagonist compounds (e.g., described herein) and at least one excipient (e.g., a pharmaceutically acceptable excipient). agent).

[0121] The compounds described herein find use in pharmaceutical compositions for administration to subjects in need thereof in a variety of therapeutic applications where inhibition or antagonism of A2A and / or A1 receptor activity is desired. be able to.

[0122] Accordingly, in a second aspect, the present disclosure provides at least one compound as described herein, a pharmaceutically acceptable salt or prodrug thereof, and at least one pharmaceutically acceptable excipient. A pharmaceutical composition comprising: The phrase "pharmaceutically acceptable excipient" means any ingredient other than the compounds of the invention described herein (e.g., a vehicle in which an active compound can be suspended or dissolved, or any other (a convenient pharmaceutically acceptable carrier, excipient or additive) that is substantially non-toxic and non-inflammatory in patients. Excipients include, for example, antiadherents, antioxidants, binders, coatings, compression aids, disintegrants, dyes (colors), emollients, emulsifiers, fillers (diluents), film formers or Coatings, flavors, fragrances, glidants (glidants), lubricants, preservatives, printing inks, adsorbents, formulating or dispersing agents, sweeteners, and water of hydration may be included. In some embodiments, the pharmaceutical composition comprises a therapeutically effective amount of a compound described herein, a pharmaceutically acceptable salt thereof, or a prodrug thereof.

[0123] Pharmaceutical compositions can be formulated according to any convenient method and can be in various forms for oral administration such as tablets, pills, powders, nanoparticles, capsules, syrups, suspensions, emulsions and microemulsions. or may be prepared in a form for parenteral administration, such as a preparation for intramuscular, intravenous or subcutaneous administration.

[0124] In certain instances, pharmaceutical compositions can include pharmaceutically acceptable carriers, excipients, or additives. Pharmaceutical compositions can be manufactured as pharmaceuticals by conventional methods, and can be manufactured as various oral pharmaceuticals such as tablets, pills, powders, capsules, syrups, emulsions, microemulsions, or intramuscular injections, intravascular injections. , can be manufactured as a parenteral drug such as subcutaneous injection.

[0125] When the pharmaceutical composition is prepared in oral dosage form, examples of excipients or carriers used include cellulose, calcium silicate, corn starch, lactose, sucrose, dextrose, calcium phosphate, stearic acid, magnesium stearate, stearate. Calcium phosphate, gelatin, talc, surfactants, suspending agents, emulsifying agents, diluents and the like may be included. When the pharmaceutical composition of the present disclosure is prepared in the form of injection, the excipients or carriers include water, saline, aqueous glucose solution, similar sugar-soluble solutions, alcohols, glycols, ethers (eg polyethylene glycol 400), Oils, fatty acids, fatty acid esters, glycerides, surfactants, suspending agents, emulsifying agents and the like may be included.

[0126] In some embodiments, pharmaceutical compositions are formulated for parenteral administration to a subject in need thereof. In some parenteral embodiments, the pharmaceutical composition is formulated for intravenous administration to a subject in need thereof. In some parenteral embodiments, the pharmaceutical composition is formulated for subcutaneous administration to a subject in need thereof. Methods of modulating A2A and / or A1 receptors

[0127] Aspects of the present disclosure include methods of modulating A2A and / or A1 receptor activity in a biological system or sample. In some embodiments, modulating A2A and / or A1 receptor activity refers to inhibiting A2A and / or A1 receptors in a sample. In some embodiments, modulating A2A and / or A1 receptor activity refers to antagonizing A2A and / or A1 receptor activity in a cell or biological system.

[0128] In some embodiments, the method comprises contacting the sample with a compound of this disclosure capable of modulating A2A and / or A1 receptor activity. In some embodiments, the method comprises contacting a cell or biological system with a compound of the present disclosure capable of modulating A2A and / or A1 receptor activity.

[0129] The present disclosure provides compounds that have A2A and / or A1 receptor modulating activity, eg, A2A and / or A1 receptor inhibitory and / or antagonistic activity. In some embodiments, the compounds have A2A receptor inhibitory and / or antagonist activity. In some embodiments, the compounds have A2A and A1 receptor inhibitory and / or antagonist activity. In some embodiments, the compounds have A1 receptor inhibitory and / or antagonist activity. The ability of a compound to modulate A2A and / or A1 receptor activity can be characterized using a variety of assays, for example, A2A and / or A1 receptor binding assays and / or A2A receptor functional assays. For example, the experimental section describes an A2A receptor binding assay. Exemplary compounds of this disclosure were evaluated and K i Values ​​were determined to demonstrate that the compounds of the disclosure are capable of providing specific binding to human A2A receptors in assay systems. In addition, the experimental section describes an A2A functional assay involving monitoring cAMP signals generated in human recombinant A2A receptor stable cell lines. Exemplary compounds of this disclosure were evaluated and IC 50 got the value. This indicates that the compound can antagonize the human A2A receptor in the assay system.

[0130] Aspects of the present disclosure include methods of modulating (eg, inhibiting or antagonizing) A2A and / or A1 receptors using the compounds described herein. Such a method comprises contacting such system with a compound (e.g., a compound having a structure according to Formulas (I)-(XVIb) or a compound of Table 1) to obtain A2A and / or A1 in a biological system. A method of modulating the receptor can be included. Biological systems can include, but are not limited to, cells, tissues, organs, fluids, organisms, non-mammalian subjects, and mammalian subjects (eg, humans). A biological system may include a subject (eg, a human subject).

[0131] In some embodiments, a method of inhibiting or antagonizing A2A and / or A1 receptors comprises adding a biological system or sample comprising A2A and / or A1 receptors to an effective amount of any of the A2A and / or A1 receptors described herein. contacting with a compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition described herein for inhibiting or antagonizing A2A and / or A1 receptors. In certain embodiments, the biological system or sample is in vitro. In another embodiment, the biological system or sample is in vivo. In some embodiments the sample is a cell sample. In some embodiments, the A2A and / or A1 receptor is bound to the cell membrane.

[0132] Compounds of the present disclosure may antagonize A2A receptors, eg, as assessed by the human A2A functional assay, eg, as described in Example 3. An A2A receptor antagonist compound by such methods has an IC 50 value (eg, as assessed by the cAMP assay of Example 3). A biological system may include a subject (eg, a human subject). A2A receptor antagonist compounds by such methods have a K of 1 μM or less, e.g. i value (eg, as assessed by the binding assay of Example 2).

[0133] In some embodiments, the compounds are A2A receptor antagonists that exhibit desirable levels of inhibitory activity at the A1 receptor. In some embodiments, the compound is a dual A2A and A1 receptor antagonist. In some embodiments, the desired level of A1 receptor inhibitory activity is K i Refers to compounds with values ​​of 1 mM or less, such as 300 μM or less, 100 μM or less, 30 μM or less, 10 μM or less, 3 μM or less, or 1 μM or less. In some embodiments, compounds of the present disclosure exhibit inhibitory activity against A2A and A1 receptors. Example 4, Table 5 in the experimental section provides A2A and A1 receptor inhibition data showing that compounds of the present disclosure can have potent activity as dual antagonists. In such cases, the compounds can be used to treat CNS and neurodegenerative diseases (eg compounds of formulas (Ib) through (XVIb)). treatment indication

[0134] Aspects of the present disclosure include methods of treating subjects for therapeutic indications of interest using the compounds and / or compositions disclosed herein. The term "therapeutic indication" means that any form of treatment or other therapeutic intervention (e.g., administration of A2A and / or A1 receptor antagonists) relieves, stabilizes, ameliorate, cures, or Refers to a symptom, condition, disorder, or disease that may be otherwise managed. Therapeutic indications associated with modulation of A2A and / or A1 receptor biological activity and / or dysfunction are referred to herein as "adenosine receptor-related indications." In some embodiments, the methods of the present disclosure comprise administering to a subject an effective amount of a compound and / or composition disclosed herein (e.g., an A2A and / or A1 receptor antagonist compound), It may include treating an adenosine receptor-related indication.

[0135] The term "treat" or "treatment" means inhibiting a disease, e.g., inhibiting a disease, condition, or disorder in a subject experiencing pathologies or symptoms of a disease, condition, or disorder, i.e., disease states and to prevent further recurrence of symptoms or to ameliorate a disease, e.g. or reversal of symptoms, eg, to reduce the severity of an illness. In the context of this disclosure, to the extent that it relates to any of the other conditions listed below, the terms "treat," "treatment," etc., include alleviating or alleviating at least one symptom associated with such condition. or refers to slowing or reversing the progression or expected progression of such a condition.

[0136] The terms "prevent" or "prevent" mean to prevent disease, e.g., the pathology or symptoms of a disease, even though the entity may be prone to the disease, condition or disorder. Refers to preventing disease, eg, preventing a disease, condition or disorder, in an entity that has not experienced or exhibited

[0137] The terms "individual," "patient," "subject," and "entity" are used interchangeably and refer to a human or non-human animal in need of treatment for disease. More specifically, it refers to mammals such as humans, non-human primates, mice, dogs, cats, horses, cows, rabbits, rats, or other mammals. Cancer and immuno-oncology

[0138] The present disclosure provides methods of treating or preventing cancer in a subject using the subject compounds as therapeutic agents, and compositions comprising the compounds. Any cancer for which an A2A receptor antagonist is believed to be useful by those of skill in the art is treatable by this embodiment, either as monotherapy or in combination with other therapeutic agents discussed below. contemplated.

[0139] “Cancer”, which is a disease targeted for prevention or treatment by the aforementioned pharmaceutical composition, includes aggressive characteristics such as cell division and proliferation ignoring normal growth limits, and cell invasion into surrounding tissues. Collective term for diseases caused by cells with invasive properties, metastatic properties that spread to other areas of the body. In some embodiments, the cancer is solid tumor cancer. Cancers targeted for prevention or treatment using the compounds and pharmaceutical compositions of the present disclosure include lung cancer, breast cancer, prostate cancer, ovarian cancer, solenoma, cervical cancer, bladder cancer, head and neck cancer, renal cell carcinoma, esophagus. cancer, pancreatic cancer, brain cancer, liver cancer, leukemia, lymphoma, melanoma, multiple myeloma, Ewing sarcoma, osteosarcoma, colorectal neoplasm, cholangiocarcinoma, choroidal cancer, mouth cancer, neuroblastoma, skin cancer, Including, but not limited to, testicular cancer, stromal tumor, germ cell tumor, and thyroid cancer.

[0140] In some embodiments, the cancer is kidney, breast, lung, or liver cancer. In some embodiments, the cancer is solid tumor cancer. In some embodiments, the liver cancer is hepatocellular carcinoma (HCC). In some embodiments, the lung cancer is non-small cell lung cancer (NSCLC). In some embodiments, the cancer is solid tumor cancer.

[0141] In some embodiments, the method further comprises identifying the subject having or having cancer.

[0142] Compounds of the disclosure can be administered alone or in combination with one or more additional agents described herein. Accordingly, the method aspect comprises co-administering to a subject an effective amount of a compound or composition of the present disclosure and an effective amount of the additional active agent. The compound and additional active agent can be administered simultaneously or sequentially.

[0143] In some embodiments of the method, the additional active agent is selected from anti-angiogenic agents, anti-inflammatory agents, immune checkpoint inhibitors, poly ADP ribose polymerase (PARP) inhibitors, chemotherapeutic agents, and immune anticancer agents. It is an anticancer drug that is used

[0144] Given the immunosuppressive role of adenosine, administration of A2A receptor antagonists of the disclosure (e.g., compounds of formulas (Ia) through (XVIa)) enhances the efficacy of immunotherapies such as immune checkpoint inhibitor therapy. be able to. In some embodiments, the additional active agent is an immune checkpoint inhibitor selected from CTLA-4 inhibitors, PD-1 inhibitors, and PD-L1 inhibitors.

[0145] In some embodiments, the immune checkpoint inhibitor is an antibody or antibody fragment. In some embodiments, the additional therapeutic agent is an anti-PD-1 antibody. In another embodiment, the additional therapeutic agent is an anti-PD-L1 antibody. In some embodiments, the additional therapeutic agent is selected from pembrolizumab, nivolumab, atezolizumab, durvalumab, and avelumab. inflammatory disease

[0146] The present disclosure provides methods of treating or preventing inflammatory diseases in a subject using the subject compounds as therapeutic agents, and compositions comprising such compounds. Any inflammatory disease for which an A2A receptor antagonist would be useful by one of skill in the art, either as a monotherapy or in combination with other therapeutic agents (eg, as described herein), is a therapeutic agent of the present disclosure. Contemplated as diseases treatable using the compounds.

[0147] In some embodiments, the method comprises administering to a subject with an inflammatory disease a therapeutically effective amount of an A2A and / or A1 receptor antagonist compound (e.g., described herein). . In some embodiments, the inflammatory disease is a chronic inflammatory disease such as rheumatoid arthritis (RA). In some embodiments, the inflammatory disease is an acute inflammatory disease.

[0148] In some embodiments, the method further comprises identifying a subject having or at risk for an inflammatory disease.

[0149] In some embodiments, the method further comprises identifying an underlying disease or condition associated with an inflammatory disease. CNS and neurodegenerative diseases

[0150] The disclosure provides methods of treating or preventing a central nervous system (CNS) or neurodegenerative disease or disorder in a subject using the compounds of the disclosure as therapeutic agents or pharmaceutical compositions comprising the compounds. In some embodiments, the CNS disease is referred to as a neurodegenerative disease or disorder of the CNS. CNS and neurodegenerative diseases targeted for prevention or treatment using the compounds and pharmaceutical compositions of the present disclosure include Parkinson's disease (PD), Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), multiple Diseases including, but not limited to, sclerosis, Huntington's disease (HD), depression, schizophrenia, and epilepsy.

[0151] In some embodiments, the method is a method of treating or preventing Parkinson's disease comprising administering to a subject having or at risk of having Parkinson's disease an effective amount of a compound of the present disclosure. Optionally, the compound has dual inhibitory activity at both the A2A and A1 receptors (eg, compounds of formulas (Ib through XVIb)).

[0152] In some embodiments, the method further comprises identifying a subject suffering from or at risk for a CNS or neurodegenerative disease.

[0153] In some embodiments, the method further comprises identifying an underlying disease or condition associated with the CNS or neurodegenerative disease.

[0154] The amount of the aforementioned pharmaceutical composition to be administered is an amount effective to treat or prevent the disease of the entity or patient, and can be administered orally or parenterally depending on the purpose. For oral administration, the dosage based on active ingredient is 0.01-1,000 mg / kg body weight, more specifically 0.1-300 mg / kg. For parenteral administration, 0.01-100 mg, based on the active ingredient, per kg body weight per day, more specifically 0.1-50 mg, once or several times. The amount to be administered to a particular entity or patient can be determined based on many relevant factors, including the patient's weight, age, sex, health condition, diet, administration time, administration method, severity of illness, and the like. It is understood by experts that they can be appropriately increased or decreased, and the aforementioned dosages in no way limit the scope of this disclosure. A physician or veterinarian having the ordinary level of knowledge in the relevant art can determine and formulate effective amounts of pharmaceutical compositions. For example, a physician or veterinarian may begin with an amount of a compound used in a pharmaceutical composition under this disclosure that is less than the amount necessary to achieve the desired therapeutic effect and then gradually increase until the desired effect is achieved. can increase the amount administered to

[0155] The compounds and compositions of this disclosure can be used alone, in combination with a compound according to another example of this disclosure, or concurrently with at least one other therapeutic agent, such as other active pharmaceutical ingredients described herein. , can be administered separately or in sequential co-administration.

[0156] In certain embodiments, the pharmaceutical compositions of the present disclosure include within its scope pharmaceutical compositions that include an effective therapeutic amount of at least one of the compounds according to the specific examples as an active ingredient, or in combination with a pharmaceutical carrier. . Optionally, compounds according to embodiments of the present disclosure can be used independently, in combination with compounds according to another specific example, or concurrently with one or more other therapeutic agents, such as anticancer agents (e.g., those described herein). ), or in combination with the active pharmaceutical ingredient, either separately or sequentially. definition

[0157] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains.

[0158] It is understood that the definitions provided herein are not intended to be mutually exclusive. Therefore, some chemical moieties may be included in the definition of multiple terms.

[0159] "C x -C y The term ", when used in conjunction with chemical moieties such as alkyl, alkenyl, or alkynyl, is meant to include groups containing from x to y carbons in the chain. For example, "C 1 -C 6 The term "alkyl" refers to substituted or unsubstituted saturated hydrocarbon groups, including straight-chain and branched-chain alkyl groups containing 1-6 carbons. In some embodiments, "(C x -C y ) The term alkylene" refers to a substituted or unsubstituted alkylene chain having from x to y carbons in the alkylene chain. For example, "(C x -C y ) Alkylene may be selected from methylene, ethylene, propylene, butylene, pentylene, and hexylene, any one of which is optionally substituted.

[0160] The term "alkyl" refers to an unbranched or branched saturated hydrocarbon chain. In some embodiments, alkyl as used herein has 1 to 20 carbon atoms ((C 1 -C 20 )alkyl), from 1 to 10 carbon atoms ((C 1 -C 10 )alkyl), from 1 to 8 carbon atoms ((C 1 -C 8 )alkyl), 1-6 carbon atoms ((C 1 -C 6 )alkyl), 1-5 carbon atoms ((C 1 -C 5 )alkyl) or 1-3 carbon atoms ((C 1 -C 3 ) alkyl). Examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, isopentyl, neopentyl, n-hexyl, 2-hexyl, 3-hexyl, and 3-methylpentyl, but are not limited to these. When an alkyl residue with a particular number of carbons is named, all geometric isomers with that number of carbons can be included. For example, "butyl" can include n-butyl, sec-butyl, isobutyl and t-butyl, and "propyl" can include n-propyl and isopropyl. Unless stated otherwise herein, alkyl chains are optionally substituted with one or more substituents, such as the substituents described herein.

[0161] The term "alkoxy" refers to an unbranched or branched alkyl group attached to an oxygen atom (alkyl-O-). In some embodiments, alkoxy as used herein has 1 to 20 carbon atoms ((C 1 -C 20 )alkoxy), from 1 to 10 carbon atoms ((C 1 -C 10 )alkoxy), 1 to 8 carbon atoms ((C 1 -C 8 )alkoxy), 1-6 carbon atoms ((C 1 -C 6 )alkoxy), 1-5 carbon atoms ((C 1 -C 5 )alkoxy) or 1-3 carbon atoms ((C 1 -C 5 ) alkoxy). Examples include, but are not limited to methoxy, ethoxy, n-propoxy, and butoxy. When naming an alkoxy residue with a particular number of carbons, all geometric isomers with that number of carbons can be included, such as isopropoxy, isobutoxy and t-butoxy. Unless stated otherwise herein, alkoxy chains are optionally substituted with one or more substituents, such as the substituents described herein.

[0162] The term "alkylene" refers to the remainder of the molecule consisting solely of carbon and hydrogen and containing no unsaturation, preferably from 1 to 20 carbon atoms ((C 1 -C 20 ) alkylene), 1-10 carbon atoms ((C 1 -C 10 ) alkylene), 1-6 carbon atoms ((C 1 -C 6 ) alkylene), or 1-5 carbon atoms ((C 1 -C 5 ) alkylene) refers to a linear divalent hydrocarbon chain attached to a radical group. Examples include, but are not limited to methylene, ethylene, propylene, butylene, and the like. The alkylene chain is attached through a single bond to the rest of the molecule and through a single bond to the radical group. The points of attachment of the alkylene chain to the rest of the molecule and to the radical group are each through the terminal carbon. Unless stated otherwise herein, alkylene chains are optionally substituted with one or more substituents, such as the substituents described herein. An example is methylene (-CH 2 -), ethylene (-CH 2 CH 2 -), propylene (-CH 2 CH 2 CH 2 -), 2-methylpropylene (-CH 2 -CH(CH 3 )-CH 2 -), hexylene (-(CH 2 ) 6 -), etc.

[0163] The term "alkenyl" refers to aliphatic hydrocarbon groups containing at least one carbon-carbon double bond, including straight-chain, branched-chain, and cyclic alkenyl groups. In some embodiments, alkenyl groups have 2-10 carbon atoms (C 2 - 10 alkenyl). In another embodiment, alkenyl groups have 2-4 carbon atoms in the chain (C 2 - 4 alkenyl). Exemplary alkenyl groups include ethenyl, propenyl, n-butenyl, i-butenyl, 3-methylbut-2-enyl, 3-methylbut-1-enyl, n-pentenyl, heptenyl, octenyl, cyclohexyl-butenyl, decenyl, and the like. , and isomers thereof. Alkylalkenyl is an alkyl group as defined herein attached to an alkenyl group as defined herein. Alkenyl groups can be unsubstituted or substituted via available carbon atoms with one or more groups as defined above for alkyl.

[0164] The term "alkynyl" has 2-6 carbon atoms, preferably 2-3 carbon atoms, and has at least 1 and preferably 1 to 2 sites of acetylenic (C≡C-) unsaturation. refers to a straight or branched monovalent hydrocarbyl group having a Examples of such alkynyl groups include acetylenyl (C≡CH), propargyl (CH 2 C≡CH), 1-propynyl, 1-butynyl, and 1-pentynyl, including but not limited to.

[0165] The term "aminoalkyl" refers to the group formed by combining an alkyl and an amino group. Examples include -NHCH 3 , -NHCH 2 CH 3 -NHCHCH 3 ) 2 , -N(CH3) 2 , -NCH 3 (CH 2 CH 3 )-NCH 3 (CH(CH 3 ) 2 ) and similar groups.

[0166] The term "aryl" refers to a monocyclic or polycyclic group having at least one hydrocarbon aromatic ring, wherein the ring atoms of the at least one hydrocarbon aromatic ring are all carbon. Aryl can include groups with single aromatic rings (eg, phenyl) and multiple fused aromatic rings (eg, naphthyl, anthryl). Aryl is a group having one or more aromatic hydrocarbon rings fused to one or more non-aromatic hydrocarbon rings (e.g., fluorene; 2,3-dihydro-1H-indene; 1,2,3 ,4-tetrahydronaphthalene). In certain embodiments, aryl includes groups having an aromatic hydrocarbon ring fused to a non-aromatic ring, wherein the non-aromatic ring is at least Contains one ring heteroatom. For example, in some embodiments, aryl includes groups having a phenyl ring fused to a non-aromatic ring, wherein the non-aromatic ring is at least Contains one ring heteroatom (eg, chroman; thiochroman; 2,3-dihydrobenzofuran; indoline). In some embodiments, aryl as used herein has 6 to 14 carbon atoms ((C 6 -C 14 )aryl), or 6 to 10 carbon atoms ((C 6 -C 10 ) aryl). When aryl contains a fused ring, the aryl can be connected to one or more substituents or moieties of the formulas described herein through any atom of the fused ring, when valences permit. .

[0167] The term "cycloalkyl" refers to a monocyclic or polycyclic saturated hydrocarbon. In some embodiments, cycloalkyl has from 3 to 20 carbon atoms ((C 3 -C 20 )cycloalkyl), 3 to 8 carbon atoms ((C 3 -C 8 )cycloalkyl), 3 to 6 carbon atoms ((C 3 -C 6 )cycloalkyl), or 3 to 5 carbon atoms ((C 3 -C 5 ) cycloalkyl). In some embodiments, cycloalkyls have 3 to 8 carbon atoms with single or multiple cyclic rings, including fused, bridged, and spiro ring systems. Examples of suitable cycloalkyl groups include adamantyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyl, octahydropentalenyl, octahydro-1H-indene, decahydronaphthalene, cubane, bicyclo[3.1.0]hexane, and bicyclo [1.1.1] Including, but not limited to, pentane and the like.

[0168] The term "carbocycle" refers to a saturated, unsaturated, or aromatic ring system in which each atom of the ring system is carbon. Carbocycles include 3-10 membered monocyclic rings, 6-12 membered bicyclic rings, and 6-12 membered bridged rings. Each ring of a bicyclic carbocycle may be selected from saturated, unsaturated and aromatic rings. In exemplary embodiments, an aromatic ring such as phenyl can be fused to a saturated or unsaturated ring such as cyclohexane, cyclopentane, or cyclohexene. Bicyclic carbocycles include any combination of saturated, unsaturated, and aromatic bicyclic rings as valences permit. Bicyclic carbocycle includes 4-5 fused ring system, 5-5 fused ring system, 5-6 fused ring system, 6-6 fused ring system, 5-7 fused ring system, 6-7 fused ring system, Any combination of ring sizes are included, such as 5-8 fused ring systems, and 6-8 fused ring systems. Exemplary carbocycles include cyclopentyl, cyclohexyl, cyclohexenyl, adamantyl, phenyl, indanyl, and naphthyl.

[0169] The term "haloalkyl" refers to monohaloalkyl or polyhaloalkyl groups that can be further substituted or unsubstituted. The terms halogen and alkyl are as defined herein.

[0170] The term "heterocycle" refers to a saturated, unsaturated, or aromatic ring containing one or more heteroatoms. Exemplary heteroatoms include N, O, Si, P, B, and S atoms. Heterocycles include 3-10 membered monocyclic rings, 6-12 membered bicyclic rings, and 6-12 membered bridged rings. Bicyclic heterocycles include any combination of saturated, unsaturated, and aromatic bicyclic rings as valences permit. In exemplary embodiments, an aromatic ring, eg, pyridyl, can be fused to a saturated or unsaturated ring, eg, cyclohexane, cyclopentane, morpholine, piperidine or cyclohexene. Bicyclic heterocycle includes 4-5 fused ring system, 5-5 fused ring system, 5-6 fused ring system, 6-6 fused ring system, 5-7 fused ring system, 6-7 fused ring system, Any combination of ring sizes are included, such as 5-8 fused ring systems, and 6-8 fused ring systems.

[0171] The term "heteroaryl" refers to a single heteroatom that may be substituted or unsubstituted containing at least one heteroatom (e.g., a heteroatom selected from B, N, O, S, P(=O), Si, and P). Refers to cyclic or bicyclic or higher aromatic groups. In some embodiments, the term refers to an aromatic group of 4 to 10 carbon atoms and 1 to 4 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur in the ring. Such heteroaryl groups can have a single ring (i.e., pyridinyl or furyl) or multiple fused rings (i.e., indolizinyl or benzothienyl), wherein the fused rings can also be aromatic. It may not be and / or if the point of attachment is through an atom of an aromatic heteroaryl group it includes heteroatoms. In one embodiment, the nitrogen and / or sulfur ring atoms of the heteroaryl group are optionally oxidized to provide N-oxide (N→O), sulfinyl, or sulfonyl moieties. Examples of monocyclic heteroaryl include pyrazolyl, pyrrolyl, thiazolyl, oxazolyl, thiophenyl, furanyl, imidazolyl, isoxazolyl, triazolyl, thiadiazolyl, tetrazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, and similar groups. include but are not limited to: Examples of bicyclic heteroaryl include indolyl, benzothiophenyl, benzofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzothiadiazole, benzotriazolyl, quinolinyl, isoquinolinyl, purinyl, furopyridinyl, Including, but not limited to, oxochromene, dioxoisoindoline, pyrazolopyridinyl, pyrazolo[1,5-a]pyridinyl, and similar groups. Preferred heteroaryls include 5- or 6-membered heteroaryls such as pyridinyl, pyrrolyl, indolyl, thiophenyl, and furanyl.

[0172] The term "heterocycloalkyl" refers to a substituted or unsubstituted monocyclic alkyl containing one or more heteroatoms selected from B, N, O, S, P(=O), Si and P . Examples include, but are not limited to, piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl, thiomorpholinyl, imidazolidinyl, tetrahydrofurfuryl, and similar groups.

[0173] The term "heteroalkyl" refers to an alkyl substituent in which one or more carbon atoms and any attached hydrogen atoms have been independently replaced with the same or different heteroatom groups. For example, 1, 2, or 3 carbon atoms can be independently replaced with the same or different heteroatom substituents.

[0174] The term "substituted" refers to one or more carbons or substitutable heteroatoms of a compound, such as NH or NH 2 Refers to a moiety that has a substituent that replaces a hydrogen above. It is understood that "substituted" or "substituted with" includes the implicit proviso that such substitution is subject to the permissible valences of the atom and substituents substituted, and that the substitution results in a stable compound. Will. For example, stable compounds include, but are not limited to, compounds that do not spontaneously undergo transformations, such as by rearrangement, cyclization, elimination, and the like. In certain embodiments, substituted is a substitution that replaces two hydrogen atoms on the same carbon atom, e.g., two hydrogen atoms on a single carbon are replaced with an oxo, imino, or thioxo group. It refers to a moiety having a group. The term "substituted" is contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic substituents of organic compounds. The permissible substituents can be one or more and the same or different for appropriate organic compounds.

[0175] It will be understood by those skilled in the art that the substituents themselves can be substituted, if desired. References to chemical moieties herein are understood to include substituted and unsubstituted variants, unless specifically stated as "unsubstituted." For example, reference to a "heteroaryl" group or moiety implicitly includes both substituted and unsubstituted variants, unless specified otherwise.

[0176] When referring to the features of a compound, the phrase "optionally substituted" may be used interchangeably with the phrase "unsubstituted or substituted," indicating that non-hydrogen substituents are present on a given atom or group. It may or may not be present, and thus the description includes structures with non-hydrogen substituents present and structures without non-hydrogen substituents. For example, "optionally substituted alkyl" encompasses both "alkyl" and "substituted alkyl" as defined herein. For any group containing one or more substituents, one skilled in the art will recognize that such groups are sterically impractical, synthetically impractical, and / or inherently unstable. It is understood that it is not intended to introduce substitutions or substitution patterns that are

[0177] It will also be understood by those skilled in the art that when "optionally substituted" is used, any portion of the term below may be substituted.

[0178] The terms "linker", "bond" and "linking group" are used interchangeably and refer to a linking moiety that covalently links two or more substituents. A linking moiety can connect two groups where the linker can be linear, branched, cyclic, or single atom. In some embodiments, the linker is bivalent. In some embodiments, the linker is a branched linker. In some embodiments, two or more substituents covalently bonded by a linking moiety are optionally substituted alkyl or alkoxy groups. In some embodiments, the linker is -CO 2 is selected from -, -O-, -°CO-, -CONH-, -NHCO- and -NH-.

[0179] In some embodiments, the substituent group is any substituent group described herein, e.g., halogen, hydroxy, oxo (= O), thioxo (= S), cyano (-CN), nitro (- NO 2 ), imino (= NH), oximo (= N-OH), hydrazino (= N-NH 2 ), -R b -OR a , -R b -℃(O)-R a , -R b -℃(O)-OR a , -R b -℃(O)-N(R a ) 2 , -R b -N(R a ) 2 , -R b -C(O)R a , -R b -C(O)OR a , -R b -C(O)N(R a ) 2 , -R b -O-R c -C(O)N(R a ) 2 , -R b -N(Ra)C(O)OR a , -R b -N(R a )C(O)R a , -R b N(R a )S(O) t R. a (where t is 1 or 2), -R b -S(O) t R. a (t is 1 or 2), -R b -S(O) t OR a (t is 1 or 2), and -R b -S(O) t N(R a ) 2 (t can be 1 or 2). In another exemplary embodiment, substituent groups include alkyl, alkenyl, alkynyl, aryl, aralkyl, aralkenyl, aralkynyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, and heteroaryl Alkyl includes any of these: alkyl, alkenyl, alkynyl, halogen, haloalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, imino, oximo, hydrazine, -R b -OR a , -R b -℃(O)-R a , -R b -℃(O)-OR a , -R b -℃(O)-N(R a ) 2 , -R b -N(R a ) 2 , -R b -C(O)R a , -R b -C(O)OR a , -R b -C(O)N(R a ) 2 , -R b -O-R c -C(O)N(R a ) 2 , -R b -N(Ra)C(O)OR a , -R b -N(R a )C(O)R a , -R b N(R a )S(O) t R. a (where t is 1 or 2), -R b -S(O) t R. a (t is 1 or 2), -R b -S(O) t OR a (t is 1 or 2), and -R b -S(O) t N(R a ) 2 (t is 1 or 2) can be optionally substituted. where each R a , R b , and R c is independently selected from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, and heteroarylalkyl. where the valences allow each R a , R b , and R c is alkyl, alkenyl, alkynyl, halogen, haloalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, imino, oximo, hydrazine, -R b -OR a , -R b -℃(O)-R a , -R b -℃(O)-OR a , -R b -℃(O)-N(R a ) 2 , -R b -N(R a ) 2 , -R b -C(O)R a , -R b -C(O)OR a , -R b -C(O)N(R a ) 2 , -R b -O-R c -C(O)N(R a ) 2 , -R b -N(Ra)C(O)OR a , -R b -N(R a )C(O)R a , -R b N(R a )S(O) t R. a (where t is 1 or 2), -R b -S(O) t R. a (t is 1 or 2), -R b -S(O) t OR a (t is 1 or 2), and -R b -S(O) t N(R a ) 2 (t is 1 or 2) can be optionally substituted.

[0180] The terms "isomer" or "three-dimensional isomer" refer to two or more compounds that contain the same number and types of atoms, groups or moieties, but differ in the structural arrangement of the atoms and in the connectivity of the atoms. The term can refer to compounds, or salts thereof, which are identical with respect to chemical equations or molecular equations but differ optically or in three dimensions, specifically partial three-dimensional isomers, They can be enantiomers, geometric isomers, or shape isomers.

[0181] The term "tautomer" refers to one of two or more structural isomers that exist in equilibrium and are readily converted from one isomer to another.

[0182] A "stereoisomer" refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures that are not interchangeable. The present disclosure contemplates various stereoisomers and mixtures thereof and includes "enantiomers," which refer to two stereoisomers whose molecules are non-superimposable mirror images of each other.

[0183] Individual enantiomers and diastereomers of the compounds of the present disclosure can be prepared synthetically from commercially available starting materials containing asymmetric or stereocenters or by preparation of racemic mixtures followed by resolution methods well known to those skilled in the art. . These separation methods include (1) attachment of a mixture of enantiomers to a chiral auxiliary, separation of the resulting mixture of diastereomers by recrystallization or chromatography, and separation of the optically pure product from the auxiliary. (2) salt formation using optically active resolving agents, (3) direct separation of mixtures of optical enantiomers on chiral liquid chromatography columns, or (4) using stereoselective chemical or enzymatic reagents. Exemplified by kinetic separation. Racemic mixtures can also be resolved into their individual enantiomers by well-known methods such as chiral phase gas chromatography or crystallization of the compound in a chiral solvent. Stereoselective syntheses, chemical or enzymatic reactions in which a single reactant forms an unequal mixture of stereoisomers during the creation of new stereocenters or the conversion of existing stereocenters, are well known in the art. Are known. Stereoselective synthesis includes both enantioselective and diastereoselective transformations. See, for example, Carreira and Kvaerno, Classics in Stereoselective Synthesis, Wiley-VCH: Weinheim, 2009.

[0184] The symbol = indicates a bond that can be a single, double, or triple bond as described herein. Substituents around a carbon-carbon double bond are designated as being in the 'Z' or 'E' configuration, the terms 'Z' and 'E' being used according to IUPAC standards. Unless otherwise specified, structures depicting double bonds include both the "E" and "Z" isomers.

[0185] Alternatively, substituents around a carbon-carbon double bond are sometimes referred to as "cis" or "trans", where "cis" denotes substituents on the same side of the double bond and "trans" denotes double represents the substituent on the opposite side of the bond. The arrangement of substituents around a carbocycle can also be designated as "cis" or "trans." The term "cis" refers to substituents on the same side of the plane of the ring and the term "trans" refers to substituents on opposite sides of the plane of the ring. Mixtures of compounds in which substituents are located on both the same side and opposite sides of the plane of the ring are termed "cis / trans."

[0186] Articles in the singular such as "a", "a", "the" and similar referents in the context of describing elements are used herein unless otherwise indicated or clearly contradicted by context. , is interpreted to cover both singular and plural forms. Recitation of ranges of values ​​herein serves as a shorthand method of referring individually to each individual value within the range, including the upper and lower limits of the range, unless stated otherwise herein. It is merely intended that each individual value be incorporated into the specification as if it were set forth individually herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. Any and all examples provided herein, or the use of exemplary language (i.e., "such as"), are intended merely to better clarify the embodiments, unless otherwise stated. It is not intended to limit the scope.

[0187] In some embodiments, where the use of the term "about" precedes a quantitative value, the disclosure also includes the particular quantitative value itself unless otherwise stated. As used herein, the term "about" refers to ±10% variation from the nominal value unless otherwise indicated or inferred. When percentages are provided for the amount of an ingredient or material in a composition, the percentages are to be understood as percentages by weight unless otherwise specified or understood from the context.

[0188] Where molecular weights are provided and not, for example, absolute values ​​for polymers, the molecular weights should be understood to be average molecular weights unless stated otherwise or understood from the context.

[0189] It should be understood that the order of steps or order for performing certain actions is immaterial so long as the disclosure remains functional. Additionally, two or more steps or actions can be performed simultaneously.

[0190] A dash (“-”) symbol that is not between two letters or symbols indicates a point of attachment or attachment for a substituent. For example, -NH 2 is attached through the nitrogen atom.

[0191] The term "pharmaceutically acceptable salt" refers to a salt that is acceptable for administration to a subject. It is understood that such salts containing counterions have acceptable mammalian safety for the given dosage regimens. Such salts can also be derived from pharmaceutically acceptable inorganic or organic bases and pharmaceutically acceptable inorganic or organic acids, and can contain organic and inorganic counterions. The neutral forms of the compounds described herein can be converted to their corresponding salt forms by contacting the compound with a base or acid and isolating the resulting salt.

[0192] The terms "pharmaceutically acceptable excipient", "pharmaceutically acceptable diluent", "pharmaceutically acceptable carrier" and "pharmaceutically acceptable adjuvant" are used interchangeably. and refers to excipients, diluents, carriers, or adjuvants useful in preparing pharmaceutical compositions that are generally safe, non-toxic, biologically or otherwise undesirable. Also included are excipients, diluents, carriers and adjuvants that can be used in veterinary and human pharmaceuticals. The phrase "pharmaceutically acceptable excipient" includes both one and more than one such excipient, diluent, carrier and / or adjuvant.

[0193] The term "pharmaceutical composition" is meant to encompass compositions suitable for administration to subjects such as mammals, particularly humans. Generally, a "pharmaceutical composition" is sterile and preferably free of contaminants that may induce an undesired response in a subject (ie, the compounds in the pharmaceutical composition are of pharmaceutical grade). Pharmaceutical compositions are administered to subjects or patients in need thereof via many different routes of administration, including oral, buccal, rectal, parenteral, intraperitoneal, intradermal, intratracheal, intramuscular, subcutaneous, and the like. can be designed to exemplary embodiment

[0194] As described herein, the text refers to various embodiments of the compounds, compositions, and methods of the invention. The various embodiments described are intended to provide various exemplary implementations and should not be construed as an illustration of alternative species. Rather, it should be noted that the descriptions of various embodiments provided herein may be of overlapping scope. The embodiments discussed herein are merely examples and are not meant to limit the scope of the technology.

[0195] Notwithstanding the claims appended hereto, aspects of the disclosure are presented by the following sections.

[0196] Item 1. A compound of Formula (Ia) or Formula (Ib), or a solvate, hydrate, prodrug, and / or stereoisomer thereof, or a pharmaceutically acceptable salt thereof. TIFF2023505915000039.tif39170 where R is H, (C 1 -C 3 ) alkyl, or substituted (C 1 -C 3 ) is an alkyl; Y 1 or Y 4 independently CR 10 and N, and Y 1 or Y 4 at least two independently CR 10 is; R. 10 are independently H, (C 1 -C 8 ) alkyl, substituted (C 1 -C 8 ) alkyl, (C 2 -C 8 ) alkenyl, substituted (C 2 -C 8 ) alkenyl, (C 2 -C 8 )alkynyl, substituted (C 2 -C 8 ) alkynyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 8 )alkoxy, substituted (C 1 -C 8 )alkoxy, -CONH 2 , substituted amides, -NH 2 , substituted amino, -CO 2 H, cyano, halogen, hydroxyl, -NO 2 , -SO 3 H, -SO 2 NH 2 , substituted sulfonamides, and thiols; R. a and R b are independently H, F, (C 1 -C 3 ) alkyl, and substituted (C 1 -C 3 ) alkyl, or Ra and R b are attached cyclically and together with the carbon atom to which they are attached form cyclopropyl, or substituted cyclopropyl; A is phenyl, substituted phenyl, pyridyl, or substituted pyridyl.

[0197] Item 2. A is phenyl, or 1, 2, or 3 R 20 is phenyl substituted with a group and each R 20 is (C 1 -C 8 ) alkyl, substituted (C 1 -C 8 ) alkyl, (C 2 -C 8 ) alkenyl, substituted (C 2 -C 8 ) alkenyl, (C 2 -C 8 )alkynyl, substituted (C 2 -C 8 ) alkynyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 8 )alkoxy, substituted (C 1 -C 8 )alkoxy, -CONH 2 , substituted amides, -NH 2 , substituted amino, -CO 2 H, cyano, halogen, hydroxyl, -NO 2 , -SO 3 H, -SO 2 NH 2 , substituted sulfonamides, and thiols.

[0198] Item 3. A is pyridyl, or one, two, or three R 20 is pyridyl substituted with a group and each R 20 is (C 1 -C 8 ) alkyl, substituted (C 1 -C 8 ) alkyl, (C 2 -C 8 ) alkenyl, substituted (C 2 -C 8 ) alkenyl, (C 2 -C 8 )alkynyl, substituted (C 2 -C 8 ) alkynyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 8 )alkoxy, substituted (C 1 -C 8 )alkoxy, -CONH 2 , substituted amides, -NH 2 , substituted amino, -CO 2 H, cyano, halogen, hydroxyl, -NO 2 , -SO 3 H, -SO 2 NH 2 , substituted sulfonamides, and thiols.

[0199] Item 4. A compound according to any one of items 1-3, wherein R is H.

[0200] Item 5. R. a and R b is each H. The compound according to any one of items 1-4.

[0201] Item 6. The compound according to item 2, wherein the compound is of formula (IIa) or (IIb): TIFF2023505915000040.tif41170 where R 1 or R 9 are independently H, (C 1 -C 8 ) alkyl, substituted (C 1 -C 8 ) alkyl, (C 2 -C 8 ) alkenyl, substituted (C 2 -C 8 ) alkenyl, (C 2 -C 8 )alkynyl, substituted (C 2 -C 8 ) alkynyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 8 )alkoxy, substituted (C 1 -C 8 )alkoxy, -CONH 2 , substituted amides, -NH 2 , substituted amino, -CO 2 H, cyano, halogen, hydroxyl, -NO 2 , -SO 3 H, -SO 2 NH 2 , substituted sulfonamides, and thiols.

[0202] Item 7. R. 1 or R 9 are independently H, (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 5 )alkoxy, substituted (C 1 -C 5 )alkoxy, -NH 2 7. The compound according to item 6, wherein the compound is selected from , substituted amino, halogen, and hydroxyl.

[0203] Item 8. R. 1 or R 9 are independently H, NH 2 , F, CH 3 , and CF 3 A compound according to item 7, selected from

[0204] Item 9. The compound according to item 6, wherein the compound is of formula (IIIa) or (IIIb): TIFF2023505915000041.tif47170 where R 21 and R 22 are independently H, (C 1 -C 8 ) alkyl, substituted (C 1 -C 8 ) alkyl, SO 2 R. 30 , and COR 30 is selected from R 30 is (C 1 -C 8 ) alkyl, or substituted (C 1 -C 8 ) alkyl.

[0205] Item ten. R. 21 and R 22 10. The compound according to item 9, wherein each is H.

[0206] Item 11. R. 5 , R 6 , R 8 and R 9 , H, (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 5 )alkoxy, substituted (C 1 -C 5 ) Compounds according to item 9 or item 10 independently selected from alkoxy, halogen and hydroxyl.

[0207] Item 12. R. 5 , R 6 , R 8 and R 9 is H, F, CH 3 , and CF 3 12. A compound according to item 11, independently selected from

[0208] Item 13. R. 5 , R 6 , R 8 and R 9 13. The compound according to item 12, wherein each is H.

[0209] Item 14. A compound according to any one of items 9 to 13, described below: R 2 or R 4 are each H; R 1 is H, (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 5 )alkoxy, substituted (C 1 -C 5 ) alkoxy, halogen, and hydroxyl.

[0210] Item 15. R. 1 is H, F, CH 3 , and CF 3 15. A compound according to item 14, selected from

[0211] Item 16. 16. The compound according to item 15, wherein the compound is selected from: TIFF2023505915000042.tif108170

[0212] Item 17. The compound according to item 9, wherein the compound is of formula (IVa) or (IVb): TIFF2023505915000043.tif41170

[0213] Item 18. R. 6 is (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 5 )alkoxy, substituted (C 1 -C 5 ) A compound according to item 17, selected from alkoxy, halogen, and hydroxyl.

[0214] Item 19. R. 6 but (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, and (C 1 -C 3 ) A compound according to item 18, selected from haloalkyl.

[0215] Item 20. R. 6 is CH 3 or CF 3 20. The compound according to item 19, which is

[0216] Item 21. A compound according to any one of items 17 to 20, described below. R. 2 or R 4 are each H; R 1 is H, (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 5 )alkoxy, substituted (C 1 -C 5 ) alkoxy, halogen, and hydroxyl.

[0217] Item 22. R. 1 is H, F, CH 3 , and CF 3 22. The compound according to item 21, selected from

[0218] Item 23. 23. The compound according to any one of items 17-22, wherein the compound is selected from: TIFF2023505915000044.tif143170

[0219] Item 24. The compound according to item 9, wherein the compound is of formula (Va) or (Vb): TIFF2023505915000045.tif41170

[0220] Item 25. R. 5 and R 9 , H, (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 5 )alkoxy, substituted (C 1 -C 5 ) Compounds according to item 24, independently selected from alkoxy, halogen, and hydroxyl.

[0221] Item 26. R. 5 and R 9 26. The compound according to item 25, wherein is independently selected from H and halogen.

[0222] Item 27. R. 5 27. The compound according to item 26, wherein is F.

[0223] Item 28. R. 9 28. The compound according to items 26 or 27, wherein is F.

[0224] Item 29. The compound according to item 26, wherein the compound is selected from: TIFF2023505915000046.tif149170

[0225] Item 30. The compound according to item 6, wherein the compound is of formula (VIa) or (VIb): TIFF2023505915000047.tif41170

[0226] Item 31. R. 5 , R 6 and R 9 , H, (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 5 )alkoxy, substituted (C 1 -C 5 )alkoxy, -NH 2 31. The compound according to item 30, which is independently selected from , substituted amino, halogen, and hydroxyl.

[0227] Item 32. R. 6 is H, (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, and (C 1 -C 3 ) A compound according to item 30 or 31, selected from haloalkyl.

[0228] Item 33. R. 6 is CH 3 or CF 3 33. The compound according to item 32, which is

[0229] Item 34. R. 6 33. The compound according to item 32, wherein is H.

[0230] Item 35. R. 5 and R 9 35. The compound according to any one of items 30-34, wherein is independently selected from H and halogen.

[0231] Item 36. R. 5 36. The compound according to item 35, wherein is F.

[0232] Item 37. R. 9 37. The compound of item 35 or 36, wherein is F.

[0233] Item 38. The compound according to item 35, wherein the compound is selected from: TIFF2023505915000048.tif85170

[0234] Item 39. Each R 10 or R 1 or R 4 , H, (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 5 )alkoxy, substituted (C 1 -C 5 )alkoxy, -NH 2 39. The compound according to any one of items 1-38, which is independently selected from , substituted amino, halogen, and hydroxyl.

[0235] Item 40. Each R 10 or R 1 or R 4 , H, (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) A compound according to item 39, independently selected from haloalkyl and halogen.

[0236] Item 41. R. 1 is H. The compound according to any one of items 6 to 40.

[0237] Item 42. R. 1 is (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) A compound according to any one of items 6 to 40, selected from haloalkyl and halogen.

[0238] Item 43. R. 1 is F, CH 3 or CF 3 43. The compound according to item 42, which is

[0239] Item 44. R.2 or R 4 are each H. The compound according to any one of items 6 to 43.

[0240] Item 45. The compound according to item 1 or item 2, wherein the compound is of formula (VIIa) or (VIIb): TIFF2023505915000049.tif42170 where R 5 or R 9 and each R 10 is H, (C 1 -C 8 ) alkyl, substituted (C 1 -C 8 ) alkyl, (C 2 -C 8 ) alkenyl, substituted (C 2 -C 8 ) alkenyl, (C 2 -C 8 )alkynyl, substituted (C 2 -C 8 ) alkynyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 8 )alkoxy, substituted (C 1 -C 8 )alkoxy, -CONH 2 , substituted amides, -NH 2 , substituted amino, -CO 2 H, cyano, halogen, hydroxyl, -NO 2 , -SO 3 H, -SO2NH 2 , substituted sulfonamides, and thiols.

[0241] Item 46. Y 1 or Y 4 46. ​​The compound according to item 45, wherein one of is N.

[0242] Item 47. R. 5 or R 9 and each R 10 , H, (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 5 )alkoxy, substituted (C 1 -C 5 )alkoxy, -NH 2 47. The compound according to item 46, which is independently selected from , substituted amino, halogen, and hydroxyl.

[0243] Item 48. R. 5 or R 9 and each R 10 is H, NH 2 , F, CH 3 , and CF 3 A compound according to item 47, independently selected from

[0244] Item 49. The compound according to item 46, wherein the compound is of formula (VIIIa) or (VIIIb): TIFF2023505915000050.tif46170 where R 21 and R 22 is H, (C 1 -C 8 ) alkyl, substituted (C 1 -C 8 ) alkyl, SO 2 R. 30 , and COR 30 is independently selected from and R 30 is (C 1 -C 8 ) alkyl, or substituted (C 1 -C 8 ) alkyl.

[0245] Item 50. R. 21 and R 22 50. The compound according to item 49, wherein each is H.

[0246] Item 51. R. 5 , R 6 , R 8 and R 9 , H, (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 5 )alkoxy, substituted (C 1 -C 5 ) Compounds according to items 49 or 50 independently selected from alkoxy, halogen and hydroxyl.

[0247] Item 52. R. 5 , R 6 , R 8 and R 9 is H, F, CH 3 , and CF 3 52. A compound according to item 51, independently selected from

[0248] Item 53. R. 5 , R 6 , R 8 and R 9 53. The compound according to item 52, wherein each is H.

[0249] Item 54. The compound according to item 53, wherein the compound is selected from: TIFF2023505915000051.tif143170

[0250] Item 55. The compound according to item 49, wherein the compound is of formula (IXa) or (IXb): TIFF2023505915000052.tif41170

[0251] Item 56. R. 6 is (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 5 )alkoxy, substituted (C 1 -C 5 ) A compound according to item 55, selected from alkoxy, halogen, and hydroxyl.

[0252] Item 57. R. 6 but (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, and (C 1 -C 3 ) A compound according to item 56, selected from haloalkyl.

[0253] Item 58. R. 6 is CH 3 or CF 3 58. The compound according to item 57, which is

[0254] Item 59. The compound according to item 58, wherein the compound is selected from: TIFF2023505915000053.tif219170 TIFF2023505915000054.tif73170

[0255] Item 60. The compound according to item 49, wherein the compound is of formula (Xa) or (Xb): TIFF2023505915000055.tif41170

[0256] Item 61. R. 5 and R 9 , H, (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 5 )alkoxy, substituted (C 1 -C 5 ) A compound according to item 60, independently selected from alkoxy, halogen, and hydroxyl.

[0257] Item 62. R. 5 and R 9 62. The compound according to item 61, wherein is independently selected from H and halogen.

[0258] Item 63. R. 5 63. The compound according to item 62, wherein is F.

[0259] Item 64. R. 9 64. The compound of item 62 or item 63, wherein is F.

[0260] Item 65. The compound according to item 62, wherein the compound is selected from: TIFF2023505915000056.tif212170 TIFF2023505915000057.tif72170

[0261] Item 66. The compound according to item 46, wherein the compound is of formula (XIa) or (XIb): TIFF2023505915000058.tif41170

[0262] Item 67. R. 5 , R 6 and R 9 , H, (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 5 )alkoxy, substituted (C 1 -C 5 )alkoxy, -NH 2 67. The compound according to item 66, wherein the compound is independently selected from , substituted amino, halogen, and hydroxyl.

[0263] Item 68. R. 6 , H, (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, and (C 1 -C 3 ) A compound according to item 66 or item 67, selected from haloalkyl.

[0264] Item 69. R. 6 is CH 3 or CF 3 69. The compound according to item 68, which is

[0265] Item 70. R. 6 69. The compound according to item 68, wherein is H.

[0266] Item 71. R. 5 and R 9 71. The compound according to any one of items 66-70, wherein is independently selected from H and halogen.

[0267] Item 72. R. 5 72. The compound according to item 71, wherein is F.

[0268] Item 73. R. 9 73. The compound of item 71 or item 72, wherein is F.

[0269] Item 74. The compound according to item 71, wherein the compound is selected from: TIFF2023505915000059.tif122170

[0270] Item 75. The compound according to item 45, wherein the compound is of formula (XIVa) or (XIVb): TIFF2023505915000060.tif47170 where Y 4 is CR 4 or N; R. 1 or R 4 is H, (C 1 -C 8 ) alkyl, substituted (C 1 -C 8 ) alkyl, (C 2 -C 8 ) alkenyl, substituted (C 2 -C 8 ) alkenyl, (C 2 -C 8 )alkynyl, substituted (C 2 -C 8 ) alkynyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 8 )alkoxy, substituted (C 1 -C 8 )alkoxy, -CONH 2 , substituted amides, -NH 2 , substituted amino, -CO 2 H, cyano, halogen, hydroxyl, -NO 2 , -SO 3 H, -SO 2 NH 2 , substituted sulfonamides, and thiols; R. 21 and R 22 is H, (C 1 -C 8 ) alkyl, substituted (C 1 -C 8 ) alkyl, SO 2 R. 30 , and COR 30 is independently selected from and R 30 is (C 1 -C 8 ) alkyl, and substituted (C 1 -C 8 ) alkyl.

[0271] Item 76. R. 5 , R 6 , R 8 and R 9 , H, (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 5 )alkoxy, substituted (C 1 -C 5 ) Compounds according to item 75, independently selected from alkoxy, halogen, and hydroxyl.

[0272] Item 77. R. 21 and R 22 77. The compound of item 75 or item 76, wherein each is H.

[0273] Item 78. A compound according to any one of items 75 to 77, described below: R. 2 or R 4 are each H; R 1 is H, (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 5 )alkoxy, substituted (C 1 -C 5 ) alkoxy, halogen, and hydroxyl.

[0274] Item 79. R. 1 is H, F, CH 3 , and CF 3 The compound according to item 78, selected from

[0275] Item 80. The compound according to item 75, wherein the compound is of formula (XVa) or (XVb): TIFF2023505915000061.tif41170

[0276] Item 81. R. 5 and R 9 , H, (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 5 )alkoxy, substituted (C 1 -C 5 ) A compound according to item 80, independently selected from alkoxy, halogen, and hydroxyl.

[0277] Item 82. R. 5 and R 9 82. The compound according to item 81, wherein is independently selected from H and halogen.

[0278] Item 83. R. 5 83. The compound according to item 82, wherein is F.

[0279] Item 84. R. 9 84. The compound of item 82 or item 83, wherein is F.

[0280] Item 85. The compound according to item 75, wherein the compound is of formula (XVIa) or (XVIb): TIFF2023505915000062.tif41170

[0281] Item 86. R. 6 is (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 5 )alkoxy, substituted (C 1 -C 5 ) The compound according to item 85, selected from alkoxy, halogen, and hydroxyl.

[0282] Item 87. R. 6 but (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, and (C 1 -C 3 ) The compound according to item 86, selected from haloalkyl.

[0283] Item 88. R. 6 is CH3 or CF 3 88. The compound according to item 87, which is

[0284] Item 89. R. 1 is H, (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 5 )alkoxy, substituted (C 1 -C 5 ) A compound according to any one of items 80-88, selected from alkoxy, halogen, and hydroxyl.

[0285] Item 90. R. 1 is H, F, CH 3 , and CF 3 90. The compound according to item 89, selected from

[0286] Item 91. Y 4 is CH. The compound according to any one of items 75 to 90.

[0287] Item 92. Y 4 is N. The compound according to any one of items 75 to 90.

[0288] Item 93. The compound according to items 75, 80 or 85, wherein the compound is selected from: TIFF2023505915000063.tif146170

[0289] Item 94. A compound according to item 1, wherein the compound is a compound of Table 1, or a solvate, hydrate, prodrug, and / or stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0290] Item 95. A compound according to any one of items 1 to 94 or a solvate, hydrate, prodrug, and / or stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable and an excipient.

[0291] Item 96. A compound for use in inhibiting or antagonizing adenosine A2A and / or A1 receptors, wherein the compound is the compound according to any one of items 1-94, or a solvate or hydrate thereof , prodrugs, and / or stereoisomers, or pharmaceutically acceptable salts thereof.

[0292] Item 97. 95. A pharmaceutical composition for use in inhibiting or antagonizing adenosine A2A and / or A1 receptors, wherein said pharmaceutical composition is described in item 95.

[0293] Item 98. 95. A method of inhibiting adenosine A2A and / or A1 receptors comprising: a sample comprising adenosine A2A and / or A1 receptors in an effective amount, according to any one of items 1-94. A compound, or solvate, hydrate, prodrug, and / or stereoisomer thereof, or a pharmaceutically acceptable salt thereof, is contacted to inhibit adenosine A2A and / or A1 receptors.

[0294] Item 99. 99. The method of item 98, wherein the sample is in vitro.

[0295] Item 100. A method of antagonizing adenosine A2A and / or A1 receptors comprising: Cells containing adenosine A2A and / or A1 receptors are treated with an effective amount of a compound according to any one of items 1-94, or a solvate, hydrate, prodrug and / or stereoisomer thereof , or a pharmaceutically acceptable salt thereof, to antagonize adenosine A2A and / or A1 receptors.

[0296] Item 101. 101. The method of item 100, wherein the cells are included in the sample of cells in vitro.

[0297] Item 102. 101. The method of item 100, wherein the cell is contained in a biological system in vivo.

[0298] Item 103. A therapeutically effective amount of an A2A and / or A1 receptor antagonist compound according to any one of items 1-94, or a solvate, hydrate, prodrug and / or steric form thereof, to a subject with cancer A method of treating cancer comprising administering an isomer, or a pharmaceutically acceptable salt thereof.

[0299] Item 104. 104. The method of item 103, wherein the cancer is solid tumor cancer.

[0300] Item 105. Cancer, lung cancer, breast cancer, prostate cancer, ovarian cancer, soleoma, cervical cancer, bladder cancer, head and neck cancer, renal cell cancer, esophageal cancer, pancreatic cancer, brain cancer, liver cancer, leukemia, lymphoma, melanoma, multiple occurrences myeloma, Ewing's sarcoma, osteosarcoma, colorectal tumor, cholangiocarcinoma, choroidal carcinoma, oral carcinoma, neuroblastoma, skin cancer, testicular cancer, stromal tumor, germ cell tumor, and thyroid cancer, The method of item 103.

[0301] Item 106. 106. The method of item 105, wherein the cancer is liver cancer, which is hepatocellular carcinoma (HCC).

[0302] Item 107. 106. The method of item 105, wherein the cancer is lung cancer, non-small cell lung cancer (NSCLC).

[0303] Item 108. 108. The method of any one of items 103-107, further comprising co-administering to the subject an additional active agent.

[0304] Item 109. 109. The method of item 108, wherein the additional active agents are selected from anti-angiogenic agents, anti-inflammatory agents, immune checkpoint inhibitors, PARP inhibitors, chemotherapeutic agents and immuno-anticancer agents.

[0305] Item 110. 109. The method of item 109, wherein the additional active agent is an immune checkpoint inhibitor selected from CTLA-4 inhibitors, PD-1 inhibitors, and PD-L1 inhibitors.

[0306] Item 111. 111. The method of item 110, wherein the immune checkpoint inhibitor is an antibody or antibody fragment.

[0307] Item 112. A therapeutically effective amount of an A2A and / or A1 receptor antagonist compound according to any one of items 1-94, or a solvate, hydrate, prodrug, and / or thereof, to a subject having an inflammatory disease or a method of treating an inflammatory disease comprising administering a stereoisomer, or a pharmaceutically acceptable salt thereof.

[0308] Item 113. 113. The method of item 112, wherein the inflammatory disease is a chronic inflammatory disease.

[0309] Item 114. 113. The method of item 112, wherein the inflammatory disease is an acute inflammatory disease.

[0310] Item 115. A therapeutically effective amount of an A2A and / or A1 receptor antagonist compound according to any one of items 1-94, or a solvate thereof, in a subject having or at risk for central nervous system disease , hydrates, prodrugs, and / or stereoisomers, or pharmaceutically acceptable salts thereof.

[0311] Item 116. 116. The method of item 115, wherein the central nervous system disease is selected from Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, depression, schizophrenia, and epilepsy.

[0312] Item 117. 117. The method of item 116, wherein the central nervous system disease is Parkinson's disease.

[0313] Item 118. A compound according to any one of items 1 to 94, or a pharmaceutical composition according to item 95, for use in treating a disease selected from cancer, inflammatory disease and central nervous system disease.

[0314] Item 119. Use of the compound according to any one of items 1 to 94 or the pharmaceutical composition according to item 95 in the manufacture of a medicament for treating a disease selected from cancer, inflammatory disease and central nervous system disease.

[0315] Item 120. A compound of the formula: TIFF2023505915000064.tif2842 or a solvate, tertiary isomer, or pharmaceutically acceptable salt thereof; wherein Cy is a fused 5-membered heterocyclic ring (e.g., heteroaryl or heterocycloalkyl ring) containing at least one heteroatom selected from nitrogen, oxygen, and sulfur; R is R 11 , R 12 , and / or R 13 is a phenyl group substituted with; R. 11 , R 12 , and / or R 13 are each independently halogen, hydroxyl, thiol, carbonyl, amido, nitro, amino, substituted or unsubstituted (C 1 -C 5 ) alkyl group, substituted or unsubstituted (C2 -C 5 ) alkenyl groups, substituted or unsubstituted (C 2 -C 5 ) alkynyl groups, substituted or unsubstituted (C 1 -C 3 ) haloalkyl groups, and substituted or unsubstituted (C 1 -C 3 ) aminoalkyl group or substituted or unsubstituted (C 1 -C 5 ) alkoxy groups, and R. 10 is hydrogen, halogen, hydroxyl group, thiol group, substituted or unsubstituted (C 1 -C 5 ) alkyl group, substituted or unsubstituted (C 2 -C 5 ) alkenyl groups, substituted or unsubstituted (C 2 -C 5 ) alkynyl groups, substituted or unsubstituted (C 1 -C 3 ) haloalkyl groups, substituted or unsubstituted (C 1 -C 5 ) alkoxy groups, or one or more groups independently selected from cyano.

[0316] Item 121. Cy contains at least one heteroatom selected from nitrogen, oxygen, and sulfur to form a 5-membered heteroaryl ring fused with the atoms of the pyrimidine ring, and R is hydrogen, halogen, amino group, hydroxyl group, respectively. , a thiol group, (C 1 -C 5 ) alkyl group, (C 2 -C 5 ) alkenyl group, (C 2 -C 5 ) alkynyl group, (C 1 -C 3 ) haloalkyl group, (C 1 -C 3 ) aminoalkyl group, or (C 1 -C 5 ) R independently selected from alkoxy groups 11 , R 12 , and / or R 13 and each R10 is hydrogen, halogen, hydroxyl, thiol, (C 1 -C 5 ) alkyl group, (C 2 -C 5 ) alkenyl group, (C 2 -C 5 ) alkynyl group, (C 1 -C 3 ) haloalkyl group, (C 1 -C 5 ) A compound or solvate, three-dimensional isomer or pharmaceutically acceptable salt of item 120 independently selected from alkoxy groups and cyano.

[0317] Item 122. Cy contains at least one nitrogen atom and forms a 5-membered heteroaryl ring fused with the atoms of the pyrimidine ring, and R is the structure TIFF2023505915000065.tif2323, attached to the nitrogen atom of the Cy ring, and R 11 , R 12 , and / or R 13 are, respectively, hydrogen, halogen, amino group, (C 1 -C 5 ) alkyl group, (C 2 -C 5 ) alkenyl group, (C 2 -C 5 ) alkynyl group, (C 1 -C 3 ) haloalkyl group, (C 1 -C 3 ) aminoalkyl group, or (C 1 -C 5 ) is an alkoxy group and each R 10 is hydrogen, halogen, hydroxyl group, thiol group, (C 1 -C 5 ) alkyl group, (C 2 -C 5 ) alkenyl group, (C 2 -C 5 ) alkynyl group, (C 1 -C 3 ) haloalkyl group, (C 1 -C 5 ) A compound or solvate, three-dimensional isomer or pharmaceutically acceptable salt of item 120 independently selected from alkoxy groups and cyano.

[0318] Item 123. Cy contains at least one nitrogen atom and forms a 5-membered heteroaryl ring with the atoms of the pyrimidine ring, and R is TIFF2023505915000066.tif2323, attached to the nitrogen atom of the Cy ring, R. 11 and R 13 are hydrogen, halogen, and (C 1 -C 5 ) alkyl group, (C 2 -C 5 ) alkenyl group, (C 2 -C 5 ) alkynyl group, (C 1 -C 3 ) a haloalkyl group, or (C 1 -C 5 ) is an alkoxy group and R 12 teeth is hydrogen or an amino group, and each R 10 is hydrogen, halogen, (C 1 -C 5 ) alkyl group, (C 2 -C 5 ) alkenyl group, (C 2 -C 5 ) alkynyl group, (C 1 -C 3 ) haloalkyl group, (C 1 -C 5 ) A compound or solvate, three-dimensional isomer or pharmaceutically acceptable salt of item 120 independently selected from alkoxy groups and cyano.

[0319] Item 124. R. 11 and R 13 are hydrogen, halogen, and (C 1 -C 5 ) alkyl group, (C 2 -C 5 ) alkenyl group, (C 2 -C 5 ) alkynyl group, (C 1 -C 3 ) a haloalkyl group, or (C 1 -C 5 ) alkoxy group, R 12 is a hydrogen or amino group, R 10 is hydrogen, halogen, (C 1 -C 5 ) alkyl group, (C 2 -C 5 ) alkenyl group, (C 2 -C 5 ) alkynyl group, (C 1 -C 3 ) a haloalkyl group, or (C 1 -C 5 ) compounds or solvates, three-dimensional isomers or pharmaceutically acceptable salts of item 123 independently selected from alkoxy groups, or cyano.

[0320] Item 125. R. 11 and R 13 are hydrogen, halogen, and C 1 -C 5 alkyl group, or C 1 -C 3 a haloalkyl group and R 12 is a hydrogen or amino group, and R 10 is hydrogen, halogen, C 1 -C 5 A compound or solvate, three-dimensional isomer or pharmaceutically acceptable salt of item 124 independently selected from an alkyl group, or cyano.

[0321] Item 126. Cy forms a pyrazolopyrimidine or purine with a pyrimidine chain attached to Cy, R is TIFF2023505915000067.tif2828 and is bonded to the nitrogen atom of Cy, R. 11 and R 13 are hydrogen, halogen, and C 1 -C 5 Alkyl group, C 2 -C 5 alkenyl group, C 2 -C 5 alkynyl group, C 1 -C 3 haloalkyl group, or C 1 -C 5 an alkoxy group and R 2 is a hydrogen or amino group, R. 10 is hydrogen, halogen, C 1 -C 5 Alkyl group, C 2 -C 5 alkenyl group, C 2 -C 5 alkynyl group, C 1 -C 3 haloalkyl group, C 1 -C 5 The compound or solvate, three-dimensional isomer or pharmaceutically acceptable salt of item 120, which is an alkoxy group, or a cyano group.

[0322] Item 127. R. 11 and R 13 are hydrogen, halogen, and C 1 -C 5 Alkyl group, C 2 -C 5alkenyl group, C 2 -C 5 alkynyl group, C 1 -C 3 haloalkyl group, or C 1 -C 5 an alkoxy group and R 2 is a hydrogen or amino group, R. 10 is hydrogen, halogen, C 1 -C 5 Alkyl group, C 2 -C 5 alkenyl, C 2 -C 5 alkynyl, C 1 -C 3 haloalkyl group, C 1 -C 5 The compound or solvate, three-dimensional isomer or pharmaceutically acceptable salt of item 126 that is alkoxy or cyano.

[0323] Item 128. A compound of item 120, or a solvate, three-dimensional isomer or pharmaceutically acceptable salt thereof, wherein said compound is selected from the group consisting of: 3-(6-amino-1-(4-aminobenzyl)-1H-pyrazolo-[3,4-d]-pyrimidin-4-yl)-benzonitrile; 3-(6-amino-1-(4-aminobenzyl)-1H-pyrazolo-[3,4-d]-pyrimidin-4-yl)-2-methylbenzonitrile; 3-(6-amino-1-(4-aminobenzyl)-1H-pyrazolo-[3,4-d]-pyrimidin-4-yl)-2-fluorobenzonitrile; 3-(2-amino-9-(4-aminobenzyl)-9H-purin-6-yl)-benzonitrile; 3-(2-amino-9-(4-aminobenzyl)-9H-purin-6-yl)-2-fluorobenzonitrile; 3-(2-amino-9-(4-aminobenzyl)-9H-purin-6-yl)-2-methylbenzonitrile; 3-(2-amino-9-(4-amino-2,6-difluorobenzyl)-9H-purin-6-yl)-benzonitrile; 3-(2-amino-9-(4-amino-2,6-difluorobenzyl)-9H-purin-6-yl)-2-fluorobenzonitrile; 3-(2-amino-9-(4-amino-2-fluorobenzyl)-9H-purin-6-yl)-benzonitrile; 3-(2-amino-9-(4-amino-2-fluorobenzyl)-9H-purin-6-yl)-2-fluorobenzonitrile; 3-(2-amino-9-(4-amino-3-methylbenzyl)-9H-purin-6-yl)-benzonitrile; 3-(2-amino-9-(4-amino-3-methylbenzyl)-9H-purin-6-yl)-2-fluorobenzonitrile; 3-(2-amino-9-(2,6-difluorobenzyl)-9H-purin-6-yl)-benzonitrile; 3-(2-amino-9-(2,6-difluorobenzyl)-9H-purin-6-yl)-2-fluorobenzonitrile; and 3-(2-amino-9-(2,6-difluorobenzyl)-9H-purin-6-yl)-2-methylbenzonitrile.

[0324] Item 129. A medicament for preventing or treating cancer comprising an effective amount of a compound of any one of paragraphs 119 to 127, or a solvate, three-dimensional isomer, or pharmaceutically acceptable salt thereof Composition.

[0325] Item 130. The pharmaceutical composition according to item 129, wherein the composition has an antagonistic effect on adenosine A2A receptors.

[0326] Item 131. Cancer, lung cancer, breast cancer, prostate cancer, ovarian cancer, soleoma, cervical cancer, bladder cancer, head and neck cancer, renal cell cancer, esophageal cancer, pancreatic cancer, brain cancer, liver cancer, leukemia, lymphoma, melanoma, multiple occurrences is myeloma, Ewing sarcoma, osteosarcoma, colorectal tumor, bile duct cancer, choroidal cancer, oral cancer, neuroblastoma, skin cancer, testicular cancer, stromal tumor, germ cell tumor, or thyroid cancer, Section 129 The pharmaceutical composition according to the paragraph.

[0327] Item 132. 130. The pharmaceutical composition according to item 129, wherein the composition is administered simultaneously, separately or sequentially with another anti-cancer agent.

[0328] Item 133. 130. The pharmaceutical composition according to item 129, wherein the composition is manufactured in a pharmaceutically acceptable form, which is a tablet, pill, powder, capsule, syrup, emulsion or microemulsion.

Example

[0329] The following examples are provided to illustrate the disclosure and should in no way be construed as limiting the scope of the technology. All methods that are functionally equivalent are within the scope of the present technology. Various modifications of the technology, in addition to those described herein, will become apparent to those skilled in the art from the foregoing description. Such modifications fall within the scope of the appended claims.

[0330] All temperatures are in degrees Celsius unless otherwise stated. Efforts have been made to ensure accuracy with respect to numbers used (amounts, temperature, etc.) but some experimental errors and deviations should be allowed for.

[0331] If an abbreviation is not defined, it has its generally accepted meaning. General synthetic method

[0332] The final compound was confirmed by high performance liquid chromatography / mass spectroscopy (HPLC / MS) analysis and judged to be >90% pure by weight. 1 The H nuclear magnetic resonance (NMR) spectrum was obtained from CDCl 3 (residual internal standard CHCl 3 = δ7.26), dimethylsulfoxide (DMSO)-d 6 (residual internal standard CD 3 SCCD 2 H=δ2.50), methanol-d 4 (residual internal standard CD 2 HOD=δ3.30), or acetone-d 6 (residual internal standard CD 3 C C D 2 H=δ2.05). Reported chemical shifts (δ) are given in parts per million (ppm) and coupling constants (J) are given in Hertz (Hz). Spin multiplicity is s=singlet, bs=broad singlet, bm=broad multiplet, d=doublet, t=triplet, q=quartet, p=quintet, dd=doublet. doublet, ddd = doublet doublet of doublets, dt = doublet of triplet, td = triplet of doublet, tt = triplet of triplet, m = multiplet.

[0333] HPLC-MS analysis was performed using gradient elution. Medium pressure liquid chromatography (MPLC) was performed using silica gel columns in both normal and reverse phase. Example 1: Preparation of compounds

[0334] The compounds of the present disclosure are made by adapting well-known chemical transformations according to the methods illustrated by Schemes 1 or 2 below. Syntheses of some exemplary compounds of Table 1 are described in Examples 1.1 to 1.69 below. Several other compounds in Table 1 were prepared by adapting the methods described herein and evaluated according to the biological assays described in Examples 2-4.

[0335] General scheme 1 An exemplary synthetic method for TIFF2023505915000068.tif79161 Scheme 1 is described in detail below.

[0336] To illustrate in more detail with reference to Scheme 1 above, compound A-2 was dissolved in a solvent of tetrahydrofuran and water and compound of Scheme A-3 was reacted with hydrazine monohydrate from 25°C to 60°C. A first step produced by chain reaction for 24 hours at °C and A-3 compound is dissolved in N,N-dimethylformamide solvent, then potassium carbonate or cesium carbonate is provided, and the solution is heated to 25°C. a second step of nucleophilic substitution reaction with the compound of Scheme A-4 at 60° C. to 60° C. for 24 hours to produce the compound of Scheme A-5; 3-(4,4,5,5-Tetramethyl-1, dissolved in water, was subjected to a Suzuki coupling reaction with the compound of Scheme A-6 at 100°C to 115°C for 2 hours to 24 hours. ,3,2-dioxaborolan-2-yl)benzonitrile and its derivatives, and tetrakis(triphenylphosphine)palladium and sodium carbonate are reacted under conditions provided, or solutions thereof undergo Suzuki coupling under the same conditions. a third step of reacting and dissolving the solution in an ethanol solvent, and producing the A compound under conditions where the solution undergoes a reduction reaction of tin(II) chloride dihydrate and acid conditions. Through a series of processes, it is possible to prepare the compounds shown by Scheme 1 above. where R in scheme 1 above a1 , R a2 , R a3 , R a4 , and R a5 is a substituent of the formulas described herein, for example R 1 or R 9 , and cyano groups.

[0337] General scheme 2 An exemplary synthetic method for TIFF2023505915000069.tif74161 Scheme 2 is described in detail below.

[0338] B-1 compound is dissolved in N,N-dimethylformamide solvent and subjected to nucleophilic substitution with the compound of scheme A-4 at 25°C to 60°C for 24 hours under conditions provided with potassium carbonate or cesium carbonate. a first step of reacting the solution to the reaction to produce the B-2 compound, and dissolving the B-2 compound in a solvent of 1,4-dioxane and distilled water and applying the solution to the compound of Scheme A-6; 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile and its The derivative, tetrakis(triphenylphosphine)palladium, and sodium carbonate are reacted under conditions provided, or the solution undergoes a Suzuki coupling reaction under the same conditions, the solution is dissolved in ethanol solvent, and the solution of which is tin(II) chloride dihydrate and a second step under acidic conditions to reduce the solution to form the B compound, through a series of processes comprising: It is possible to manufacture where R in scheme 2 above a1 , R a2 , R a3 , R a4 , and R a5 is a substituent of the formulas described herein, for example R of formula (IIa) 1 or R 9 , and cyano groups.

[0339] Example 1.1: Preparation of 3-(6-amino-1-(4-aminobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)benzonitrile (Compound 201)

[0340] 1.1.1. Preparation of 4-chloro-(4-nitrobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine TIFF2023505915000070.tif36130 Reagents and Conditions: (a) Hydrazine, TEA, THF:H 2 O (3:1), room temperature to 50°C, 3 hours, quant; (b) 4-nitrobenzyl bromide, K 2 CO 3 , DMF, 0° C. to RT, 12 h, 58%.

[0341] Step 1: Preparation of 4-chloro-1H-pyrazolo[3,4-d]pyrimidin-6-amine

[0342] 2-Amino-4,6-dichloropyrimidine-5-carbaldehyde (S1, 4 g, 20.83 mmol) was treated with tetrahydrofuran (THF) and H 2 The hydrazine monohydrate (0.78 ml, 24.99 mmol) and triethylamine (TEA, 3.51 ml, 24.99 mmol) were added, dissolved in a solvent of O. The above reaction mixture was then heated to 50° C., stirred for 3 hours and concentrated. The above concentrate was then washed and distilled with distilled water to give the intermediate compound (S2, 3.45g, 100%). 1 H-NMR (DMSO-d 6 , 400 MHz): δ 13.25 (s, 1H), 8.02 (s, 1H), 7.14 (s, 2H).

[0343] Step 2: Preparation of 4-chloro-1-(4-nitrobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine

[0344] The intermediate compound (S2, 3.0 g, 18.12 mmol) produced in Step 1 above was dissolved in dimethylformamide (DMF), 4-nitrobenzyl bromide (3.92 g, 18.12 mmol) and treated with potassium carbonate (K 2 CO 3 , 3.75 g, 27.18 mmol) was added to this. Then it was stirred at room temperature for 12 hours. The above reaction mixture was diluted with ethyl acetate (EA) and washed by distillation. It was then dried over magnesium sulfate, filtered and concentrated. The above concentrate was then purified by silica gel chromatography to give the desired compound (S3, 3.2g, 58%). 1 H-NMR (DMSO-d 6 , 400 MHz): δ 8.19 (d, 2H), 8.09 (s, 1H), 7.40-7.38 (m, 4H), 5.56 (s, 2H).

[0345] 1.1.2. Preparation of 3-(6-amino-1-(4-aminobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)benzonitrile (compound 201). TIFF2023505915000071.tif36161 Reagents and conditions: (c) 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile, Pd(PPh 3 ) 4 , Na 2 CO 3 , dioxane: H 2 O(8:1), rt to 105 °C, 12 h, 70%; (d) SnCl 2 .2H 2 O, conc. HCl, EtOH, rt to 50° C., 3 h, 45%.

[0346] Step 1: Preparation of 3-(6-amino-1-(4-nitrobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)benzonitrile

[0347] The compound (S3, 1.0 g, 3.28 mmol) of Example 1-1 above was treated with 1,4-dioxane and H 2 dissolved in O and 3-(4,4,5,5-tetramethyl-1,3,2-dioxaneborolan-2-yl)benzonitrile (1.12 g, 4.92 mmol), tetrakis(triphenylphosphine) Palladium((0)(Pd(PPh 3 ) 4 , 758 mg, 0.65 mmol), and sodium carbonate (Na 2 CO 3 , 695 mg, 6.56 mmol) was added to this. The above reaction mixture was then stirred using a sealed tube at 105° C. for 12 hours, then diluted with dichloromethane (DCM), which was then washed with distilled water. It was then dried over magnesium sulfate, then filtered and concentrated, and the previous concentrate was washed with ethyl acetate / hexane (EA / Hex) to give intermediate compound (S4, 852 mg, 70%). rice field. 1 H-NMR (DMSO-d 6 , 400 MHz): 8.54 (s, 1H), 8.51-8.49 (m, 2H), 8.08 (dd, 1H), 7.80 (t, 1H), 7.42 (d, 2H), 7.15 (s, 2H), 5.62(s, 2H).

[0348] Step 2: Preparation of 3-(6-amino-1-(4-aminobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)benzonitrile

[0349] The intermediate compound (S4, 400 mg, 1.07 mmol) produced in Step 1 above was dissolved in ethanol (EtOH) and then tin(II) chloride dihydrate (SnCl 2 2H 2 O, 730 mg, 3.23 mmol) and concentrated HCl (aq) (1.8 mL, 21.54 mmol) were added to it. The above reaction mixture was then stirred at 50° C. for 3 hours, then diluted with dichloromethane (DCM) and washed with distilled water. It was then dried over magnesium sulfate, then dried, filtered and concentrated. The above concentrate was then purified by silica gel chromatography to give the desired compound (201, 161 mg, 45%). 1 H-NMR (DMSO-d 6 8.50(s, 1H), 8.48-8.45(m, 1H), 8.35(s, 1H), 8.07-8.04(m, 1H), 7.79(t, 1H), 7.07(s, 2H) ), 6.95 (d, 2H), 6.47 (d, 2H), 5.23 (s, 2H), 5.04 (s, 2H).

[0350] Example 1.2: Preparation of 3-(6-amino-1-(4-aminobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-2-methylbenzonitrile (Compound 205) TIFF2023505915000072.tif36161 Reagents and conditions: (a) 2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile, Pd(PPh 3 ) 4 , Na 2 CO 3 , dioxane: H 2 O(8:1), rt to 105 °C, 12 h, 81%; (b) SnCl 2 .2H 2 O, concentrated HCl, EtOH, rt to 50° C., 3 h, 74%.

[0351] Step 1: Preparation of 3-(6-amino-1-(4-nitrobenzyl[3,4-d]pyrimidin-4-yl)-2-methylbenzonitrile

[0352] In step 1 of Example 1.1.2 above, instead of 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile (1.12 g, 4.92 mmol) Example 1.1 above, except using 2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxyborolan-2-yl)benzonitrile (120 mg, 0.49 mmol). Using the same process as in step 1 of .2, intermediate compound (S5, 103 mg, 81%) was obtained. 1 H-NMR (DMSO-d6 , 400 MHz): δ 8.21 (d, 2H), 7.97 (d, 1H), 7.90 (s, 1H), 7.82 (d, 1H), 7.56 (t, 1H), 7.46 (d, 2H), 7.13 ( s, 2H), 5.59 (s, 2H), 2.52 (s, 3H)

[0353] Step 2: Preparation of 3-(6-amino-1-(4-aminobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-2-methylbenzonitrile

[0354] In step 2 of Example 1.2 above, tin(II) chloride dihydrate (SnCl 2 .2H 2 O, 180 mg, 0.80 mmol) and conc. (S5, 103 mg, 0.26 mmol) to give the desired compound (205, 71 mg, 74%). 1 H-NMR (DMSO-d 6 , 400MHz): δ7.95(d, 1H), 7.79(d, 1H), 7.77(s, 1H), 7.54(t, 1H), 7.05(s, 2H), 6.98(d, 2H), 6.48( d, 2H), 5.21 (s, 2H), 5.04 (s, 2H), 2.49 (s, 3H).

[0355] Example 1.3: Preparation of 3-(6-amino-1-(4-aminobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-2-fluorobenzonitrile (Compound 202) TIFF2023505915000073.tif36161 Reagents and conditions: (a) 2-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile, Pd(PPh 3 ) 4 , Na 2 CO 3 , dioxane: H 2 O(8:1), rt to 105 °C, 12 h, 90%; (b) SnCl 2 .2H 2 O, conc. HCl, EtOH, rt to 50° C., 3 h, 92%.

[0356] Step 1: Preparation of 3-(6-amino-1-(4-nitrobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-2-fluorobenzonitrile In step 1 of Example 1.1.2 above, instead of 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile (1.12 g, 4.92 mmol) except that 2-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile (1.21 g, 4.92 mmol) was used, and tetrakis ( Triphenylphosphine)palladium(0)(Pd(PPh 3 ) 4 , 758 mg, 0.65 mmol) and sodium carbonate (Na 2 CO 3 The intermediate compound (S6, 1.15 g, 90%) was obtained by carrying out the same process as in Step 1 of Example 1.1.2 above, except that the amount was changed by S6, 695 mg, 6.56 mmol). 1 H-NMR (DMSO-d 6 .

[0357] Step 2: Preparation of 3-(6-amino-1-4(4-aminobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-2-fluorobenzonitrile

[0358] In step 2 of Example 1.1.2 above, tin(II) chloride dihydrate (SnCl 2 .2H 2 O, 250 mg, 1.11 mol) and conc. The compound (S6, 144mg, 0.37mmol) gave the desired compound (202, 131mg, 92%). 1 H-NMR (DMSO-d 6 , 400MHz): δ8.14(t, 2H) 7.96(d, 1H), 7.11(s, 2H), 6.96(d, 2H), 6.48(d, 2H), 5.22(s, 2H), 5.04(s , 2H).

[0359] Example 1.4: Preparation of 3-(2-amino-9-(4-aminobenzyl)-9H-purin-6-yl)benzonitrile (Compound 101)

[0360] 1.4.1. Preparation of 6-chloro-9(4-nitrobenzyl)-9H-purin-2-amine TIFF2023505915000074.tif3687 Reagents and conditions: (a) 4-nitrobenzyl bromide, K 2 CO 3 , DMF, room temperature.

[0361] 6-Chloro-9H-purin-2-amine (S12, 3 g, 18.12 mmol) was dissolved in N,N-dimethylformamide (DMF) and 4-nitrobenzyl bromide (4.1 g, 19.30 mmol) and potassium carbonate was added. (K 2 CO 3 , 3.76 g, 27.18 mmol) was added. The mixture was then stirred at room temperature. The above reaction mixture was then diluted with dichloromethane (DCM) and washed with distilled water. It was then dried over magnesium sulfate, filtered and concentrated, and the above concentrate was purified by silica gel chromatography to give intermediate compound (S8, 395 mg, 42%). 1 H-NMR (DMSO-d 6 , 400 MHz): δ 8.27 (s, 1H), 8.22-8.20 (m, 2H), 7.47-7.45 (m, 2H), 6.96 (s, 2H), 5.46 (s, 2H).

[0362] 1.4.2.3-(2-Amino-9-(4-aminobenzyl)-9H-purin-6-yl)benzonitrile Preparation TIFF2023505915000075.tif28170 Reagents and conditions: (a) H 2 Pd(PPh in O,1,4-dioxane 3 ) 4 , Na 2 CO 3 , microwave, 105 °C, 30 min. (b) SnCl 2 2H 2 O, concentrated HCl(aq), EtOH, 55° C., 4 hours.

[0363] Step 1: Preparation of 3-(2-amino-9-(4-nitrobenzyl)-9H-purin-6-yl)benzonitrile

[0364] Intermediate compound (S8, 200 mg, 0.652 mmol) was dissolved in 1,4-dioxane and 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile ( 224 mg, 0.978 mmol) and tetrakis(triphenylphosphine)palladium(0)((Pd(PPh 3 ) 4 , 151 mg, 0.131 mmol), and sodium carbonate (Na 2 CO 3 , 139 mg, 1.304 mmol) was added, then the solution was heated using a microwave at 105° C. and stirred for 30 minutes. The above reaction mixture was then diluted with dichloromethane (DCM) and washed with distilled water. It was then dried over magnesium sulfate, filtered and concentrated, and the above concentrate was purified by silica gel chromatography to give intermediate compound (S9, 395mg, 54%). 1 H-NMR (DMSO-d 6 , 400MHz): δ9.10-9.08(m, 1H), 9.05-9.02(m, 1H), 8.39(s, 1H), 8.22(d, 2H), 8.03-8.01(m, 1H), 7.80(t , 1H), 7.51-7.49 (m, 2H), 6.73 (s, 2H), 5.53 (s, 2H).

[0365] Step 2: Preparation of 3-(2-amino-9-(4-aminobenzyl)-9H-purin-6-yl)benzonitrile

[0366] The intermediate compound (S9, 244 mg, 0.624 mmol) produced in Step 1 above was dissolved in ethanol (EtOH) and tin(II) chloride dihydrate (SnCl 2 .2H 2 O, 423 mg, 1.872 mmol) and concentrated HCl (aq) (1.1 mL, 12.48 mmol) were added and the solution was stirred at 55° C. for 4 hours. The above reaction mixture was then diluted with dichloromethane (DCM) and then washed with distilled water. The solution was then dried over magnesium sulfate, filtered, concentrated and the previous concentrate was purified by silica gel chromatography to give the desired compound (101, 41 mg, 38%). 1 H-NMR (DMSO-d 6 , 400 MHz): δ 9.07 (s, 1H), 9.02 (d, 1H), 8.24 (s, 1H), 8.00 (d, 1H), 7.78 (t, 1H), 7.05-7.03 (m, 2H), 6.69 (br, 2H), 6.52-6.50 (m, 2H), 5.11 (d, 4H).

[0367] Example 1.5: Preparation of 3-(2-amino-9-(4-aminobenzyl)-9H-purin-6-yl)-2-fluorobenzonitrile (Compound 102) TIFF2023505915000076.tif28161 Reagents and conditions: (a) H 2 Pd(PPh 3 ) 4 , Na 2 CO 3 , microwave, 105 °C, 1 h. (b) SnCl 2 .2H 2 O, concentrated HCl(aq), EtOH, 55° C., 4 hours.

[0368] Step 1: Preparation of 3-(2-amino-9-(4-nitrobenzyl)-9H-purin-6-yl)-2-fluorobenzonitrile

[0369] 2-Fluoro -3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile (224 mg, 0.978 mmol) was used as in Example 1.1 above. The same process as 1 was performed to give the intermediate compound (S10, 395mg, 54%). 1 H-NMR (DMSO-d 6 , 400MHz): 8.29(s, 1H), 8.27-8.17(m, 2H), 8.13-8.07(m, 1H), 7.65-7.50(m, 4H), 6.78(d, 2H), 5.51(d , 2H).

[0370] Step 2: Preparation of 3-(2-amino-9-(4-aminobenzyl)-9H-purin-6-yl)-2-fluorobenzonitrile

[0371] The same process as in Step 2 of Example 1.1 above was performed on the intermediate compound of Step 1 above (S10, 244 mg, 0.624 mmol) to give the desired compound (102, 52 mg, 48%) . 1 H-NMR (DMSO-d 6 , 400MHz): 8.22-8.13 (m, 2H), 8.13-8.07 (m, 1H), 7.57 (t, 1H), 7.05 (d, 2H), 6.73 (s, 2H), 6.51 (d, 2H) ), 5.11 (d, 4H).

[0372] Example 1.6: Preparation of 3-(2-amino-9-(4-aminobenzyl)-9H-purin-6-yl)-2-methylbenzonitrile (Compound 105) TIFF2023505915000077.tif28161 Reagents and conditions: (a) H 2 Pd(PPh 3 ) 4 , Na 2 CO 3 , Microwave, T=105 °C, 1 h. (b) SnCl 2 .2H 2 O, concentrated HCl(aq), EtOH, 55° C., 4 hours.

[0373] Step 1: Preparation of 3-(2-amino-9-(4-nitrobenzyl)-9H-purin-6-yl)-2-methylbenzonitrile

[0374] 2-Methyl -3-(4,4,5,5,5,-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile (224 mg, 0.978 mmol) Intermediate compound (S11, 395 mg, 54%) by following the same process as step 1 of 1.1. 1 H-NMR (DMSO-d 6 , 400MHz): δ8.27-8.22(m, 2H), 7.83(d, 1H), 7.88(d, 1H), 7.65-7.52(m, 4H), 6.71(s, 2H), 5.50(s, 2H) ).

[0375] Step 2: Preparation of 3-(2-amino-9-(4-aminobenzyl)-9H-purin-6-yl)-2-methylbenzonitrile

[0376] The same process as in Step 2 of Example 1.1 above was performed on the intermediate compound of Step 1 above (S11, 244 mg, 0.624 mmol) to give the desired compound (105, 52 mg, 48%) . 1 H-NMR (DMSO-d 6 , 400 MHz): 8.10 (d, 1H), 7.91 (d, 1H), 7.83 (d, 1H), 7.51 (t, 1H), 7.06 (d, 2H), 6.66 (s, 2H), 6.55- 6.46 (m, 2H), 5.10 (d, 4H), 3.32 (s, 3H).

[0377] Example 1.7: Preparation of 3-(2-amino-9-(4-amino-2,6-difluorobenzyl)-9H-purin-6-yl)benzonitrile (Compound 107) TIFF2023505915000078.tif36117 TIFF2023505915000079.tif36117 Reagents and conditions: (a) 2-(bromomethyl)-1,3-difluoro-5-nitrobenzene, K 2 CO 3 , DMF, room temperature, overnight; (b) Pd(PPh 3 ) 4 , K 2 CO 3 , 1,4-dioxane, H 2 O, 115°C, 4 hours; (c) SnCl 2 .2H 2 O, concentrated HCl(aq), EtOH, 55° C., 4 hours.

[0378] Step 1: Preparation of 6-chloro-9-(2,6-difluoro-4-nitrobenzyl)-9H-purin-2-amine

[0379] 6-Chloro-9H-purin-2-amine (S12, 500 mg, 2.95 mmol) dissolved in dimethylformamide (DMF) and 2-(bromomethyl)-1,3-difluoro-5-nitrobenzene (817.4 mg, 3.24 mmol) and potassium carbonate (K 2 CO 3 , 611.6 mg, 4.43 mmol) was added and the solution was stirred at room temperature for 1 day. The above reaction mixture was then diluted with dichloromethane (DCM), then washed with distilled water, dried over magnesium sulfate, filtered, concentrated, and the above concentrate was purified by silica gel chromatography to yield the intermediate. Compound (S13, 300 mg, 33%) was obtained. 1 H-NMR (DMSO-d 6 , 400 MHz): δ 8.68 (s, 1H), 7.55 (d, 2H), 6.93 (s, 2H), 4.99 (s, 2H).

[0380] Step 2: Preparation of 3-(2-amino-9-(2,6-difluoro-4-nitrobenzyl)-9H-purin-6-yl)benzonitrile

[0381] The intermediate compound (S13, 150 mg, 0.44 mmol) produced in step 1 above was dissolved in 1,4-dioxane and 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane -2-yl)benzonitrile (151mg, 0.66mmol), tetrakis(triphenylphosphine)palladium(0)(Pd(PPh 3 ) 4 , 25.4 mg, 0.022 mmol), and potassium carbonate (K 2 CO 3 , 121.6 mg, 0.88 mmol) was added, heated at 115° C. and stirred for 4 hours. The above reaction mixture was then diluted with dichloromethane (DCM), then washed with distilled water, dried over magnesium sulfate, filtered, concentrated, and the above concentrate was purified by silica gel chromatography to yield the intermediate. Compound (S14, 95.5 mg, 53.3%) was obtained. 1 H-NMR (methanol-d 4 , 400 MHz): 8.98 (s, 1H), 8.93 (dd, 1H), 8.18 (s, 1H), 8.01-7.96 (m, 2H), 7.86 (dd, 1H), 7.70 (t, 1H), 5.56(s, 2H).

[0382] Step 3: Preparation of 3-(2-amino-9-(4-amino-2,6-difluorobenzyl)-9H-purin-6-yl)benzonitrile

[0383] The intermediate compound (S14, 95.1 mg, 0.23 mmol) produced in Step 2 above was dissolved in ethanol (EtOH) and to this was added tin(II) chloride dihydrate (SnCl 2 .2H 2 O, 263.4 mg, 1.17 mmol) was added and the solution was stirred at 55° C. for 4 hours. After that, the above reaction mixture was diluted with dichloromethane (DCM), then washed with distilled water, then dried over magnesium sulfate, filtered and concentrated, and the above concentrate was purified by silica gel chromatography. to give the desired compound (107, 38.7 mg, 44.6%). 1 H-NMR (DMSO-d 6 , 400 MHz): δ9.06 (s, 1H), 8.99 (dd, 1H), 8.05 (s, 1H), 7.98 (dd, 1H), 7.78 (t, 1H), 6.67 (s, 2H), 6.25- 6.18(m, 2H), 5.89(s, 2H), 5.17(s, 2H).

[0384] Example 1.8: Preparation of 3-(2-amino-9-(4-amino-2,6-difluorobenzyl)-9H-purin-6-yl)-2-fluorobenzonitrile (Compound 108) TIFF2023505915000080.tif28161 Reagents and conditions: (a) Pd(PPh 3 ) 4 , K 2 CO 3 1,4-dioxane, H 2 O, 115°C, overnight; (b) SnCl 2 .2H 2 O, concentrated HCl(aq), EtOH, 55° C., 3 hours.

[0385] Step 1: Preparation of 3-(2-amino-9-(2,6-difluoro-4-nitrobenzyl)-9H-purin-6-yl)-2-fluorobenzonitrile

[0386] 2-Fluoro -3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile (130.5 mg, 0.53) was used as in Example 1.4 above. The same process as 2 was carried out to give the intermediate compound (S15, 100mg, 53.4%). 1 H-NMR (CDCl 3 , 400MHz): δ8.15-8.13(m, 1H), 7.90-7.87(m, 3H), 7.75-7.74(m, 1H), 7.40(t, 1H), 5.54(s, 2H), 5.12(s , 2H).

[0387] Step 2: Preparation of 3-(2-amino-9-(4-amino-2,6-difluorobenzyl)-9H-purin-6-yl)-2-fluorobenzonitrile

[0388] The intermediate compound (S15, 100 mg, 0.24 mmol) produced in Step 1 above was dissolved in ethanol (EtOH) and tin(II) chloride dihydrate (SnCl 2 .2H 2 O, 265 mg, 1.18 mmol) was added to the solution and the solution was stirred at 50° C. for 3 hours. After that, the above reaction mixture was diluted with dichloromethane (DCM), then washed with distilled water, then dried over magnesium sulfate, filtered and concentrated, and the above concentrate was purified by silica gel chromatography. to give the desired compound (108, 32.9 mg, 34.7%). 1 H-NMR (methanol-d 4 , 400 MHz): δ 8.12-8.08 (m, 1H), 7.96-7.91 (m, 2H), 7.53 (t, 1H), 6.26 (d, 2H), 5.29 (s, 2H).

[0389] Example 1.9: Preparation of 3-(2-amino-9-(4-amino-2-fluorobenzyl)-9H-purin-6-yl)benzonitrile (Compound 109) TIFF2023505915000081.tif36115 TIFF2023505915000082.tif33110 Reagents and conditions: (a) 1-(bromomethyl)-2-fluoro-4-nitrobenzene, K 2 CO 3 , DMF, room temperature, overnight; (b) Pd(PPh 3 ) 4 , K 2 CO 3 , 1,4-dioxane, H 2 O, 115°C, 5 hours; (c) SnCl 2 .2H 2 O, EtOH, 50°C, 1 hour.

[0390] Step 1: Preparation of 6-chloro-9-(2-fluoro-4-nitrobenzyl)-9H-purin-2-amine

[0391] 6-Chloro-9H-purin-2-amine (S12, 500 mg, 2.95 mmol) was dissolved in dimethylformamide (DMF) and 1-(bromomethyl)-2-fluoro-4-nitrobenzene (758.2 mg, 3.24 mmol) and potassium carbonate (K 2 CO 3 , 611.6 mg, 4.43 mmol) was added to the solution and the solution was stirred for 1 day. Thereafter, the above reaction mixture was diluted with dichloromethane (DCM), then washed with distilled water, dried over magnesium sulfate, dried, filtered and concentrated, and the above concentrate was purified by silica gel chromatography. The intermediate compound (S16, 742 mg, 77%) was obtained. 1 H-NMR (DMSO-d 6 , 400 MHz): 8.23 ​​(s, 1H), 8.18 (dd, 1H), 8.03 (dd, 1H), 7.30 (t, 1H), 6.97 (s, 2H), 5.49 (s, 2H).

[0392] Step 2: Preparation of 3-(2-amino-9-(2-fluoro-4-nitrobenzyl)-9H-purin-6-yl)-benzonitrile

[0393] The intermediate compound (S16, 300 mg, 0.93 mmol) produced in step 1 above was treated with 1,4-dioxane and H 2 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-benzonitrile (318.4 mg, 1.39 mmol) and tetrakis(triphenylphosphine) to the solution. Palladium((0)Pd(PPh 3 ) 4 , 53.7 mg, 0.05 mmol), and potassium carbonate (K 2 CO 3 , 257 mg, 1.86 mmol) was added to the solution and the solution was heated to 115° C. and stirred for 5 hours. The above reaction mixture was then diluted with dichloromethane (DCM), washed with distilled water, dried over magnesium sulfate, filtered, concentrated, and the concentrate was purified by silica gel chromatography to give the intermediate compound. (S17, 162 mg, 44.8%) was obtained. 1 H-NMR (DMSO-d 6 , 400 MHz): δ9.09 (s, 1H), 9.02 (dd, 1H), 8.35 (s, 1H), 8.19 (dd, 1H), 8.06-8.01 (m, 2H), 7.81 (t, 1H), 7.31(t, 1H), 6.75(s, 2H), 5.55(s, 2H).

[0394] Step 3: Preparation of 3-(2-amino-9-(4-amino-2-fluorobenzyl)-9H-purin-6-yl)benzonitrile

[0395] The intermediate compound (S17, 89 mg, 0.23 mmol) produced in the second step above was dissolved in ethanol (EtOH) and then tin(II) chloride dihydrate (SnCl 2 .2H 2 O, 257 mg, 1.14 mmol) was added to the solution and the solution was stirred at 50° C. for 1 hour. The above reaction mixture was then diluted with dichloromethane (DCM), then washed with distilled water, dried over magnesium sulfate, filtered and concentrated, and the above concentrate was purified by silica gel chromatography to yield the desired product. (109, 19 mg, 23%) was obtained. 1 H-NMR (DMSO-d 6 , 400 MHz): δ 9.06 (s, 1H), 9.01 (d, 1H), 8.14 (s, 1H), 8.00 (d, 1H), 7.79 (t, 1H), 6.98 (t, 1H), 6.69 ( s, 2H), 6.32 (d, 2H), 5.48 (s, 2H), 5.16 (s, 2H).

[0396] Example 1.10: Preparation of 3-(2-amino-9-(4-amino-2-fluorobenzyl)-9H-purin-6-yl)-2-fluorobenzonitrile (Compound 103) TIFF2023505915000083.tif28161 Reagents and conditions: (a) Pd(PPh 3 ) 4 , K 2 CO 3 1,4-dioxane, H 2 O, 115°C, overnight; (b) SnCl 2 .2H 2 O, EtOH, 50°C, 3 hours.

[0397] Step 1: Preparation of 3-(2-amino-9-(2-fluoro-4-nitrobenzyl)-9H-purin-6-yl)-2-fluorobenzonitrile

[0398] In step 2 of Example 1.6 above, 2-fluoro- Step 2 of Example 1.6 above, except 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile (138 mg, 0.56 mmol) was used. The same process as was carried out to give the intermediate compound (S18, 80mg, 42.7%). 1 H-NMR (methanol-d 4 , 400 MHz): δ 8.21 (s, 1H), 8.15-8.07 (m, 3H), 7.98-7.93 (m, 1H), 7.59-7.52 (m, 2H), 5.60 (s, 2H).

[0399] Step 2: Preparation of 3-(2-amino-9-(4-amino-2-fluorobenzyl)-9H-purin-6-yl)-2-fluorobenzonitrile

[0400] In step 3 of Example 1.6 above, tin(II) chloride dihydrate (SnCl2 .2H 2 O, 180 mg, 0.80 mmol), the same process as in Step 3 of Example 1.6 above was carried out on the intermediate compound of Step 1 above (S18, 65 mg, 0.16 mmol), changing only the amount of The desired compound (103, 14.4mg, 24%) was obtained. 1 H-NMR (DMSO-d 6 , 400 MHz): 8.17 (t, 1H), 8.10 (t, 1H), 8.05 (s, 1H), 7.58 (t, 1H), 7.01 (t, 1H), 6.74 (s, 2H), 6.36- 6.32(m, 2H), 5.50(s, 2H), 5.15(s, 2H).

[0401] Example 1.11: Preparation of 3-(2-amino-9-(4-amino-3-methylbenzyl)-9H-purin-6-yl)benzonitrile (Compound 104) TIFF2023505915000084.tif36115 TIFF2023505915000085.tif33110 Reagents and conditions: (a) 4-(bromomethyl)-2-methyl-1-nitrobenzene, K 2 CO 3 , DMF, room temperature, overnight; (b) Pd(PPh 3 ) 4 , K 2 CO 3 , 1,4-dioxane, H 2 O, 115°C, 2 hours; (c) SnCl 2 .2H 2 O, EtOH, 55°C, overnight.

[0402] Step 1: Preparation of 6-chloro-9-(3-methyl-4-nitrobenzyl)-9H-purin-2-amine

[0403] 6-Chloro-9H-purin-2-amine (S12, 846 mg, 4.99 mmol) was dissolved in N,N-dimethylformamide (DMF) and 4-(bromomethyl)-2-methyl-1-nitrobenzene (1.263 g, 5.49 mmol) and potassium carbonate (K 2 CO 3 , 1.03 g, 7.49 mmol) was added to the solution and the solution was then stirred at room temperature for 1 day. The reaction mixture was then diluted with dichloromethane (DCM), washed with distilled water, dried over magnesium sulfate, filtered, concentrated, and the previous concentrate was purified by silica gel chromatography to yield intermediate compound (S19). , 1.28 g, 80.5%). 1 H-NMR (CDCl 3 , 400 MHz): δ 7.97 (d, 1H), 7.77 (s, 1H), 7.22-7.18 (m, 2H), 5.30 (s, 2H), 2.59 (s, 3H).

[0404] Step 2: Preparation of 3-(2-amino-9-(3-methyl-4-nitrobenzyl)-9H-purin-6-yl)benzonitrile

[0405] The intermediate compound (S19, 278 mg, 0.87 mmol) produced in Step 1 above was treated with 1,4-dioxane and H 2 3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-benzonitrile (300 mg, 1.31 mmol) and tetrakis(triphenylphosphine)palladium dissolved in a solvent of O (0)((Pd(PPh 3 ) 4 , 50.3 mg, 0.043 mmol), and potassium carbonate (K 2 CO 3 , 240.4 mg, 1.74 mmol) was added to the solution and the solution was heated to 105° C. and stirred for 2 hours. The above reaction mixture was then diluted with dichloromethane (DCM), washed with distilled water, dried over magnesium sulfate, filtered, concentrated, and the concentrate was purified by silica gel chromatography to give the intermediate compound. (S20, 143 mg, 42.7%) was obtained. 1 H-NMR (CDCl 3 , 400 MHz): δ 9.07 (s, 1H), 9.02 (d, 1H), 7.98 (d, 1H), 7.84 (s, 1H), 7.78 (d, 1H), 7.59-7.51 (m, 1H), 7.50-7.44(m, 2H), 5.36(s, 2H), 5.08(s, 2H), 2.59(s, 3H).

[0406] Step 3: Preparation of 3-(2-amino-9-(4-amino-3-methylbenzyl)-9H-purin-6-yl)benzonitrile

[0407] The intermediate compound (S20, 143 mg, 0.37 mmol) produced in step 2 above was dissolved in ethanol (EtOH) and tin(II) chloride dihydrate (SnCl 2 .2H 2 O, 418.6 mg, 1.86 mmol) was added and the solution was stirred at 55° C. for 1 day. The above reaction mixture was then diluted with dichloromethane (DCM), washed with dilute water, dried over magnesium sulfate, filtered, concentrated and the above concentrate was purified by silica gel chromatography to give the desired compound. (104, 23.6 mg, 18%) was obtained. 1 H-NMR (DMSO-d 6 , 400 MHz): δ 9.08 (s, 1H), 9.02 (d, 1H), 8.23 ​​(s, 1H), 7.99 (d, 1H), 7.79 (t, 1H), 6.96 (s, 1H), 6.91 ( d, 1H), 6.86 (s, 2H), 6.55 (d, 1H), 5.11 (s, 2H), 4.87 (s, 2H), 2.01 (s, 3H).

[0408] Example 1.12: Preparation of 3-(2-amino-9-(4-amino-3-methylbenzyl)-9H-purin-6-yl)-2-fluorobenzonitrile (Compound 106) TIFF2023505915000086.tif28158 Reagents and conditions: (a) Pd(PPh 3 ) 4 , K 2 CO 3 , 1,4-dioxane, H 2 O, 115°C, 2 hours; (c) SnCl 2 .2H 2 O, EtOH, 55 °C, overnight

[0409] Step 1: Preparation of 3-(2-amino-9-(3-methyl-4-nitrobenzyl)-9H-purin-6-yl)-2-fluorobenzonitrile

[0410] Intermediate compound (S19, 300 mg, 0.94 mmol) was reacted with 1,4-dioxane and H 2 O solvent, then 2-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile (349 mg, 1.41 mmol) and tetrakis ( Triphenylphosphine)palladium(0)((Pd(PPh 3 ) 4 , 54.3 mg, 0.05 mmol), and potassium carbonate (K 2 CO 3 , 260 mg, 1.88 mmol) was added to the solution and the solution was heated to 115° C. and stirred for 2 hours. The above reaction mixture was then diluted with dichloromethane (DCM), washed with distilled water, dried over magnesium sulfate, filtered, concentrated, and the concentrate was purified by silica gel chromatography to give the intermediate compound. (S21, 298.2 mg, 78.6%) was obtained. 1 H-NMR (CDCl 3 , 400MHz): δ8.22-8.16(m, 1H), 7.99(d, 1H), 7.83(s, 1H), 7.79(t, 1H), 7.70-7.64(m, 1H), 7.43(t, 1H) ), 7.25(s, 1H), 5.13(s, 2H), 2.60(s, 3H).

[0411] Step 2: Preparation of 3-(2-amino-9-(4-amino-3-methylbenzyl)-9H-purin-6-yl)-2-fluorobenzonitrile

[0412] The intermediate compound (S21, 298.2 mg, 0.74 mmol) produced in Step 1 above was dissolved in ethanol (EtOH) and then tin(II) chloride dihydrate (SnCl 2 .2H 2 O, 835 mg, 3.7 mmol) was added to the solution and the solution was stirred at 55° C. for 1 day. The above reaction mixture was then diluted with dichloromethane (DCM), washed with distilled water, dried over magnesium sulfate, filtered, concentrated and the concentrate was purified by silica gel chromatography to give the desired compound. (106, 98 mg, 35.5%) was obtained. 1 H-NMR (DMSO-d 6 , 400MHz): 8.19-8.14 (m, 2H), 8.10-8.07 (m, 1H), 7.57 (t, 1H), 6.97 (s, 1H), 6.92 (d, 1H), 6.73 (s, 2H) ), 6.55 (d, 1H), 5.09 (s, 2H), 4.88 (s, 2H), 2.01 (s, 3H).

[0413] Example 1.13: Preparation of 3-(2-amino-9-(2,6-difluorobenzyl)-9H-purin-6-yl)benzonitrile (Compound 112) TIFF2023505915000087.tif30153 Reagents and Conditions: (a) 2,6-difluorobenzyl bromide, K 2 CO 3 , DMF, room temperature, 4 h; (b) Pd(PPh 3 ) 4 , K 2 CO 3 , 1,4-dioxane, H 2 O, 115°C, overnight.

[0414] Step 1: Preparation of 6-chloro-9-(2,6-difluorobenzyl)-9H-purin-2-amine

[0415] 6-Chloro-9H-purin-2-amine (S12, 800 mg, 4.72 mmol) was dissolved in dimethylformamide (DMF), 2,6-difluorobenzyl bromide (1.46 g, 7.08 mmol) and potassium carbonate (K 2 CO 3 , 1.95 g, 14.16 mmol) was added to the solution and the solution was stirred at room temperature for 4 hours. The above reaction mixture was then filtered through a celite pad and the remaining liquid was diluted with ethyl acetate (EA). The solution was then washed with diluted water, then dried over sodium sulfate, filtered and concentrated, and the above concentrate was purified by silica gel chromatography to give intermediate compound (S22, 850 mg, 58% ). 1 H-NMR (DMSO-d 6 , 400 MHz): δ 8.10 (s, 1H), 7.49-7.46 (m, 1H), 7.15 (t, 2H), 6.68 (s, 2H), 5.35 (s, 2H).

[0416] Step 2: Preparation of 3-(2-amino-9-(2,6-difluorobenzyl)-9H-purin-6-yl)benzonitrile

[0417] The intermediate compound (S22, 100 mg, 0.31 mmol) produced in Step 1 above was treated with 1,4-dioxane and H 2 3-(4,4,5,5-tetramethyl-1,3,2)-dioxaborolan-2-yl)benzonitrile (85.2 mg, 0.37 mmol) and tetrakis(triphenylphosphine) dissolved in a solvent of O Palladium(0)((Pd(PPh 3 ) 4 , 18 mg, 0.02 mmol), and potassium carbonate (K 2 CO 3 , 85.7 mg, 0.62 mmol) and the solution was heated to 115° C. and stirred for 1 day. The above reaction mixture was then diluted with dichloromethane (DCM), washed with distilled water, dried over magnesium sulfate, filtered, concentrated and the concentrate was purified by silica gel chromatography to give the desired compound. (112, 81 mg, 89%) was obtained. 1 H-NMR (CDCl 3 , 400 MHz): δ 9.02 (s, 1H), 8.98 (dd, 1H), 7.87 (s, 1H), 7.75 (dd, 1H), 7.61 (t, 1H), 7.39-7.32 (m, 1H), 6.97(t, 2H), 5.39(s, 2H), 5.07(s, 2H).

[0418] Example 1.14: Preparation of 3-(2-amino-9-(2,6-difluorobenzyl)-9H-purin-6-yl)-2-fluorobenzonitrile (Compound 113) TIFF2023505915000088.tif36137 Reagents and conditions: (a) Pd(PPh 3 ) 4 , K 2 CO 3 , 1,4-dioxane, H 2 O, 115°C, overnight.

[0419] The intermediate compound (S22, 50 mg, 0.17 mmol) produced in Step 1 of Example 1.10 above was treated with 1,4-dioxane and H 2 2-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaneborolan-2-yl)benzonitrile (49.4 mg, 0.20 mmol), tetrakis, dissolved in a solvent of O (Triphenylphosphine)palladium(0)((Pd(PPh 3 ) 4 , 8.7 mg, 0.008 mmol), and potassium carbonate (K 2 CO 3 , 47 mg, 0.34 mmol) was added to the solution and the solution was heated to 115° C. and stirred for 1 day. The above reaction mixture was then diluted with dichloromethane (DCM), washed with dilute water, dried over magnesium sulfate, filtered, concentrated and the above concentrate was purified by silica gel chromatography to give the desired compound. (113, 45 mg, 70%) was obtained. 1 H-NMR (DMSO-d 6 , 400MHz): δ8.18-8.11(m, 1H), 8.10-8.08(m, 2H), 7.57(t, 1H), 7.51-7.46(m, 1H), 7.16(t, 2H), 6.73(s , 2H), 5.39(s, 2H).

[0420] Example 1.15: Preparation of 3-(2-amino-9-(2,6-difluorobenzyl)-9H-purin-6-yl)-2-methylbenzonitrile (Compound 114) TIFF2023505915000089.tif36140 Reagents and conditions: (a) Pd(PPh 3 ) 4 , K 2 CO 3 , 1,4-dioxane, H 2 O, 115°C, 4 hours.

[0421] The intermediate compound (S22, 50 mg, 0.17 mmol) produced in Step 1 of Example 1.10 above was treated with 1,4-dioxane and H 2 2-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaneborolan-2-yl)benzonitrile (48.6 mg, 0.20 mmol) and tetrakis dissolved in a solvent of O (Triphenylphosphine)palladium(0)((Pd(PPh 3 ) 4 , 8.7 mg, 0.008 mmol), and potassium carbonate (K 2 CO 3 , 47 mg, 0.34 mmol) was added and the solution was heated to 115° C. and stirred for 4 hours. The reaction mixture was then diluted with dichloromethane (DCM), washed with distilled water, dried over magnesium sulfate, filtered, concentrated, and the above concentrate purified by silica gel chromatography to give the desired compound (114). , 47.6 mg, 74%). 1 H-NMR (methanol-d 4 , 400 MHz): 8.07 (s, 1H), 7.83 (dd, 1H), 7.77 (dd, 1H), 7.54-7.46 (m, 2H), 7.07 (t, 2H), 5.50 (s, 2H), 2.51(s, 3H).

[0422] Example 1.16: Preparation of 3-[2-amino-9-[[4-amino-3-(trifluoromethyl)phenyl]methyl]purin-6-yl]benzonitrile (Compound 110) TIFF2023505915000090.tif69150 Reagents and conditions: (a) K 2 CO 3 , DMAc, 25 °C, 3 hours. (b) Pd(dppf)Cl 2 , K 2 CO 3 , dioxane / H 2 O, 110°C, 15 hours; (c) Fe, NH 4 Cl, EtOH / H 2 O, 80°C, 2 hours.

[0423] Step 1: Preparation of 6-chloro-9-[[4-nitro-3-(trifluoromethyl)phenyl]methyl]purin-2-amine.

[0424] Intermediate S12, 6-chloro-9H-purin-2-amine ( 1.79 g, 10.56 mmol) and K 2 CO 3 (2.92 g, 21.12 mmol) was added. The mixture was then stirred at 25° C. for 3 hours. After that, water (80 mL) was added to the mixture and extracted with ethyl acetate (80 mL×3). The organic phases were combined and washed with brine (150 mL×2), dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give a residue. The residue was purified by flash silica gel chromatography (80 g Sepa Flash® silica flash column, 20-100% ethyl acetate / petroleum ether gradient @ 60 mL / min eluent). Compound S23, 6-chloro-9-[[4-nitro-3-(trifluoromethyl)phenyl]methyl]purin-2-amine (2.5 g, 6.62 mmol, 63% yield, 98.7% purity) was obtained as a yellow Obtained as a solid. 1 H NMR (400 MHz, DMSO-d 6 ): 8.27 (s, 1H), 8.12 (d, J=8.3Hz, 1H), 8.05 (s, 1H), 7.67 (dd, J=8.3Hz, 1H), 6.97 (s, 2H), 5.50 (s, 2H). MS: m / z=373.0 (M+1, ESI+).

[0425] Step 2: Preparation of 3-[2-amino-9-[[4-nitro-3-(trifluoromethyl)phenyl]methyl]purin-6-yl]benzonitrile

[0426] Compound S23, 6-chloro-9-[[4-nitro-3-(trifluoromethyl)phenyl]methyl]purin-2-amine (2.5 g, 6.71 mmol, 1 eq.) in dioxane (40 mL) and water (10 mL) ), (3-cyanophenyl)boronic acid (1.97 g, 13.42 mmol, 2 eq), Pd(dppf)Cl 2 (490 mg, 670.80 μmol, 0.1 equiv) and K 2 CO 3(1.85 g, 13.42 mmol, 2 eq) was added. The mixture was then stirred at 110° C. for 15 hours. The mixture was concentrated in vacuo to give a residue. The residue was purified by flash silica gel chromatography (40 g Sepa Flash® silica flash column, 20-60% ethyl acetate / petroleum ether gradient @ 50 mL / min eluent). Compound S24, 3-[2-amino-9-[[4-nitro-3-(trifluoromethyl)phenyl]methyl]purin-6-yl]benzonitrile (2.3 g, 4.56 mmol, 68% yield, 87 % Purity) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 ): δ9.08 (t, J=1.5Hz, 1H), 9.02 (td, J=1.4, 8.0Hz, 1H), 8.38 (s, 1H), 8.13 (d, J=8.4Hz, 1H), 8.08 (d, J=1.2Hz, 1H), 8.01(td, J=1.3, 7.8Hz, 1H), 7.79(t, J=7.8Hz, 1H), 7.71(dd, J=1.5, 8.4Hz, 1H) , 6.73(s, 2H), 5.56(s, 2H). MS: m / z=440.0 (M+1, ESI+).

[0427] Step 3: Preparation of 3-[2-amino-9-[[4-amino-3-(trifluoromethyl)phenyl]methyl]purin-6-yl]benzonitrile 3-[2-amino-9-[[4-nitro-3-(trifluoromethyl)phenyl]methyl]purin-6-yl]benzonitrile (2.3 g, 4.55 g) in ethanol (30 mL) and water (6 mL) iron powder (1.27 g, 22.77 mmol, 5 eq) and NH 4 Cl (1.95 g, 36.44 mmol, 8 eq) was added. The mixture was then stirred at 80° C. for 2 hours. The reaction mixture was filtered and the filtrate was concentrated in vacuo. Water (80 mL) was added to the mixture and extracted with ethyl acetate (80 mL×3). The combined organic phases were filtered and concentrated in vacuo to give a residue. The residue was purified by preparative HPLC (column: Welch Ultimate XB-CN 250*70*10 μm; mobile phase: [hexane-EtOH (0.1% ammonium hydroxide)]; B%: 30%-70%, 15 min). and got the product. The product was purified by recrystallization from THF (20 mL) at 70° C. to give crude product. The crude product was purified by preparative HPLC (column: Welch Ultimate XB-SiOH 250*50*10um; mobile phase: [hexane-EtOH (0.1% ammonium hydroxide)]; B%: 5%-45%, 15 min). Refined. Compound 110 or 3-[2-amino-9-[[4-amino-3-(trifluoromethyl)phenyl]methyl]purin-6-yl]benzonitrile (602.34 mg, 1.44 mmol, 32% yield, 97.62 % purity) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 )δ=9.07(s, 1H), 9.01(brd, J=7.9Hz, 1H), 8.30(s, 1H), 8.00(brd, J=7.7Hz, 1H), 7.78(t, J=7.9Hz, 1H), 7.41(s, 1H), 7.29(brd, J=8.6Hz, 1H), 6.79(d, J=8.6Hz, 1H), 6.71(s, 2H), 5.65(s, 2H), 5.19( s, 2H). HRMS-TOF: 410.1347

[0428] Example 1.17: Preparation of 3-[2-amino-9-[[4-amino-3-(trifluoromethyl)phenyl]methyl]purin-6-yl]2-fluorobenzonitrile (Compound 111) TIFF2023505915000091.tif44154 Reagents and conditions: (a) Pd(PPh 3 ) 4 , K 2 CO 3 , dioxane / H 2 O, 110°C, 15 hours; (b) Fe, NH 4 Cl, EtOH / H 2 O, 60°C, 1 hour.

[0429] Step 1: Preparation of 3-[2-amino-9-[[4-nitro-3-(trifluoromethyl)phenyl]methyl]purin-6-yl]-2-fluorobenzonitrile

[0430] (3-Cyano-2-fluorophenyl)boronic acid (265 mg, 1.61 mmol, 1.5 equiv) in dioxane (10 mL) and water (1 mL), intermediate compound S23 or 6-chloro-9-[[4-nitro- 3-(Trifluoromethyl)phenyl]methyl]purin-2-amine (400mg, 1.07mmol), Pd(PPh 3 ) 4 (124 mg, 107.00 μmol) and K 2 CO 3 A mixture of (296 mg, 2.14 mmol) was degassed and purged with nitrogen three times, then the mixture was stirred at 100° C. under a nitrogen atmosphere for 15 hours. The reaction mixture was concentrated under reduced pressure to remove dioxane and water to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 12 g Sepa Flash® silica flash column, 0-100% ethyl acetate / petroleum ether gradient @ 35 mL / min eluent). Intermediate compound 3-[2-amino-9-[[4-nitro-3-(trifluoromethyl)phenyl]methyl]purin-6-yl]-2-fluorobenzonitrile (200 mg, 437.31 μmol, 41% yield). ) was obtained as a yellow solid. . MS: m / z=440.3 (M+1, ESI+).

[0431] Step 2: Preparation of 3-[2-amino-9-[[4-amino-3-(trifluoromethyl)phenyl]methyl]purin-6-yl]2-fluorobenzonitrile.

[0432] 3-[2-Amino-9-[[4-nitro-3-(trifluoromethyl)phenyl]methyl]purin-6-yl]-2-fluorobenzonitrile ( 300 mg, 655.97 μmol, 1 equiv) to NH 4 Cl (292 mg, 5.25 mmol, 8 eq) and iron powder (183 mg, 3.28 mmol, 5 eq) were added. The mixture was stirred at 60° C. for 1 hour. The reaction mixture was concentrated under reduced pressure to remove ethanol to give a residue. The residue was purified by preparative HPLC (column: Phenomenex Luna C18 150*25mm*10μm; mobile phase: [water (0.225% FA)-ACN]; B%: 40%-70%, 10 min). Compound 111 or 3-[2-amino-9-[[4-amino-3-(trifluoromethyl)phenyl]methyl]purin-6-yl]benzonitrile (75.32 mg, 175.81 μmol, 27% yield, 99.75 % Purity) was obtained as a white solid. 1 H NMR (400 MHz, DMSO-d 6 ): δ 8.21 (s, 1H), 8.17 (t, 1H), 8.09 (t, 1H), 7.57 (t, 1H), 7.41 (s, 1H), 7.30 (brd, 1H), 6.80 (d, 1H), 6.75(s, 2H), 5.65(s, 2H), 5.17(s, 2H). HRMS-TOF: 428.1244.

[0433] Example 1.18: Preparation of 6-[2-amino-9-[(4-aminophenyl)methyl]purin-6-yl]pyridine-2-carbonitrile (Compound 115) TIFF2023505915000092.tif39153 Reagents and Conditions: (a) XPhos-Pd-G3, THF, 90° C., 15 hours. (b) Fe, NH 4 Cl, THF / H 2 O, 80°C, 2 hours.

[0434] Step 1: Preparation of 6-[2-amino-9-[(4-nitrophenyl)methyl]purin-6-yl]pyridine-2-carbonitrile

[0435] To a solution of intermediate compound S8, 6-chloro-9-[(4-nitrophenyl)methyl]purin-2-amine (800 mg, 2.63 mmol, 1 eq) in THF (20 mL) was added 6-tributylstannylpyridine- 2-Carbonitrile (2.06 g, 5.25 mmol, 2 eq) and XPhos-Pd-G3 (222 mg, 262.56 μmol, 0.1 eq) were added. The mixture was then stirred at 90° C. for 15 hours. Water (30 mL) was added to the mixture and extracted with ethyl acetate (30 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give a residue. The residue was purified by flash silica gel chromatography (12 g SepaFlash® silica flash column, 0-100% ethyl acetate / petroleum ether gradient @ 35 mL / min eluent). The compound 6-[2-amino-9-[(4-nitrophenyl)methyl]purin-6-yl]pyridine-2-carbonitrile (167 mg, 372.27 μmol, 14% yield, 83% purity) was a yellow solid. obtained as 1 H NMR (400 MHz, DMSO-d 6 ): δ8.91(dd, J=0.9, 8.1Hz, 1H), 8.37(s, 1H), 8.31-8.25(m, 1H), 8.22(d, J=8.7Hz, 2H), 8.18(dd, J=0.9, 7.6Hz, 1H), 7.50(d, J=8.7Hz, 2H), 6.85(brs, 1H), 5.53(s, 2H). MS: m / z = 373.1 (M+1, ESI+).

[0436] Step 2: Preparation of 6-[2-amino-9-[(4-aminophenyl)methyl]purin-6-yl]pyridine-2-carbonitrile

[0437] 6-[2-Amino-9-[(4-nitrophenyl)methyl]purin-6-yl]pyridine-2-carbonitrile (160 mg, 429.72 μmol, 1 eq.) in water (3 mL) and THF (9 mL). NH in solution 4 Cl (184 mg, 3.44 mmol, 8 eq) and iron powder (120 mg, 2.15 mmol, 5 eq) were added. The mixture was then stirred at 80° C. for 2 hours. The reaction mixture was filtered and the filtrate was saturated NaHCO 3 Solution (30 mL) was added and extracted with ethyl acetate (80 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give a residue. The residue was subjected to preparative HPLC (column: Waters Xbridge C18 150*50mm*10μm; mobile phase: [water (10mM NH 4 HCOs 3 )-ACN]; B%: 5%-41%, 10 min). Compound 115 or 6-[2-amino-9-[(4-aminophenyl)methyl]purin-6-yl]pyridine-2-carbonitrile (18.59 mg, 53.55 μmol, 12% yield, 95.94% purity) was Obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 )δ=8.92(brd, J=7.9Hz, 1H), 8.34-8.22(m, 2H), 8.16(brd, J=7.5Hz, 1H), 7.05(brd, J=8.0Hz, 2H), 6.81( brs, 2H), 6.52 (brd, J=8.0Hz, 2H), 5.13 (brd, J=7.3Hz, 4H). HRMS-TOF: 343.1415.

[0438] Example 1.19: Preparation of 6-[2-amino-9-[(4-amino-2-fluorophenyl)methyl]purin-6-yl]pyridine-2-carbonitrile (Compound 119) TIFF2023505915000093.tif38153 Reagents and Conditions: (a) XPhos-Pd-G3, THF, 90° C., 15 hours. (b) Fe, NH 4 Cl, THF / H 2 O, 80°C, 1.5 hours.

[0439] Step 1: Preparation of 6-[2-amino-9-[(2-fluoro-4-nitro-phenyl)methyl]purin-6-yl]pyridine-2-carbonitrile.

[0440] To a mixture of intermediate compound S16 or 6-chloro-9-[(2-fluoro-4-nitro-phenyl)methyl]purin-2-amine (0.8 g, 2.48 mmol, 1 eq) in THF (10 mL) was added 6 -tributylstannylpyridine-2-carbonitrile (1.8 g, 4.58 mmol, 1.85 eq) and XPhos-Pd-G3 (210 mg, 247.92 μmol, 0.1 eq) were added. The mixture was then stirred at 90° C. for 15 hours. A saturated aqueous potassium fluoride solution (30 mL) was added to the mixture, and the mixture was extracted with ethyl acetate (30 mL×3). The organic phases were combined and concentrated in vacuo to give a residue. The residue was purified by flash silica gel chromatography (25 g SepaFlash® silica flash column, 0-100% ethyl acetate / petroleum ether gradient 50 mL / min eluent). Compound 6-[2-amino-9-[(2-fluoro-4-nitro-phenyl)methyl]purin-6-yl]pyridine-2-carbonitrile (260 mg, 652.78 μmol, 26% yield, 98.0% purity ) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 )δ=8.90(d, J=7.9Hz, 1H), 8.33(s, 1H), 8.28(t, J=7.9Hz, 1H), 8.21-8.15(m, 2H), 8.05(dd, J=1.8 , 8.5Hz, 1H), 7.33(t, J=8.1Hz, 1H), 6.84(brs, 2H), 5.55(s, 2H). MS: m / z=391.0 (M+1, ESI+).

[0441] Step 2: Preparation of 6-[2-amino-9-[(4-amino-2-fluorophenyl)methyl]purin-6-yl]pyridine-2-carbonitrile

[0442] 6-[2-amino-9-[(2-fluoro-4-nitro-phenyl)methyl]purin-6-yl]pyridine-2-carbonitrile (150 mg, iron powder (107 mg, 1.92 mmol, 5 eq) and NH 4 Cl (164 mg, 3.07 mmol, 8 eq) was added. The mixture was then stirred at 80° C. for 1.5 hours. The reaction mixture was filtered. Saturated NaHCO in the filtrate 3 Solution (30 mL) was added and extracted with ethyl acetate (30 mL×2). The combined organic phase was washed with anhydrous Na 2 SO 4 , filtered, and concentrated in vacuo to give a residue. The residue was subjected to preparative HPLC (column: Phenomenex Gemini NX-C18 (75*30mm*3μm); mobile phase: [water (0.05% ammonium hydroxide v / v)-ACN]; B%: 13%-40%, 7 min). Compound 119 or 6-[2-amino-9-[(4-amino-2-fluoro-phenyl)methyl]purin-6-yl]pyridine-2-carbonitrile (21.61 mg, 58.63 μmol, 15% yield, 98.70% purity) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 )δ=8.91(dd, J=1.0, 8.0Hz, 1H), 8.30-8.24(m, 1H), 8.16(d, J=7.8Hz, 1H), 8.14(s, 1H), 6.99(t, J =8.5Hz, 1H), 6.81(s, 2H), 6.41-6.28(m, 2H), 5.49(brs, 2H), 5.18(s, 2H). HRMS-TOF: 361.1321.

[0443] Example 1.20: Preparation of 6-[2-amino-9-[(4-amino-2,6-difluoro-phenyl)methyl]purin-6-yl]pyridine-2-carbonitrile (Compound 123) TIFF2023505915000094.tif38158 Reagents and conditions: (a) XPhos-Pd-G3, THF, 90°C, 15 hours. (b) Fe, NH 4 Cl, THF / H 2 O, 80°C, 1.5 hours.

[0444] Step 1: Preparation of 6-[2-amino-9-[(2,6-difluoro-4-nitro-phenyl)methyl]purin-6-yl]pyridine-2-carbonitrile

[0445] Intermediate compound S13 or 6-chloro-9-[(2,6-difluoro-4-nitro-phenyl)methyl]purin-2-amine (1 g, 2.94 mmol, 1 eq), 6- A mixture of tributylstannylpyridine-2-carbonitrile (2.31 g, 5.87 mmol, 2 eq) and XPhos-Pd-G3 (250 mg, 293.54 μmol, 0.1 eq) was degassed with nitrogen and heated at 90 °C for 15 h. . Water (30 mL) was added to the mixture and extracted with ethyl acetate (30 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give a residue. The residue was subjected to column chromatography (SiO 2 , petroleum ether / ethyl acetate = 50 / 1 to 0 / 1). Compound 6-[2-amino-9-[(2,6-difluoro-4-nitro-phenyl)methyl]purin-6-yl]pyridine-2-carbonitrile (500 mg, 1.05 mmol, 36% yield, 85 % Purity) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 )δ=8.86(d, J=8.0Hz, 1H), 8.31-8.23(m, 2H), 8.15(d, J=7.6Hz, 1H), 8.09(d, J=7.4Hz, 2H), 6.76( brs, 2H), 5.52(s, 2H) MS: m / z = 409.1 (M+1, ESI+).

[0446] Step 2: Preparation of 6-[2-amino-9-[(4-amino-2,6-difluoro-phenyl)methyl]purin-6-yl]pyridine-2-carbonitrile

[0447] 6-[2-amino-9-[(2,6-difluoro-4-nitro-phenyl)methyl]purin-6-yl]pyridine-2-carbonitrile (200 mg) in THF (8 mL) and water (2 mL) , 489.81 μmol, 1 eq.), iron powder (137 mg, 2.45 mmol, 5 eq.) and NH 4 Cl (210 mg, 3.92 mmol, 8 eq) was added. The mixture was then stirred at 80° C. for 1.5 hours. The reaction mixture was filtered and the filtrate was saturated NaHCO 3 An aqueous solution (30 mL) was added and extracted with ethyl acetate (80 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give a residue. The residue was subjected to preparative HPLC (column: Waters Xbridge 150*25mm*5μm; mobile phase: [water (10mM NH 4 HCOs 3 )-ACN]; B%: 18%-38%, 9 min). Compound 123 or 6-[2-amino-9-[(4-amino-2,6-difluoro-phenyl)methyl]purin-6-yl]pyridine-2-carbonitrile (31.07 mg, 79.80 μmol, 16% yield) yield, 99.33% purity) was obtained as a white solid. 1 H NMR (400 MHz, DMSO-d 6)δ=8.88(dd, J=1.1, 8.1Hz, 1H), 8.29-8.22(m, 1H), 8.15(dd, J=1.0, 7.8Hz, 1H), 8.03(s, 1H), 6.77(s , 2H), 6.22 (d, J=10.5 Hz, 2H), 5.88 (s, 2H), 5.17 (s, 2H). HRMS-TOF: 379.1235.

[0448] Example 1.21: Preparation of 6-[2-amino-9-[(2,6-difluorophenyl)methyl]purin-6-yl]pyridine-2-carbonitrile (Compound 131) TIFF2023505915000095.tif36146 Reagents and conditions: (a) XPhos-Pd-G3, THF, 90°C, 15 hours.

[0449] Intermediate compound S22 or 6-chloro-9-[(2,6-difluorophenyl)methyl]purin-2-amine (200 mg, 676.42 μmol, 1 eq) and 6-tributylstannylpyridine- in THF (10 mL) XPhos-Pd-G3 (57.26 mg, 67.64 μmol, 0.1 eq) was added to a solution of 2-carbonitrile (266 mg, 676.42 μmol, 1 eq). The mixture was then stirred at 90° C. for 15 hours. An aqueous potassium fluoride solution (30 mL) was added to the mixture, and the mixture was extracted with ethyl acetate (30 mL×3). The combined organic phase was washed with anhydrous Na 2 SO 4 , filtered, and concentrated in vacuo to give a residue. The residue was purified by flash silica gel chromatography (12 g SepaFlash® silica flash column, 0-100% ethyl acetate / petroleum ether gradient @ 35 mL / min eluent). Compound 133 or 6-[2-amino-9-[(2,6-difluorophenyl)methyl]purin-6-yl]pyridine-2-carbonitrile (40.26 mg, 110.81 μmol, 16% yield, 96.84% purity ) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ = 8.87 (dd, J = 1.0, 8.1Hz, 1H), 8.29-8.22 (m, 1H), 8.18 (s, 1H), 8.15 (dd, J = 1.0, 7.7Hz, 1H), 7.58-7.39 (m, 1H), 7.16 (t, J=8.1Hz, 2H), 6.77 (s, 2H), 5.42 (s, 2H). HRMS-TOF: 364.1121.

[0450] Example 1.22: Preparation of 6-[2-amino-9-[(4-amino-3-methyl-phenyl)methyl]purin-6-yl]pyridine-2-carbonitrile (Compound 127) TIFF2023505915000096.tif38155 Reagents and Conditions: (a) XPhos-Pd-G3, THF, 90° C., 15 hours. (b) Fe, NH 4 Cl, THF / H 2 O, 80°C, 1 hour.

[0451] Step 1: Preparation of 6-[2-amino-9-[(3-methyl-4-nitro-phenyl)methyl]purin-6-yl]pyridine-2-carbonitrile

[0452] Intermediate compound S19 or 6-chloro-9-[(3-methyl-4-nitro-phenyl)methyl]purin-2-amine (0.8 g, 2.51 mmol, 1 eq), 6-tributyl in THF (10 mL) A mixture of stannylpyridine-2-carbonitrile (1.80 g, 4.58 mmol, 1.82 eq) and XPhos-Pd-G3 (212 mg, 251.01 μmol, 0.1 eq) was degassed and heated to 90° C. under nitrogen for 15 h. . A saturated aqueous potassium fluoride solution (30 mL) was added to the mixture, and the mixture was extracted with ethyl acetate (30 mL×2). The combined organic phase was washed with anhydrous Na 2 SO 4 , filtered, and concentrated in vacuo to give a residue. The residue was purified by flash silica gel chromatography (25 g SepaFlash® silica flash column, 0-100% ethyl acetate / petroleum ether gradient @ 50 mL / min eluent). Compound 6-[2-amino-9-[(3-methyl-4-nitro-phenyl)methyl]purin-6-yl]pyridine-2-carbonitrile (350 mg, 900.89 μmol, 35% yield, 99.45% purity ) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 )δ=8.91(dd, J=0.8, 8.0Hz, 1H), 8.36(s, 1H), 8.32-8.24(m, 1H), 8.17(dd, J=0.9, 7.7Hz, 1H), 7.98(d , J=8.4Hz, 1H), 7.41(s, 1H), 7.28(brd, J=8.4Hz, 1H), 6.83(s, 2H), 5.45(s, 2H). MS: m / z = 387.1 (M+1, ESI+).

[0453] Step 2: Preparation of 6-[2-amino-9-[(4-amino-3-methyl-phenyl)methyl]purin-6-yl]pyridine-2-carbonitrile

[0454] 6-[2-amino-9-[(3-methyl-4-nitro-phenyl)methyl]purin-6-yl]pyridine-2-carbonitrile (150 mg, 388.23) in water (1 mL) and THF (4 mL) μmol, 1 eq) of iron powder (108 mg, 1.94 mmol, 5 eq) and NH 4 Cl (166 mg, 3.11 mmol, 8 eq) was added. The mixture was then stirred at 80° C. for 1 hour. The reaction mixture was filtered. Saturated NaHCO in the filtrate 3 Solution (80 mL) was added and extracted with ethyl acetate (80 mL×3). The combined organic phase was washed with anhydrous Na 2 SO 4 , filtered, and concentrated in vacuo to give a residue. The residue was subjected to preparative HPLC (column: Phenomenex Gemini NX-C18 75*30mm*3μm; mobile phase: [water (10mM NH 4 HCOs 3 )-ACN]; B%: 10%-40%, 8 min). Compound 127 or 6-[2-amino-9-[(4-amino-3-methyl-phenyl)methyl]purin-6-yl]pyridine-2-carbonitrile (37.55 mg, 101.86 μmol, 26% yield, >99% purity) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 )δ=8.90(dd, J=1.0, 8.1Hz, 1H), 8.28-8.23(m, 1H), 8.22(s, 1H), 8.15(dd, J=1.1, 7.7Hz, 1H), 6.95(s , 1H), 6.91(dd, J=1.9, 8.1Hz, 1H), 6.79(s, 2H), 6.55(d, J=8.1Hz, 1H), 5.11(s, 2H), 4.89-4.83(m, 2H), 2.01(s, 3H). HRMS-TOF: 357.1571.

[0455] Example 1.23: Preparation of 2-[2-amino-9-[(4-aminophenyl)methyl]purin-6-yl]pyridine-4-carbonitrile (Compound 116) TIFF2023505915000097.tif69153 Reagents and conditions: (a) CuI, DMSO, 110°C, 15 hours; (b) NaOMe, MeOH, 25°C, 0.5 hours; (c) Pd(OAc). 2 , Cy 3 P, K 2 CO 3 , dioxane, 130 °C, 10 h, MW; (d) Fe, NH 4 Cl, EtOH / H 2 O, 60°C, 1 hour.

[0456] Step 1: Preparation of methyl 3-((4-cyanopyridin-2-yl)sulfonyl)propanoate

[0457] 2-bromopyridine-4-carbonitrile (4.4 g, 24.04 mmol, 1 eq), sodium 3-methoxy-3-oxo-propane-1-sulfinate (5.02 g, 28.85 mmol, 1.2 eq) in DMSO (50 mL) ), CuI (5.49 g, 28.85 mmol, 1.2 eq) was degassed and purged with nitrogen three times, then the mixture was stirred at 110° C. under a nitrogen atmosphere for 15 h. The mixture was then cooled to room temperature, diluted with ethyl acetate (50 mL) and filtered through a pad of silica. The filtrate was washed with water (2×20 mL), brine (20 mL), dried over anhydrous sodium sulfate, filtered through a pad of silica and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (ISCO®; 20 g Sepa Flash® silica flash column, 0-100% ethyl acetate / petroleum ether gradient @ 35 mL / min eluent). Compound methyl 3-[(4-cyano-2-pyridyl)sulfonyl]propanoate (3 g, 11.80 mmol, 49% yield) was obtained as a white solid. MS: m / z=254.9 (M+1, ESI+).

[0458] Step 2: Preparation of (4-cyano-2-pyridyl)sulfinyloxysodium

[0459] To a solution of methyl 3-[(4-cyano-2-pyridyl)sulfonyl]propanoate (1.1 g, 4.33 mmol, 1 eq) in methanol (10 mL) was added sodium methoxide (233 mg, 4.33 mmol, 1 eq). . The mixture was stirred at 25° C. for 0.5 hours. The reaction mixture was concentrated under reduced pressure to remove methanol to give a residue. The crude intermediate compound S25 or (4-cyano-2-pyridyl)sulfinyloxysodium (700 mg, crude) was obtained as a yellow solid and used in the next step without further purification. MS: m / z=167.0 (M+1, ESI+).

[0460] Step 3: Preparation of 2-[2-amino-9-[(4-nitrophenyl)methyl]purin-6-yl]pyridine-4-carbonitrile

[0461] Intermediate compound S25 or (4-cyano-2-pyridyl)sulfinyloxysodium (374mg, 1.97mmol, 1.2eq), intermediate compound S8 or 6-chloro-9-[(4-nitrophenyl)methyl]purine-2 -amine (500 mg, 1.64 mmol, 1 eq), tricyclohexylphosphine (92 mg, 328.20 μmol, 0.2 eq), K 2 CO 3 (453 mg, 3.28 mmol, 2 eq) and Pd(OAc) 2 A mixture of (36 mg, 164.10 μmol, 0.1 eq) in dioxane (2 mL) was taken in a microwave tube. The sealed tube was heated under microwave at 130° C. for 10 hours. The reaction mixture was concentrated under reduced pressure to remove dioxane to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 20 g Sepa Flash® silica flash column, 0-100% ethyl acetate / petroleum ether gradient @ 40 mL / min eluent). The compound 2-[2-amino-9-[(4-nitrophenyl)methyl]purin-6-yl]pyridine-4-carbonitrile (360 mg, 734.81 μmol, 45% yield, 76% purity) was a yellow solid. obtained as MS: m / z = 373.1 (M+1, ESI+).

[0462] Step 4: Preparation of 2-[2-amino-9-[(4-aminophenyl)methyl]purin-6-yl]pyridine-4-carbonitrile

[0463] Intermediate compound S26 or 2-[2-amino-9-[(4-nitrophenyl)methyl]purin-6-yl]pyridine-4-carbonitrile (150 mg, 402.86 mg) in ethanol (9 mL) and water (3 mL) μmol, 1 eq) and NH 4 Iron powder (112 mg, 2.01 mmol, 5 eq) was added to a solution of Cl (172 mg, 3.22 mmol, 8 eq). The mixture was stirred at 60° C. for 1 hour. The reaction mixture was concentrated under reduced pressure to remove ethanol and water to give a residue. The residue was purified by preparative HPLC (column: Phenomenex Luna C18 150*25mm*10μm; mobile phase: [water (0.225% FA)-ACN]; B%: 5%-25%, 10 min). Compound 116 or 2-[2-amino-9-[(4-aminophenyl)methyl]purin-6-yl]pyridine-4-carbonitrile (22.85 mg, 64.35 μmol, 16% yield, 96.90% purity, 0.2 FA) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ = 9.01 (dd, 1H), 8.94 (s, 1H), 8.22 (s, 1H), 7.98 (dd, 1H), 7.04 (d, 2H), 6.74 (s, 2H), 6.51 (d, 2H ), 5.13 (s.4H). HRMS-TOF: 343.1415.

[0464] Example 1.24: Preparation of 2-[2-amino-9-[(4-amino-2-fluoro-phenyl)methyl]purin-6-yl]pyridine-4-carbonitrile (Compound 120) TIFF2023505915000098.tif38154 Reagents and Conditions: (a) Pd(OAc) 2 , Cy 3 P, K 2 CO 3 , dioxane, 130 °C, 10 h, MW; (b) Fe, NH 4 Cl, EtOH / H 2 O, 60°C, 1 hour.

[0465] Step 1: Preparation of 2-[2-amino-9-[(2-fluoro-4-nitro-phenyl)methyl]purin-6-yl]pyridine-4-carbonitrile.

[0466] Intermediate compound S25 or (4-cyano-2-pyridyl)sulfinyloxysodium (424 mg, 2.23 mmol, 1.2 eq), intermediate compound S16 or 6-chloro-9-[(2-fluoro-4-nitro-phenyl) Methyl]purin-2-amine (600 mg, 1.86 mmol, 1 eq), Tricyclohexylphosphine (104 mg, 371.88 μmol, 0.2 eq), K 2 CO 3 A mixture of (513 mg, 3.72 mmol, 2 eq) and palladium acetate (42 mg, 185.94 μmol, 0.1 eq) in dioxane (4 mL) was taken in a microwave tube. The sealed tube was heated under microwave at 130° C. for 10 hours. The reaction mixture was concentrated under reduced pressure to remove dioxane to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 20 g Sepa Flash® silica flash column, 0-100% ethyl acetate / petroleum ether gradient @ 35 mL / min eluent). The compound 2-[2-amino-9-[(2-fluoro-4-nitro-phenyl)methyl]purin-6-yl]pyridine-4-carbonitrile (300 mg, 768.58 μmol, 41% yield) was obtained as a white solid. obtained as MS: m / z=391.1 (M+1, ESI+)

[0467] Step 2: Preparation of 2-[2-amino-9-[(4-amino-2-fluoro-phenyl)methyl]purin-6-yl]pyridine-4-carbonitrile

[0468] 2-[2-Amino-9-[(2-fluoro-4-nitro-phenyl)methyl]purin-6-yl]pyridine-4-carbonitrile (150 mg, 230.57 mg) in ethanol (15 mL) and water (5 mL) μmol, 1 eq.) and NH 4 Iron powder (64 mg, 1.15 mmol, 5 eq) was added to a solution of Cl (98 mg, 1.84 mmol, 8 eq). The mixture was stirred at 60° C. for 1 hour. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was subjected to preparative HPLC (column: Waters Xbridge 150*25mm*5μm; mobile phase: [water (10mM NH 4 HCOs 3 )-ACN]; B%: 10%-40%, 9 min) to give 87% pure product. Then preparative HPLC (column: Waters Xbridge C18 150*50mm*10μm; mobile phase: [water (10mM NH 4 HCOs 3 )-ACN]; B%: 8%-38%, 10 min). Finally, compound 120 or 2-[2-amino-9-[(4-amino-2-fluoro-phenyl)methyl]purin-6-yl]pyridine-4-carbonitrile (9.83 mg, 26.40 μmol, 11% Yield, 97.25% purity) was obtained as a white solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ = 9.02 (d, 1H), 8.89 (s, 1H), 8.13 (s, 1H), 7.99 (d, 1H), 6.98 (t, 1H), 6.75 (s, 2H), 6.33 (d, 2H ), 5.48(s, 2H), 5.17(s2H). HRMS-TOF: 361.1319.

[0469] Example 1.25: Preparation of -[2-amino-9-[(4-amino-2,6-difluoro-phenyl)methyl]purin-6-yl]pyridine-4-carbonitrile (Compound 124) TIFF2023505915000099.tif38154 Reagents and conditions: (a) Pd(OAc) 2 , Cy 3 P, K 2 CO 3 , dioxane, 130 °C, 10 h, MW; (b) Fe, NH 4 Cl, EtOH / H 2 O, 60°C, 1 hour. Step 1: 2-[2-Amino-9-[(2,6-difluoro-4-nitro-phenyl)methyl]purin-6-yl]pyridine-4-carbonitrile (4-Cyano-2-pyridyl)sulfinyloxysodium (419 mg, 2.20 mmol, 1.5 eq), 6-chloro-9-[(2,6-difluoro-4-nitro-phenyl)methyl]purin-2-amine ( 500 mg, 1.47 mmol, 1 equiv), tricyclohexylphosphine (123 mg, 440.31 μmol, 0.3 equiv), K 2 CO 3 (405 mg, 2.94 mmol, 2 eq) and palladium acetate (50 mg, 223.09 μmol, 0.15 eq) were taken in a microwave tube in dioxane (10 mL). The sealed tube was heated under microwave at 130° C. for 10 hours. The reaction mixture was concentrated under reduced pressure to remove dioxane to give a residue. The residue was purified by preparative HPLC (column: Phenomenex Luna C18 150*25mm*10μm; mobile phase: [water (0.225% FA)-ACN]; B%: 23%-53%, 10 min). The compound 2-[2-amino-9-[(2,6-difluoro-4-nitro-phenyl)methyl]purin-6-yl]pyridine-4-carbonitrile (120 mg, 293.89 μmol, 20% yield) was Obtained as a white solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ = 9.02(d, 1H), 8.85(s, 1H), 8.28(s, 1H), 8.11-8.07(m, 2H), 7.99(d, 1H), 6.72(s, 2H), 5.52(s , 2H). MS: m / z=409.1(M+1, ESI+) Step 2: 2-[2-amino-9-[(4-amino-2,6-difluoro-phenyl)methyl]purin-6-yl]pyridine-4-carbonitrile 2-[2-Amino-9-[(2,6-difluoro-4-nitro-phenyl)methyl]purin-6-yl]pyridine-4-carbonitrile (100 mg) in ethanol (9 mL) and water (3 mL) , 244.91 μmol, 1 equiv) and NH 4 Iron powder (68 mg, 1.22 mmol, 5 eq) was added to a solution of Cl (104 mg, 1.96 mmol, 8 eq). The mixture was stirred at 60° C. for 1 hour. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (column: Phenomenex Luna C18 150*25mm*10μm; mobile phase: [water (0.225% FA)-ACN]; B%: 13%-43%, 10 min) to obtain 90% The product was obtained with a purity of Second preparative HPLC (column: Waters Xbridge 150*25mm*5μm; mobile phase: [water (10mM NH 4 HCOs 3 )-ACN]; B%: 22%-52%, 9 min). Compound 2-[2-amino-9-[(4-amino-2,6-difluoro-phenyl)methyl]purin-6-yl]pyridine-4-carbonitrile (34.57 mg, 89.87 μmol, 37% yield, 97.96% purity) was obtained as a white solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ = 9.01 (dd, 1H), 8.87 (s, 1H), 8.03 (s, 1H), 7.99 (dd, 1H), 6.72 (s, 2H), 6.22 (d, 2H), 5.88 (s, 2H ), 5.17(s, 2H). HRMS (TOF): 379.1229

[0470] Example 1.26: Preparation of 2-[2-amino-9-[(4-amino-2,6-difluoro-phenyl)methyl]purin-6-yl]pyridine-4-carbonitrile (Compound 132) TIFF2023505915000100.tif39158 Reagents and Conditions: (a) Pd(OAc) 2 , Cy 3 P, K 2 CO 3 , dioxane, 130 °C, 10 h, MW.

[0471] Intermediate compound S25 or (4-cyano-2-pyridyl)sulfinyloxysodium (231 mg, 1.22 mmol, 1.2 eq), intermediate compound S22 or 6-chloro-9-[(2,6- Difluorophenyl)methyl]purin-2-amine (300 mg, 1.01 mmol, 1 eq), palladium acetate (22 mg, 101.46 μmol, 0.1 eq), tricyclohexylphosphine (56 mg, 202.93 μmol, 0.2 eq) and K 2 CO 3 After the mixture of (280 mg, 2.03 mmol, 2 eq) was degassed and purged with nitrogen three times, the mixture was stirred under microwave conditions at 130° C. for 10 h. The mixture was concentrated under reduced pressure to remove dioxane to give a residue. The residue was purified by preparative HPLC (column: Phenomenex Gemini-NX C18 75*30mm*3μm; mobile phase: [water (0.05% ammonium hydroxide v / v)-ACN]; B%: 15%-45% ,7 minutes). Compound 132 or 2-[2-amino-9-[(2,6-difluorophenyl)methyl]purin-6-yl]pyridine-4-carbonitrile (49.39 mg, 130.41 μmol, 13% yield, 93.37% purity ) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ = 9.01 (dd, 1H), 8.87 (s, 1H), 8.18 (s, 1H), 7.99 (dd, 1H), 7.54-7.43 (m, 1H), 7.21-7.12 (m, 2H), 6.73 (s, 2H), 5.41 (s, 2H). HRMS-TOF: 364.1121.

[0472] Example 1.27: Preparation of 2-[2-amino-9-[(4-amino-3-methyl-phenyl)methyl]purin-6-yl]pyridine-4-carbonitrile (Compound 128) TIFF2023505915000101.tif38155 Reagents and conditions: (a) Pd(OAc) 2 , Cy 3 P, K 2 CO 3 , dioxane, 130 °C, 10 h, MW; (b) Fe, NH 4 Cl, EtOH / H 2 O, 60°C, 1 hour.

[0473] Step 1: Preparation of 2-[2-amino-9-[(3-methyl-4-nitro-phenyl)methyl]purin-6-yl]pyridine-4-carbonitrile

[0474] Intermediate compound S25 or sodium 4-cyanopyridine-2-sulfinate (357 mg, 1.88 mmol, 1.2 eq) in dioxane (2 mL), intermediate compound S19 or 6-chloro-9-[(3-methyl-4- Nitro-phenyl)methyl]purin-2-amine (500 mg, 1.57 mmol, 1 eq), palladium acetate (35 mg, 157.00 μmol, 0.1 eq), tricyclohexylphosphine (87 mg, 314.00 μmol, 0.2 eq) and K 2 CO 3 After the mixture of (433 mg, 3.14 mmol, 2 eq) was degassed and purged with nitrogen three times, the mixture was stirred under microwave conditions at 130° C. for 10 h. The reaction mixture was concentrated under reduced pressure to remove dioxane to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 20 g Sepa Flash® silica flash column, 0-10% ethyl acetate / petroleum ether gradient @ 30 mL / min eluent). Compound 2-[2-amino-9-[(3-methyl-4-nitro-phenyl)methyl]purin-6-yl]pyridine-4-carbonitrile (300 mg, 535.76 μmol, 34% yield, 69% purity ) was obtained as a yellow solid. MS: m / z = 387.3 (M+1, ESI+).

[0475] Step 2: Preparation of 2-[2-amino-9-[(4-amino-3-methyl-phenyl)methyl]purin-6-yl]pyridine-4-carbonitrile 2-[2-amino-9-[(3-methyl-4-nitro-phenyl)methyl]purin-6-yl]pyridine-4-carbonitrile (150 mg, 388.23) in water (5 mL) and ethanol (15 mL) μmol, 1 eq) and NH 4 Iron powder (108 mg, 1.94 mmol, 5 eq) was added to a solution of Cl (7 M, 444 μL, 8 eq). The mixture was stirred at 60° C. for 1 hour. The reaction mixture was concentrated under reduced pressure to remove ethanol and water to give a residue. The residue was purified by preparative HPLC (column: Phenomenex Luna C18 150*25mm*10μm; mobile phase: [water (0.225% FA)-ACN]; B%: 8%-28%, 9 min). Compound 128 or 2-[2-amino-9-[(4-amino-3-methyl-phenyl)methyl]purin-6-yl]pyridine-4-carbonitrile (21.82 mg, 58.15 μmol, 15% yield, 96.70% purity) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ = 9.02(d, 1H), 8.90(s, 1H), 8.23(s, 1H), 7.99(d, 1H), 6.95(s, 1H), 6.93-6.90(m, 1H), 6.75(s , 2H), 6.55 (d, 1H), 5.12 (s, 2H), 4.87 (s, 2H), 2.06 (s, 3H). HRMS-TOF: 357.1569.

[0476] Example 1.28: Preparation of 2-[2-amino-9-[[4-amino-3-(trifluoromethyl)phenyl]methyl]purin-6-yl]pyridine-4-carbonitrile (Compound 135) TIFF2023505915000102.tif42155 Reagents and Conditions: (a) Pd(OAc) 2 , Cy 3 P, K 2 CO 3 , dioxane, 130 °C, 10 h, MW; (b) Fe, NH 4 Cl, EtOH / H 2 O, 60°C, 1 hour.

[0477] Step 1: Preparation of 2-[2-amino-9-[[4-nitro-3-(trifluoromethyl)phenyl]methyl]purin-6-yl]pyridine-4-carbonitrile.

[0478] Intermediate compound S25 or sodium 4-cyanopyridine-2-sulfinate (230 mg, 1.21 mmol, 1.5 eq) in dioxane (5 mL), intermediate compound S23 or 6-chloro-9-[[4-nitro-3 -(trifluoromethyl)phenyl]methyl]purin-2-amine (300 mg, 804.96 μmol, 1 eq), potassium carbonate (222 mg, 1.61 mmol, 2 eq) and Cy 3 After degassing a mixture of P-Pd-G3 (52 mg, 80.50 μmol, 0.1 eq) and purging with nitrogen three times, the mixture was stirred at 120° C. for 16 h under a nitrogen atmosphere. The reaction mixture was concentrated under reduced pressure to remove dioxane to give a residue. The residue was purified by preparative HPLC (column: Simpack C18 150*25*10 μm; mobile phase: [water (0.225% FA)-ACN]; B%: 34%-54%, 10 min). Compound 135 or 2-[2-amino-9-[[4-nitro-3-(trifluoromethyl)phenyl]methyl]purin-6-yl]pyridine-4-carbonitrile (300 mg, 647.23 μmol, 80% yield) 95% purity) was obtained as a white solid. 1 H NMR (400 MHz, DMSO-d 6) δ = 9.04 (dd, J = 0.7, 4.9 Hz, 1H), 8.90 (s, 1H), 8.37 (s, 1H), 8.13 (s, 1H), 8.08 (s, 1H), 8.01 (dd, J =1.5, 5.0Hz, 1H), 7.71(dd, J=1.2, 8.4Hz, 1H), 6.80(s, 2H), 5.57(s, 2H).

[0479] Step 2: Preparation of 2-[2-amino-9-[[4-amino-3-(trifluoromethyl)phenyl]methyl]purin-6-yl]pyridine-4-carbonitrile.

[0480] 2-[2-Amino-9-[[4-nitro-3-(trifluoromethyl)phenyl]methyl]purin-6-yl]pyridine-4-carbonitrile ( Iron powder (190 mg, 3.41 mmol, 5 eq) and NH 4 Cl (292 mg, 5.45 mmol, 8 eq) was added. The mixture was stirred at 60° C. for 1 hour. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (column: Simpack C18 150*25*10 μm; mobile phase: [water (0.225% FA)-ACN]; B%: 17%-47%, 10 min). Compound 135 or 2-[2-amino-9-[[4-amino-3-(trifluoromethyl)phenyl]methyl]purin-6-yl]pyridine-4-carbonitrile (40.01 mg, 96.51 μmol, 14% Yield, 98.98% purity) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ = 9.02(d, 1H), 8.89(s, 1H), 8.29(s, 1H), 7.99(dd, 1H), 7.40(d, 1H), 7.29(dd, 1H), 6.82-6.74(m , 3H), 5.64(s, 2H), 5.20(s, 2H) HRMS-TOF: 411.1281.

[0481] Example 1.29: Preparation of 5-[2-amino-9-[(4-aminophenyl)methyl]purin-6-yl]pyridine-3-carbonitrile (Compound 117) TIFF2023505915000103.tif42158 Reagents and Conditions: (a) Pd(dppf)Cl 2 , K 2 CO 3 , dioxane / H 2 O, 110°C, 15 hours. (b) Fe, NH 4 Cl, EtOH / H 2 O, 80°C, 1 hour.

[0482] Step 1: Preparation of 5-[2-amino-9-[(4-nitrophenyl)methyl]purin-6-yl]pyridine-3-carbonitrile.

[0483] Intermediate compound S8 or 6-chloro-9-[(4-nitrophenyl)methyl]purin-2-amine (200 mg, 656.40 μmol, 1 eq), 5-( 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-3-carbonitrile (181 mg, 787.68 μmol, 1.2 eq), Pd(dppf)Cl 2 (48 mg, 65.64 μmol, 0.1 equiv) and K 2 CO 3 A mixture of (181 mg, 1.31 mmol, 2 eq) was degassed and then heated to 110° C. under nitrogen for 15 hours. Water (130 mL) was added to the mixture and extracted with ethyl acetate (130 mL×2). The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give a residue. Preparative TLC (SiO 2 , PE:EA=1:1). The compound 5-[2-amino-9-[(4-nitrophenyl)methyl]purin-6-yl]pyridine-3-carbonitrile (150 mg, 330.34 μmol, 50% yield, 82% purity) was a yellow solid. obtained as MS: m / z=373 (M+1, ESI+).

[0484] Step 2: Preparation of 5-[2-amino-9-[(4-aminophenyl)methyl]purin-6-yl]pyridine-3-carbonitrile

[0485] 5-[2-amino-9-[(4-nitrophenyl)methyl]purin-6-yl]pyridine-3-carbonitrile (150 mg, 330.34 μmol, 1 equiv.) in ethanol (9 mL) and water (3 mL) ) and iron powder (92 mg, 1.65 mmol, 5 equivalents) and NH 4 Cl (141 mg, 2.64 mmol, 8 eq) was added. The mixture was then stirred at 80° C. for 1 hour. The reaction mixture was filtered and the filtrate was concentrated in vacuo. Water (50 mL) was then added to the mixture and extracted with ethyl acetate (80 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give a residue. The residue was purified by preparative HPLC (column: Waters Xbridge 150*25mm*5μm; mobile phase: [water (0.05% ammonium hydroxide v / v)-ACN]; B%: 14%-44%, 10 min). bottom. Compound 117 or 5-[2-amino-9-[(4-aminophenyl)methyl]purin-6-yl]pyridine-3-carbonitrile (20.59 mg, 58.88 μmol, 18% yield, 98.45% purity) was Obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 )δ=10.01(d, J=1.8Hz, 1H), 9.30(s, 1H), 9.16(d, J=1.8Hz, 1H), 8.29(s, 1H), 7.05(brd, J=8.3Hz, 2H), 6.77(s, 2H), 6.52(d, J=8.3Hz, 2H), 5.14(s, 2H), 5.11(s, 2H). HRMS-TOF: 343.1410.

[0486] Example 1.30: Preparation of 5-[2-amino-9-[(4-amino-2-fluoro-phenyl)methyl]purin-6-yl]pyridine-3-carbonitrile (Compound 121) TIFF2023505915000104.tif39158 Reagents and Conditions: (a) Pd(dppf)Cl 2 , K 2 CO 3 , dioxane / H 2 O, 110°C, 15 hours. (b) Fe, NH 4 Cl, EtOH / H 2 O, 80°C, 1 hour.

[0487] Step 1: Preparation of 5-[2-amino-9-[(2-fluoro-4-nitro-phenyl)methyl]purin-6-yl]pyridine-3-carbonitrile.

[0488] Intermediate compound S16 or 6-chloro-9-[(2-fluoro-4-nitro-phenyl)methyl]purin-2-amine (300 mg, 929.71 μmol, 1 eq.) in dioxane (10 mL) and water (0.5 mL) ), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-3-carbonitrile (320 mg, 1.39 mmol, 1.5 eq), K 2 CO 3 (257 mg, 1.86 mmol, 2 eq) and Pd(dppf)Cl 2 A mixture of (68 mg, 92.97 μmol, 0.1 eq) was degassed and heated to 110° C. under nitrogen for 15 hours. Water (30 mL) was added to the mixture and then extracted with ethyl acetate (30 mL×3). The combined organic phases were washed with brine (50 mL x 2) and dried over anhydrous Na. 2 SO 4 , filtered, and concentrated in vacuo to give a residue. The residue was purified by flash silica gel chromatography (20 g SepaFlash® silica flash column, 0-80% ethyl acetate / petroleum ether gradient @ 35 mL / min eluent). Compound 121 or 5-[2-amino-9-[(2-fluoro-4-nitro-phenyl)methyl]purin-6-yl]pyridine-3-carbonitrile (200 mg, 502.14 μmol, 54% yield, 98 % Purity) was obtained as a yellow solid. MS: m / z=391.2 (M+1, ESI+).

[0489] Step 2: Preparation of 5-[2-amino-9-[(4-amino-2-fluoro-phenyl)methyl]purin-6-yl]pyridine-3-carbonitrile.

[0490] 5-[2-amino-9-[(2-fluoro-4-nitro-phenyl)methyl]purin-6-yl]pyridine-3-carbonitrile (200 mg, 512.39 mg) in ethanol (9 mL) and water (3 mL) μmol, 1 eq) and NH 4 Iron powder (143 mg, 2.56 mmol, 5 eq) was added to a solution of Cl (220 mg, 4.10 mmol, 8 eq). The mixture was then stirred at 80° C. for 1 hour. The mixture was concentrated in vacuo to give a residue. Water (30 mL) was added to the residue and extracted with ethyl acetate (30 mL×3). Combine the organic phases and add anhydrous Na 2 SO 4 , filtered, and concentrated in vacuo to give a residue. The crude product was triturated with methanol (10 mL) and THF (1 mL) at 60° C. for 30 minutes. Compound 121 or 5-[2-amino-9-[(4-amino-2-fluoro-phenyl)methyl]purin-6-yl]pyridine-3-carbonitrile (60 mg, 166.51 μmol, 32% yield, 95.08 % Purity) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6)δ=10.01(d, J=2.0Hz, 1H), 9.30(t, J=2.1Hz, 1H), 9.17(d, J=2.0Hz, 1H), 8.20(s, 1H), 6.99(t, J=8.4Hz, 1H), 6.79(s, 2H), 6.44-6.28(m, 2H), 5.50(s, 2H), 5.18(s, 2H). HRMS-TOF: 361.1319.

[0491] Example 1.31: Preparation of 5-[2-amino-9-[(4-amino-2,6-difluoro-phenyl)methyl]purin-6-yl]pyridine-3-carbonitrile (Compound 125) TIFF2023505915000105.tif39158 Reagents and Conditions: (a) Pd(dppf)Cl 2 , K 2 CO 3 , dioxane / H 2 O, 110°C, 2 hours; (b) Fe, NH 4 Cl, EtOH / H 2 O, 80°C, 1 hour.

[0492] Step 1: Preparation of 5-[2-amino-9-[(2,6-difluoro-4-nitro-phenyl)methyl]purin-6-yl]pyridine-3-carbonitrile.

[0493] Intermediate compound S13 or 6-chloro-9-[(2,6-difluoro-4-nitro-phenyl)methyl]purin-2-amine (200 mg, 587.07 μmol, 1 eq), 5-(4,4,5 ,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-3-carbonitrile (270 mg, 1.17 mmol, 2 eq), Pd(dppf)Cl 2 (43 mg, 58.71 μmol, 0.1 equiv) and K 2 CO 3 A mixture of (162 mg, 1.17 mmol, 2 eq) was taken in a microwave tube in dioxane (10 mL) and water (2 mL). The sealed tube was heated at 110° C. for 2 hours under microwave conditions. After that, water (130 mL) was added to the mixture and extracted with ethyl acetate (130 mL×2). Combine the organic phases and add anhydrous Na 2 SO 4 , filtered, and concentrated in vacuo to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 20 g Sepa Flash® silica flash column, 0-100% ethyl acetate / petroleum ether gradient @ 40 mL / min eluent). Compound 125 or 5-[2-amino-9-[(2,6-difluoro-4-nitro-phenyl)methyl]purin-6-yl]pyridine-3-carbonitrile (200 mg, 426.14 μmol, 72% yield , 87% purity) was obtained as a yellow solid. MS: m / z = 408.9 (M+1, ESI+).

[0494] Step 2: Preparation of 5-[2-amino-9-[(4-amino-2,6-difluoro-phenyl)methyl]purin-6-yl]pyridine-3-carbonitrile.

[0495] 5-[2-amino-9-[(2,6-difluoro-4-nitro-phenyl)methyl]purin-6-yl]pyridine-3-carbonitrile (200 mg) in ethanol (8 mL) and water (2 mL) , 489.81 μmol, 1 eq.), iron powder (137 mg, 2.45 mmol, 5 eq.) and NH 4 Cl (210 mg, 3.92 mmol, 8 eq) was added. The mixture was then stirred at 80° C. for 1 hour. After that, the reaction mixture was filtered and the filtrate was concentrated in vacuo, then water (50 mL) was added to the residue and extracted with ethyl acetate (50 mL x 3). Combine the organic phases and add anhydrous Na 2 SO 4 , filtered, and concentrated in vacuo to give a residue. The residue was subjected to preparative HPLC (column: Waters Vinridis Silica 2-EP OBD 50*150mm*5μm; mobile phase: [heptane-EtOH (0.1% NH 3 ·H 2 O)]; B%: 5%-45%, 10 min). Compound 125 or 5-[2-amino-9-[(4-amino-2,6-difluoro-phenyl)methyl]purin-6-yl]pyridine-3-carbonitrile (16.22 mg, 40.31 μmol, 8% yield) yield, 96.64% purity) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 )δ=9.99(d, J=2.0Hz, 1H), 9.28(t, J=2.1Hz, 1H), 9.15(d, J=2.1Hz, 1H), 8.09(s, 1H), 6.74(s, 2H), 6.22(d, J=10.4Hz, 2H), 5.88(s, 2H), 5.17(s, 2H). HRMS-TOF: 379.1229.

[0496] Example 1.32: Preparation of 5-[2-amino-9-[(2,6-difluorophenyl)methyl]purin-6-yl]pyridine-3-carbonitrile (Compound 133) TIFF2023505915000106.tif38150 Reagents and Conditions: (a) Pd(dppf)Cl 2 , K 2 CO 3 , dioxane / H 2 O, 110°C, 15 hours.

[0497] Intermediate compound S22 or 6-chloro-9-[(2,6-difluorophenyl)methyl]purin-2-amine (150 mg, 507.31 μmol, 1 eq), 5- (4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-3-carbonitrile (140 mg, 608.78 μmol, 1.2 eq), Pd(dppf)Cl 2 (37 mg, 50.73 μmol, 0.1 equiv) and K 2 CO 3 A mixture of (140 mg, 1.01 mmol, 2 eq) was degassed and heated to 110° C. under nitrogen for 15 hours. The mixture was concentrated in vacuo to give a residue. The residue was purified by preparative HPLC (column: Xtimate C18 150*40mm*10μm; mobile phase: [water (0.05% ammonium hydroxide v / v)-ACN]; B%: 30%-60%, 10 min) . Compound 133 or 5-[2-amino-9-[(2,6-difluorophenyl)methyl]purin-6-yl]pyridine-3-carbonitrile (60.03 mg, 161.42 μmol, 32% yield, 96.75% purity ) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 )δ=9.98(d, J=1.7Hz, 1H), 9.27(s, 1H), 9.16(d, J=1.7Hz, 1H), 8.24(s, 1H), 7.55-7.42(m, 1H), 7.16(t, J=8.1Hz, 2H), 6.74(s, 2H), 5.42(s, 2H). HRMS-TOF: 364.1121.

[0498] Example 1.33: Preparation of 5-[2-amino-9-[(4-amino-3-methyl-phenyl)methyl]purin-6-yl]pyridine-3-carbonitrile (Compound 129) TIFF2023505915000107.tif39158 Reagents and Conditions: (a) Pd(dppf)Cl 2 , K 2 CO 3 , dioxane / H 2 O, 110°C, 15 hours. (b) Fe, NH 4 Cl, EtOH / H 2 O, 80°C, 1 hour.

[0499] Step 1: Preparation of 5-[2-amino-9-[(3-methyl-4-nitro-phenyl)methyl]purin-6-yl]pyridine-3-carbonitrile

[0500] Intermediate compound S19 or 6-chloro-9-[(3-methyl-4-nitro-phenyl)methyl]purin-2-amine (300 mg, 941.27 μmol, 1 eq.) in dioxane (10 mL) and water (0.5 mL) ), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-3-carbonitrile (325 mg, 1.41 mmol, 1.5 eq), Pd(dppf)Cl 2 (69 mg, 94.13 μmol, 0.1 equiv) and K 2 CO 3 A mixture of (260 mg, 1.88 mmol, 2 eq) was degassed and heated to 110° C. under nitrogen for 15 hours. After that, water (80 mL) was added to the mixture and extracted with ethyl acetate (80 mL×3). Combine the organic phases and add anhydrous Na 2 SO 4 , filtered, and concentrated in vacuo to give a residue. The residue was purified by flash silica gel chromatography (12 g SepaFlash® silica flash column, 0-80% ethyl acetate / petroleum ether gradient @ 30 mL / min eluent). Compound 5-[2-amino-9-[(3-methyl-4-nitro-phenyl)methyl]purin-6-yl]pyridine-3-carbonitrile (300 mg, 750.84 μmol, 79% yield, 96.7% purity ) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 )δ=10.02(d, J=2.0Hz, 1H), 9.31(t, J=2.1Hz, 1H), 9.17(d, J=2.0Hz, 1H), 8.41(s, 1H), 7.97(d, J=8.4Hz, 1H), 7.41(s, 1H), 7.28(dd, J=1.5, 8.4Hz, 1H), 6.80(s, 2H), 5.45(s, 2H), 2.49(brs, 3H). MS: m / z=387 (M+1, ESI+).

[0501] Step 2: Preparation of 5-[2-amino-9-[(4-amino-3-methyl-phenyl)methyl]purin-6-yl]pyridine-3-carbonitrile

[0502] 5-[2-Amino-9-[(3-methyl-4-nitro-phenyl)methyl]purin-6-yl]pyridine-3-carbonitrile (300 mg, 722.1 mg) in ethanol (9 mL) and water (3 mL) μmol, 1 eq) of iron powder (202 mg, 3.61 mmol, 5 eq) and NH 4 Cl (310 mg, 5.78 mmol, 8 eq) was added. The mixture was then stirred at 80° C. for 1 hour. The reaction mixture was filtered and the filtrate was concentrated in vacuo. Water (50 mL) was then added to the residue and extracted with ethyl acetate (50 mL×3). The combined organic phase was washed with anhydrous Na 2 SO 4 , filtered, and concentrated in vacuo to give a residue. The crude product was triturated with methanol (8 mL) at 25° C. for 30 minutes, then filtered and the solid dried under reduced pressure. Compound 129 or 5-[2-amino-9-[(4-amino-3-methyl-phenyl)methyl]purin-6-yl]pyridine-3-carbonitrile (36.5 mg, 99.14 μmol, 13% yield, 96.26% purity) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 )δ=10.01(d, J=2.0Hz, 1H), 9.29(t, J=2.0Hz, 1H), 9.15(d, J=2.0Hz, 1H), 8.28(s, 1H), 6.96(s, 1H), 6.92 (dd, J=1.7, 8.1Hz, 1H), 6.76 (s, 2H), 6.56 (d, J=8.1Hz, 1H), 5.12 (s, 2H), 2.01 (s, 3H). HRMS-TOF: 357.1555.

[0503] Example 1.34: Preparation of 4-[2-amino-9-[(4-aminophenyl)methyl]purin-6-yl]pyridine-2-carbonitrile (Compound 118) TIFF2023505915000108.tif39158 Reagents and Conditions: (a) Pd(dppf)Cl 2 , K 2 CO 3 , dioxane / H 2 O, 110°C, 2 hours, MW. (b) Fe, NH 4 Cl, EtOH / H 2 O, 80°C, 1 hour.

[0504] Step 1: Preparation of 4-[2-amino-9-[(4-nitrophenyl)methyl]purin-6-yl]pyridine-2-carbonitrile.

[0505] Intermediate compound S8 or 6-chloro-9-[(4-nitrophenyl)methyl]purin-2-amine (200 mg, 656.40 μmol, 1 eq), 4-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)pyridine-2-carbonitrile (755 mg, 3.28 mmol, 5 eq), K 2 CO 3 (181 mg, 1.31 mmol, 2 eq) and Pd(dppf)Cl 2 A mixture of (48 mg, 65.64 μmol, 0.1 eq) in dioxane (10 mL) and water (2 mL) was taken in a microwave tube. The sealed tube was heated at 110° C. for 2 hours under microwave conditions. After that, water (130 mL) was added to the mixture and extracted with ethyl acetate (130 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give a residue. The residue was purified by flash silica gel chromatography (12 g SepaFlash® silica flash column, 0-80% ethyl acetate / petroleum ether gradient @ 35 mL / min eluent). The compound 4-[2-amino-9-[(4-nitrophenyl)methyl]purin-6-yl]pyridine-2-carbonitrile (200 mg, 504.92 μmol, 77% yield, 94% purity) was a yellow solid. obtained as MS: m / z = 373.1 (M+1, ESI+).

[0506] Step 2: Preparation of 4-[2-amino-9-[(4-aminophenyl)methyl]purin-6-yl]pyridine-2-carbonitrile

[0507] 4-[2-amino-9-[(4-nitrophenyl)methyl]purin-6-yl]pyridine-2-carbonitrile (200 mg, 537.14 μmol, 1 eq) in ethanol (8 mL) and water (2 mL) and NH 4 Iron powder (150 mg, 2.69 mmol, 5 eq) was added to a solution of Cl (230 mg, 4.30 mmol, 8 eq). The mixture was then stirred at 80° C. for 1 hour. The reaction mixture was filtered and the filtrate was concentrated in vacuo, then water (50 mL) was added to the residue and extracted with ethyl acetate (50 mL x 3). The organic phases were combined and concentrated in vacuo to give a residue. The residue was subjected to preparative HPLC (column: Waters Vinridis Silica 2-EP OBD 50*150mm*5μm; mobile phase: [Heptane-EtOH (0.1% NH 3 H. 2 O)]; B%: 5%-45%, 10 min). Compound 118 or 4-[2-amino-9-[(4-aminophenyl)methyl]purin-6-yl]pyridine-2-carbonitrile (38.42 mg, 107.37 μmol, 20% yield, 92.28% purity) was Obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ = 9.05 (s, 1H), 8.98 (d, J = 5.3Hz, 1H), 8.89 (dd, J = 1.4, 5.2Hz, 1H), 8.33 (s, 1H), 7.05 (brd, J = 8.3 Hz, 2H), 6.82(s, 2H), 6.52(d, J=8.4Hz, 2H), 5.14(s, 2H), 5.11(s, 2H). HRMS-TOF: 343.1413.

[0508] Example 1.35: Preparation of 4-[2-amino-9-[(4-amino-2-fluoro-phenyl)methyl]purin-6-yl]pyridine-2-carbonitrile (Compound 122) TIFF2023505915000109.tif39158 Reagents and Conditions: (a) Pd(dppf)Cl 2 , K 2 CO 3 , dioxane / H 2 O, 110°C, 2 hours, MW. (b) Fe, NH 4 Cl, THF / H 2 O, 80°C, 1 hour.

[0509] Step 1: Preparation of 4-[2-amino-9-[(2-fluoro-4-nitro-phenyl)methyl]purin-6-yl]pyridine-2-carbonitrile

[0510] Intermediate compound S16 or 6-chloro-9-[(2-fluoro-4-nitro-phenyl)methyl]purin-2-amine (300 mg, 929.71 μmol, 1 eq), 4-(4,4,5,5 -tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-2-carbonitrile (428 mg, 1.86 mmol, 2 eq), K 2 CO 3 (257 mg, 1.86 mmol, 2 eq) and Pd(dppf)Cl 2 A mixture of (68 mg, 92.97 μmol, 0.1 equiv) was taken in a microwave tube in dioxane (8 mL) and water (2 mL). The sealed tube was heated at 110° C. for 2 hours under microwave conditions. The mixture was concentrated in vacuo to give a residue. The residue was purified by flash silica gel chromatography (12 g SepaFlash® silica flash column, 0-50% ethyl acetate / petroleum ether gradient @ 60 mL / min eluent). Compound 4-[2-amino-9-[(2-fluoro-4-nitro-phenyl)methyl]purin-6-yl]pyridine-2-carbonitrile (200 mg, 478.83 μmol, 52% yield, 93.45% purity ) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ = 9.04 (s, 1H), 8.99 (d, J = 4.6Hz, 1H), 8.88 (dd, J = 1.5, 5.1Hz, 1H), 8.41 (s, 1H), 8.18 (dd, J = 2.1 , 9.9Hz, 1H), 8.04(dd, J=1.9, 8.6Hz, 1H), 7.35(t, J=8.0Hz, 1H), 6.86(s, 2H), 5.56(s, 2H). MS: m / z = 391.1 (M+1, ESI+).

[0511] Step 2: Preparation of 4-[2-amino-9-[(4-amino-2-fluoro-phenyl)methyl]purin-6-yl]pyridine-2-carbonitrile

[0512] 4-[2-amino-9-[(2-fluoro-4-nitro-phenyl)methyl]purin-6-yl]pyridine-2-carbonitrile (200 mg, 512.39 mg) in ethanol (9 mL) and water (3 mL) μmol, 1 eq) of iron powder (143 mg, 2.56 mmol, 5 eq) and NH 4 Cl (219 mg, 4.10 mmol, 8 eq) was added. The mixture was then stirred at 80° C. for 1 hour. The reaction mixture was filtered and the filtrate was concentrated in vacuo. Water (80 mL) was added to the residue and extracted with ethyl acetate (80 mL×3). The combined organic phase was washed with brine (100 mL x 2) and dried over anhydrous Na. 2 SO 4 , filtered, and concentrated in vacuo to give a residue. The residue was subjected to preparative HPLC (column: Phenomenex Gemini NX-C18 (75*30mm*3μm); mobile phase: [water (10mM NH 4 HCOs 3)-ACN]; B%: 18%-48%, 8 min). Compound 122 or 4-[2-amino-9-[(4-amino-2-fluoro-phenyl)methyl]purin-6-yl]pyridine-2-carbonitrile (20.14 mg, 54.73 μmol, 11% yield, 98.80% purity) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ = 9.04 (s, 1H), 8.97 (d, J = 5.1Hz, 1H), 8.87 (dd, J = 1.5, 5.1Hz, 1H), 8.22 (s, 1H), 6.99 (t, J = 8.5 Hz, 1H), 6.81(s, 2H), 6.34(s, 1H), 6.32(brd, J=1.2Hz, 1H), 5.48(s, 2H), 5.18(s, 2H). HRMS-TOF: 361.1317.

[0513] Example 1.36: Preparation of 4-[2-amino-9-[(4-amino-2,6-difluoro-phenyl)methyl]purin-6-yl]pyridine-2-carbonitrile (Compound 126) TIFF2023505915000110.tif39158 Reagents and Conditions: (a) Pd(dppf)Cl 2 , K 2 CO 3 , dioxane / H 2 O, 110°C, 2 hours. (b) Fe, NH 4 Cl, THF / H 2 O, 80°C, 0.5 hours.

[0514] Step 1: Preparation of 4-[2-amino-9-[(2,6-difluoro-4-nitro-phenyl)methyl]purin-6-yl]pyridine-2-carbonitrile

[0515] Intermediate compound S13 or 6-chloro-9-[(2,6-difluoro-4-nitro-phenyl)methyl]purin-2-amine (160 mg, 469.66 μmol, 1 eq.), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-2-carbonitrile (540 mg, 2.35 mmol, 5 eq.) in a solution of K 2 CO 3 (130 mg, 939.32 μmol, 2 eq) and Pd(dppf)Cl 2 (34 mg, 46.97 μmol, 0.1 eq) was added. The mixture was stirred at 110° C. for 2 hours. Water (30 mL) was added to the mixture, extracted with ethyl acetate (30 mL×3), and the combined organic phase was washed with anhydrous Na 2 SO 4 , filtered, and concentrated in vacuo to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 12 g Sepa Flash® silica flash column, 0-42% ethyl acetate / petroleum ether gradient @ 40 mL / min eluent). Compound 4-[2-amino-9-[(2,6-difluoro-4-nitro-phenyl)methyl]purin-6-yl]pyridine-2-carbonitrile (75 mg, 174.50 μmol, 37% yield, 95 % Purity) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 )δ=9.02-9.00(m, 1H), 8.97(dd, J=0.6, 5.1Hz, 1H), 8.85(dd, J=1.6, 5.1Hz, 1H), 8.38(s, 1H), 8.10(d , J=7.5Hz, 2H), 6.79(s, 2H), 5.53(s, 2H). MS: m / z=409.1(M+1, ESI+)

[0516] Step 2: Preparation of 4-[2-amino-9-[(4-amino-2,6-difluoro-phenyl)methyl]purin-6-yl]pyridine-2-carbonitrile

[0517] 4-[2-amino-9-[(2,6-difluoro-4-nitro-phenyl)methyl]purin-6-yl]pyridine-2-carbonitrile (92 mg) in ethanol (8 mL) and water (2 mL) , 225.31 μmol, 1 eq.), iron powder (63 mg, 1.13 mmol, 5 eq.) and NH 4 Cl (96 mg, 1.80 mmol, 8 eq) was added. The mixture was stirred at 80° C. for 0.5 hours. The mixture was filtered and the filtrate was concentrated in vacuo to give a residue. Water (40 mL) was added to the residue and extracted with ethyl acetate (30 mL×3). The combined organic layers were concentrated under reduced pressure to give a residue. The residue was subjected to preparative HPLC (column: Welch Ultimate XB-CN 250*25*10 μm; mobile phase: [heptane-EtOH (0.1% NH 3 ·H 2 O)]; B%: 25%-65%, 15 min). Compound 126 or 4-[2-amino-9-[(4-amino-2,6-difluoro-phenyl)methyl]purin-6-yl]pyridine-2-carbonitrile (38 mg, 99.43 μmol, 44% yield , 97.67% purity) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ = 9.03 (dd, J = 0.8, 1.6Hz, 1H), 8.97 (dd, J = 0.9, 5.1Hz, 1H), 8.86 (dd, J = 1.6, 5.1Hz, 1H), 8.13 (s, 1H ), 6.79(s, 2H), 6.21(d, J=10.5Hz, 2H), 5.88(s, 2H), 5.18(s, 2H). HRMS-TOF: 379.1231.

[0518] Example 1.37: Preparation of 4-[2-amino-9-[(2,6-difluorophenyl)methyl]purin-6-yl]pyridine-2-carbonitrile (Compound 134) TIFF2023505915000111.tif37150 Reagents and Conditions: (a) Pd(dppf)Cl 2 , K 2 CO 3 , dioxane / H 2 O, 110°C, 15 hours.

[0519] Intermediate compound S22 or 6-chloro-9-[(2,6-difluorophenyl)methyl]purin-2-amine (100 mg, 338.21 μmol, 1 eq) in dioxane (5 mL) and water (0.5 mL), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-2-carbonitrile (117 mg, 507.31 μmol, 1.5 eq), K 2 CO 3 (94 mg, 676.42 μmol, 2 eq) and Pd(dppf)Cl 2 A mixture of (25 mg, 33.82 μmol, 0.1 eq) was degassed and heated to 110° C. under nitrogen for 15 hours. Water (20 mL) was added to the mixture and extracted with ethyl acetate (30 mL×3). The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give a residue. The residue was purified by flash silica gel chromatography (4 g SepaFlash® silica flash column, 0-100% ethyl acetate / petroleum ether gradient @ 30 mL / min eluent) to give impure product. The impure product was purified by preparative HPLC (column: Xtimate C18 150*40mm*10μm; mobile phase: [water (0.05% ammonium hydroxide v / v)-ACN]; B%: 30%-60%, 10 min). Refined. Compound 134 or 4-[2-amino-9-[(2,6-difluorophenyl)methyl]purin-6-yl]pyridine-2-carbonitrile (18.9 mg, 50.98 μmol, 15% yield, 98.03% purity ) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 )δ=9.03(s, 1H), 8.98(dd, J=0.6, 5.1Hz, 1H), 8.86(dd, J=1.6, 5.1Hz, 1H), 8.29(s, 1H), 7.54-7.43(m , 1H), 7.17(t, J=8.1Hz, 2H), 6.80(s, 2H), 5.44(s, 2H). HRMS-TOF: 364.1120.

[0520] Example 1.38: Preparation of 4-[2-amino-9-[(4-amino-3-methyl-phenyl)methyl]purin-6-yl]pyridine-2-carbonitrile (Compound 130) TIFF2023505915000112.tif40155 Reagents and Conditions: (a) Pd(dppf)Cl 2 , K 2 CO 3 , dioxane / H 2 O, 110°C, 2 hours, MW. (b) Fe, NH 4 Cl, THF / H 2 O, 80°C, 1 hour.

[0521] Step 1: Preparation of 4-[2-amino-9-[(3-methyl-4-nitro-phenyl)methyl]purin-6-yl]pyridine-2-carbonitrile

[0522] Intermediate compound S19 or 6-chloro-9-[(3-methyl-4-nitro-phenyl)methyl]purin-2-amine (100 mg, 313.76 μmol, 1 eq.) in dioxane (3 mL) and water (0.3 mL) ), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-2-carbonitrile (144 mg, 627.51 μmol, 2 eq), Pd(dppf)Cl 2 (23 mg, 31.38 μmol, 0.1 equiv) and K 2 CO 3 A mixture of (87 mg, 627.51 μmol, 2 eq) was degassed and purged with nitrogen three times before stirring at 110° C. for 2 hours under microwave irradiation. Water (30 mL) was added to the mixture and extracted with ethyl acetate (30 mL×3). The combined organic phase was washed with anhydrous Na 2 SO 4, filtered, and concentrated in vacuo to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 12 g Sepa Flash® silica flash column, 0-80% ethyl acetate / petroleum ether gradient @ 35 mL / min eluent). Compound 4-[2-amino-9-[(3-methyl-4-nitro-phenyl)methyl]purin-6-yl]pyridine-2-carbonitrile (104 mg, 242.26 μmol, 77% yield, 90% purity ) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ = 9.05 (s, 1H), 8.99 (d, J = 5.1Hz, 1H), 8.89 (dd, J = 1.6, 5.1Hz, 1H), 8.44 (s, 1H), 7.97 (d, J = 8.4 Hz, 1H), 7.41(s, 1H), 7.28(dd, J=1.4, 8.5Hz, 1H), 6.85(s, 2H), 5.45(s, 2H), 2.51(s, 3H). MS: m / z=387.1 (M+1, ESI+)

[0523] Step 2: Preparation of 4-[2-amino-9-[(4-amino-3-methyl-phenyl)methyl]purin-6-yl]pyridine-2-carbonitrile

[0524] 4-[2-amino-9-[(3-methyl-4-nitro-phenyl)methyl]purin-6-yl]pyridine-2-carbonitrile (200 mg, 517.64 μmol, 1 eq.) to a solution of iron powder (145 mg, 2.59 mmol, 5 eq.) and NH 4 Cl (221 mg, 4.14 mmol, 8 eq) was added. The mixture was stirred at 80° C. for 1 hour. The mixture was filtered and the filtrate was concentrated in vacuo to give a residue. Water (40 mL) was added to the residue and extracted with ethyl acetate (30 mL×3). The combined organic layers were concentrated under reduced pressure to give a residue. The crude product was triturated with THF at 70° C. for 30 minutes. Compound 130 or 4-[2-amino-9-[(4-amino-3-methyl-phenyl)methyl]purin-6-yl]pyridine-2-carbonitrile (62 mg, 167.01 μmol, 32% yield, 96.73 % purity) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 )δ=9.04(s, 1H), 8.97(d, J=5.1Hz, 1H), 8.87(dd, J=1.5, 5.1Hz, 1H), 8.32(s, 1H), 6.99-6.88(m, 2H ), 6.85(s, 2H), 6.54(d, J=8.0Hz, 1H), 5.12(s, 2H), 4.87(s, 2H), 2.00(s, 3H). HRMS-TOF: 357.1568.

[0525] Example 1.39: Preparation of 4-[2-amino-9-[[4-amino-3-(trifluoromethyl)phenyl]methyl]purin-6-yl]pyridine-2-carbonitrile (Compound 136) TIFF2023505915000113.tif42155 Reagents and conditions: (a) APhos-Pd-G3, K 3 P.O. 4 , DMAc, 60°C, 16 hours (b) Fe, NH 4 Cl, EtOH / H 2 O, 60°C, 1 hour.

[0526] Step 1: Preparation of 4-[2-amino-9-[[4-nitro-3-(trifluoromethyl)phenyl]methyl]purin-6-yl]pyridine-2-carbonitrile

[0527] Intermediate compound S23 or 6-chloro-9-[[4-nitro-3-(trifluoromethyl)phenyl]methyl]purin-2-amine (50 mg, 134.16 μmol, 1 eq) in DMAc (2 mL), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-2-carbonitrile (34 mg, 147.58 μmol, 1.1 eq), K 3 P.O. 4 (1.5 M aqueous solution, 90 µL, 1 eq.) and APhos-Pd-G3 (8.52 mg, 13.42 µmol, 0.1 eq.) was degassed and purged with nitrogen three times, after which the mixture was heated at 60 °C under a nitrogen atmosphere. Stirred for 16 hours. The reaction mixture was concentrated under reduced pressure to remove solvent. Prep-TLC (SiO 2 , ethyl acetate / petroleum ether=1:1). Compound 4-[2-amino-9-[[4-nitro-3-(trifluoromethyl)phenyl]methyl]purin-6-yl]pyridine-2-carbonitrile (40 mg, 90.84 μmol, 68% yield) was obtained as a yellow oil. MS: m / z = 441.1 (M+1, ESI+).

[0528] Step 2: Preparation of 4-[2-amino-9-[[4-amino-3-(trifluoromethyl)phenyl]methyl]purin-6-yl]pyridine-2-carbonitrile 4-[2-amino-9-[[4-nitro-3-(trifluoromethyl)phenyl]methyl]purin-6-yl]pyridine-2-carbonitrile ( iron powder (25 mg, 454.2 μmol, 5 eq) and NH 4 Cl (39 mg, 726.72 μmol, 8 eq) was added. The mixture was stirred at 60° C. for 1 hour. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (column: Welch Ultimate XB-SiOH 250*50*10 μm; mobile phase: [hexane-EtOH (0.1% ammonium hydroxide)]; B%: 10%-50%, 15 min). bottom. Compound 136 or 4-[2-amino-9-[[4-amino-3-(trifluoromethyl)phenyl]methyl]purin-6-yl]pyridine-2-carbonitrile (8.9 mg, 20.71 μmol, 23% Yield, 95.51% purity) was obtained as a white solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ = 9.03 (s, 1H), 8.97 (d, J = 5.1Hz, 1H), 8.87 (dd, J = 1.3, 5.1Hz, 1H), 8.38 (s, 1H), 7.41 (s, 1H), 7.29 (brd, J=8.4Hz, 1H), 6.84 (s, 2H), 6.79 (d, J=8.5Hz, 1H), 5.66 (s, 2H), 5.20 (s, 2H). HRMS-TOF: 411.1305.

[0529] Example 1.40: Preparation of 3-(6-amino-1-(4-amino-3-methylbenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)benzonitrile (Compound 204)

[0530] 1.40.1. Preparation of 3-(6-amino-1H-pyrazolo[3,4-d]pyrimidin-4-yl)benzonitrile (Intermediate Compound S107) TIFF2023505915000114.tif33122 Reagents and conditions: (a) Pd(PPh 3 ) 4 , Na 2 CO 3 , dioxane / H 2 O, 100°C, 16 hours.

[0531] 4-chloro-1H-pyrazolo[3,4-d]pyrimidin-6-amine (500 mg, 1 eq), (3-cyanophenyl)boronic acid (519 mg, 1.2 eq), Pd(PPh) in dioxane (20 mL) 3 ) 4 (340 mg, 0.1 eq.) and Na 2 CO 3 A mixture of (625 mg, 2 eq) was degassed and purged with nitrogen three times, then the mixture was stirred at 100° C. for 16 h under nitrogen atmosphere. The reaction mixture was partitioned between ethyl acetate (100 mL) and water (30 mL). The organic phase was separated, washed with brine (20 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The crude product 3-(6-amino-1H-pyrazolo[3,4-d]pyrimidin-4-yl)benzonitrile (500 mg, crude) was obtained as a yellow solid and carried on to the next step without further purification. Used. MS: m / z=237.1 (M+1, ESI+).

[0532] 1.40.2. Preparation of 3-(6-amino-1-(4-amino-3-methylbenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)benzonitrile (Compound 204). TIFF2023505915000115.tif36148 Reagents and conditions: (a) K 2 CO 3 , DMF, 80 °C, 16 h; (b) Fe, NH 4 Cl, EtOH / H 2 O, 60°C, 1 hour.

[0533] Step 1: Preparation of 3-[6-amino-1-[(3-methyl-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]benzonitrile

[0534] 4-(Chloromethyl)-2-methyl-1-nitrobenzene (500 mg, 1.27 equiv) and intermediate compound S107 or 3-(6-amino-1H-pyrazolo[3,4-d]pyrimidine in DMF (10 mL) K in a solution of -4-yl)benzonitrile (500 mg, 1 eq.) 2 CO 3(585 mg, 2 eq) was added. The mixture was stirred at 80° C. for 16 hours. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (column: Phenomenex Luna C18 150*25mm*10μm; mobile phase: [water (0.225% FA)-ACN]; B%: 40%-70%, 10 min). The compound 3-[6-amino-1-[(3-methyl-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]benzonitrile (200 mg, 24% yield) was Obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ = 8.56-8.42 (m, 3H), 8.10-8.06 (m, 1H), 8.00-7.92 (m, 1H), 7.86-7.76 (m, 1H), 7.40-7.30 (m, 1H), 7.24- 7.08(m, 3H), 5.65-5.43(m, 2H), 2.49(s, 3H). MS: m / z=386.0 (M+1, ESI+).

[0535] Step 2: Preparation of 3-(6-amino-1-(4-amino-3-methylbenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)benzonitrile (Compound 204)

[0536] 3-[6-amino-1-[(3-methyl-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]benzonitrile in ethanol (12 mL) and water (4 mL) (150 mg, 1 eq) iron powder (108 mg, 1.95 mmol, 5 eq) and NH 4 Cl (166 mg, 8 eq) was added. The mixture was stirred at 60° C. for 1 hour. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (column: Phenomenex Luna C18 150*25mm*10μm; mobile phase: [water (0.225% FA)-ACN]; B%: 23%-53%, 10 min). Compound 204 or 3-[6-amino-1-[(4-amino-3-methyl-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]benzonitrile (54.26 mg, 38% yield) , 98.27% purity) was obtained as a white solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ = 8.54-8.49 (m, 1H), 8.49-8.45 (m, 1H), 8.37-8.31 (m, 1H), 8.09-8.01 (m, 1H), 7.84-7.70 (m, 1H), 7.16- 6.99(m, 2H), 6.91-6.86(m, 1H), 6.86-6.80(m, 1H), 6.58-6.45(m, 1H), 5.33-5.14(m, 2H)), 4.98-4.57(m, 2H), 2.02-1.96(m, 3H).

[0537] Example 1.41: 3-(6-Amino-1-(4-amino-3-methylbenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-2-fluorobenzonitrile (Compound 206) Manufacturing of

[0538] 1.41.1. Preparation of 4-chloro-1-(3-methyl-4-nitrobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine (Intermediate Compound S108) TIFF2023505915000116.tif42120 Reagents and conditions: (a) K 2 CO 3 , DMAc, 80 °C, 16 h.

[0539] 4-chloro-1H-pyrazolo[3,4-d]pyrimidin-6-amine (0.8 g, 1 eq) and 4-(chloromethyl)-2-methyl-1-nitrobenzene (720 mg, 0.8) K in the solution 2 CO 3 (1.30 g, 2 eq) was added. The mixture was stirred at 80° C. for 16 hours. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The crude product 4-chloro-1-[(3-methyl-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-6-amine (800 mg, crude) was obtained as a yellow solid, plus Used for next step without purification. MS: m / z = 354.9 (M+1, ESI+).

[0540] 1.41.2. 3-(6-Amino-1-(4-amino-3-methylbenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-2-fluorobenzonitrile (compound 206) Manufacturing of TIFF2023505915000117.tif39153 Reagents and conditions: (a) Pd(PPh 3 ) 4 , K 2 CO 3 , dioxane / H 2 O, 100°C, 16 hours; (b) Fe, NH 4 Cl, EtOH / H 2 O, 60°C, 1 hour.

[0541] Step 1: Preparation of 3-(6-amino-1-(3-methyl-4-nitrobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-2-fluorobenzonitrile

[0542] (3-Cyano-2-fluoro-phenyl)boronic acid (434 mg, 1.2 eq) in dioxane (10 mL) and water (2 mL), intermediate compound S108 or 4-chloro-1-[(3-methyl-4- Nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-6-amine (700mg, 1eq), Pd(PPh 3 ) 4 (253 mg, 219.63 μmol, 0.1 equiv) and Na 2 CO 3 A mixture of (465 mg, 2 eq) was degassed and purged with nitrogen three times, then the mixture was stirred at 110° C. for 16 h under nitrogen atmosphere. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 40 g Sepa Flash® silica flash column, 0-80% ethyl acetate / petroleum ether gradient @ 40 mL / min eluent). Compound 3-[6-amino-1-[(3-methyl-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]-2-fluoro-benzonitrile (800mg, 90% yield) was obtained as a yellow solid. MS: m / z=386.0 (M+1, ESI+).

[0543] Step 2: Preparation of 3-(6-amino-1-(4-amino-3-methylbenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-2-fluorobenzonitrile (Compound 206) manufacturing

[0544] 3-[6-amino-1-[(3-methyl-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]-2 in water (4 mL) and ethanol (12 mL) Iron powder (138 mg, 5 eq) and NH 4 Cl (212 mg, 8 eq) was added. The mixture was stirred at 60° C. for 1 hour. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (Column: Phenomenex Synergi C18 150*25mm*10μm; mobile phase: [water (0.225%FA)-ACN]; B%: 16%-46%, 11min) and subjected to the first 89% pure compound was obtained after purification. The residue was purified by preparative HPLC (column: Phenomenex Luna C18 150*25mm*10μm; mobile phase: [water (0.225% FA)-ACN]; B%: 18%-48%, 10 min). Compound 206 or 3-[6-amino-1-[(4-amino-3-methyl-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]-2-fluoro-benzonitrile (111.35mg , 59% yield, 97.78% purity) was obtained as a white solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ = 8.21-8.10 (m, 2H), 8.00-7.94 (m, 1H), 7.66-7.52 (m, 1H), 7.16-7.07 (m, 2H), 6.92-6.80 (m, 2H), 6.56- 6.46(m, 1H), 5.34-5.15(m, 2H), 4.93-4.67(m, 2H), 2.06-1.88(m, 3H).

[0545] Example 1.42: 3-(6-Amino-1-(4-amino-3-(trifluoromethyl)benzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)benzonitrile (Compound 210) Manufacturing of

[0546] 1.42.1. Preparation of 4-chloro-1-(4-nitro-3-(trifluoromethyl)benzyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine (Intermediate Compound S109) TIFF2023505915000118.tif41132 Reagents and conditions: (a) K 2 CO 3 , DMAc, 80°C, 16 hours.

[0547] 4-(Chloromethyl)-1-nitro-2-(trifluoromethyl)benzene (3.39 g, 1.2 eq) and 4-chloro-1H-pyrazolo[3,4-d]pyrimidine-6 ​​in DMF (20 mL) - K in a solution of amine (2 g, 1 eq.) 2 CO 3(3.26 g, 2 eq) was added. The mixture was stirred at 80° C. for 16 hours. The reaction mixture was concentrated under reduced pressure to remove DMF to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 40 g Sepa Flash® silica flash column, 0-100% ethyl acetate / petroleum ether gradient @ 45 mL / min). Compound 4-chloro-1-[[4-nitro-3-(trifluoromethyl)phenyl]methyl]pyrazolo[3,4-d]pyrimidin-6-amine (2 g, 45% yield) as a yellow solid Got. MS: m / z=373.3 (M+1, ESI+)

[0548] 1.42.2. 3-(6-Amino-1-(4-amino-3-(trifluoromethyl)benzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)benzonitrile (Compound 210) Manufacturing of TIFF2023505915000119.tif42160 Reagents and conditions: (a) Pd(PPh 3 ) 4 , K 2 CO 3 , dioxane / H 2 O, 100°C, 15 hours; (b) Fe, NH 4 Cl, EtOH / H 2 O, 60°C, 2 hours.

[0549] Step 1: Preparation of 3-(6-amino-1-(4-nitro-3-(trifluoromethyl)benzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)benzonitrile

[0550] (3-Cyanophenyl)boronic acid (236 mg, 1.5 eq) in dioxane (10 mL) and water (1 mL), intermediate compound S109 or 4-chloro-1-[[4-nitro-3-(trifluoromethyl) Phenyl]methyl]pyrazolo[3,4-d]pyrimidin-6-amine (400mg, 1eq), Pd(PPh 3 ) 4 (124 mg, 0.1 eq), K 2 CO 3 A mixture of (296 mg, 2 eq) was degassed and purged with nitrogen three times, then the mixture was stirred at 100° C. for 15 h under nitrogen atmosphere. The reaction mixture was concentrated under reduced pressure to remove dioxane and water to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 12 g Sepa Flash® silica flash column, 0-100% ethyl acetate / petroleum ether gradient @ 35 mL / min eluent). Compound 3-[6-amino-1-[[4-nitro-3-(trifluoromethyl)phenyl]methyl]pyrazolo[3,4-d]pyrimidin-4-yl]benzonitrile (300mg, 63% yield) ) was obtained as a yellow oil. MS: m / z = 440.1 (M+1, ESI+).

[0551] Step 2: Preparation of 3-(6-amino-1-(4-amino-3-(trifluoromethyl)benzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)benzonitrile (Compound 210) manufacturing

[0552] 3-[6-amino-1-[[4-nitro-3-(trifluoromethyl)phenyl]methyl]pyrazolo[3,4-d]pyrimidin-4-yl in water (5 mL) and ethanol (15 mL) ] iron powder (190 mg, 5 eq) and NH 4 Cl (292 mg, 8 eq) was added. The mixture was stirred at 60° C. for 2 hours. The reaction mixture was concentrated under reduced pressure to remove ethanol to give a residue. The residue was purified by preparative HPLC (column: Unisil 3-100 C18 Ultra 150*50mm*3μm; mobile phase: [water (0.225% FA)-ACN]; B%: 43%-63%, 10 min). . Compound 210 or 3-[6-amino-1-[[4-amino-3-(trifluoromethyl)phenyl]methyl]pyrazolo[3,4-d]pyrimidin-4-yl]benzonitrile (59.98 mg, 21 % yield, purity 99.14%) was obtained as a white solid. 1 H NMR (400 MHz, DMSO-d 6 )δ=8.52(s, 1H), 8.47(d, J=8.1Hz, 1H), 8.38(s, 1H), 8.06(d, J=7.7Hz, 1H), 7.79(t, J=7.8Hz, 1H), 7.30(d, J=1.5Hz, 1H), 7.23-7.17(m, 1H), 7.10(s, 2H), 6.78(d, J=8.4Hz, 1H), 5.59(s, 2H), 5.30(s, 2H).

[0553] Example 1.43: 3-(6-Amino-1-(4-amino-3-(trifluoromethyl)benzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-2-fluorobenzonitrile Production of (compound 211) TIFF2023505915000120.tif42161 Reagents and conditions: (a) Pd(PPh 3 ) 4 , K 2 CO 3 , dioxane / H 2 O, 100°C, 15 hours; (b) Fe, NH 4 Cl, EtOH / H 2 O, 60°C, 2 hours.

[0554] Step 1: 3-(6-Amino-1-(4-nitro-3-(trifluoromethyl)benzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-2-fluorobenzonitrile manufacturing

[0555] (3-Cyano-2-fluoro-phenyl)boronic acid (265 mg, 1.5 eq) in dioxane (10 mL) and water (1 mL), intermediate compound S109 or 4-chloro-1-[[4-nitro-3- A mixture of (trifluoromethyl)phenyl]methyl]pyrazolo[3,4-d]pyrimidin-6-amine (400 mg, 1 eq), Pd(PPh 3 ) 4 (124 mg, 0.1 eq), K 2 CO 3 A mixture of (296 mg, 2 eq) was degassed and purged with nitrogen three times, then the mixture was stirred at 100° C. for 15 h under nitrogen atmosphere. The reaction mixture was concentrated under reduced pressure to remove dioxane and water to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 12 g Sepa Flash® silica flash column, 0-100% ethyl acetate / petroleum ether gradient @ 35 mL / min eluent). Compound 3-[6-amino-1-[[4-nitro-3-(trifluoromethyl)phenyl]methyl]pyrazolo[3,4-d]pyrimidin-4-yl]-2-fluoro-benzonitrile (350mg , 71% yield) was obtained as a yellow oil. MS: m / z=458.3 (M+1, ESI+).

[0556] Step 2: 3-(6-amino-1-(4-amino-3-(trifluoromethyl)benzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-2-fluorobenzonitrile ( Production of compound 211)

[0557] 3-[6-amino-1-[[4-nitro-3-(trifluoromethyl)phenyl]methyl]pyrazolo[3,4-d]pyrimidin-4-yl in ethanol (15 mL) and water (5 mL) Iron powder (183 mg, 5 eq) and NH 4 Cl (280 mg, 8 eq) was added. The mixture was stirred at 60° C. for 2 hours. The reaction mixture was concentrated under reduced pressure to remove ethanol to give a residue. The residue was purified by preparative HPLC (column: Unisil 3-100 C18 Ultra 150*50mm*3μm; mobile phase: [water (0.225% FA)-ACN]; B%: 43%-63%, 10 min). . Compound 211 or 3-[6-amino-1-[[4-amino-3-(trifluoromethyl)phenyl]methyl]pyrazolo[3,4-d]pyrimidin-4-yl]-2-fluoro-benzonitrile (41.58 mg, 15% yield, 98.23% purity) was obtained as a pale yellow solid. 1 H NMR (400 MHz, DMSO-d 6 )δ=8.20-8.11(m, 2H), 8.00(d, J=3.5Hz, 1H), 7.60(t, J=7.8Hz, 1H), 7.30(d, J=1.6Hz, 1H), 7.23- 7.17(m, 1H), 7.15(s, 2H), 6.78(d, J=8.4Hz, 1H), 5.60(s, 2H), 5.29(s, 2H).

[0558] Example 1.44: Preparation of 3-(6-amino-1-(2,6-difluorobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-2-fluorobenzonitrile (Compound 213) TIFF2023505915000121.tif40164 Reagents and conditions: (a) K 2 CO 3 , DMAc, 80 °C, 16 h; (b) Pd(PPh 3 ) 4 , K 2 CO 3 , dioxane / H 2 O, 80°C, 16 hours.

[0559] Step 1: Preparation of 4-chloro-1-[(2,6-difluorophenyl)methyl]pyrazolo[3,4-d]pyrimidin-6-amine (intermediate compound S110)

[0560] 4-chloro-1H-pyrazolo[3,4-d]pyrimidin-6-amine (8 g, 47.18 mmol, 1 equiv) and 2-(bromomethyl)-1,3-difluorobenzene (11.72 g56 in DMAc (100 mL) .61 mmol, 1.2 equivalents) of K 2 CO 3 (13.04g, 94.36mmol, 2eq) was added. The mixture was stirred at 80° C. for 16 hours. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 80 g Sepa Flash® silica flash column, 0-100% ethyl acetate / petroleum ether gradient @ 60 mL / min eluent). Intermediate compound S110 or 4-chloro-1-[(2,6-difluorophenyl)methyl]pyrazolo[3,4-d]pyrimidin-6-amine (4 g, 13.53 mmol, 29% yield) as a white solid. Obtained. 1 H NMR (400 MHz, DMSO-d 6 ) δ = 8.35-7.77 (m, 1H), 7.53-7.41 (m, 1H), 7.40-7.31 (m, 2H), 7.19-6.98 (m, 2H), 5.60-5.20 (m, 2H).

[0561] Step 2: Preparation of 3-(6-amino-1-(2,6-difluorobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-2-fluorobenzonitrile (Compound 213)

[0562] (3-Cyano-2-fluoro-phenyl)boronic acid (251 mg, 1.5 eq) in dioxane (10 mL) and water (2 mL), intermediate compound S110 or 4-chloro-1-[(2,6-difluorophenyl )methyl]pyrazolo[3,4-d]pyrimidin-6-amine (300 mg, 1 eq), Pd(PPh 3 ) 4 (117 mg, 0.1 eq), K 2 CO 3 (280 mg, 2 eq.) The mixture was degassed and purged with nitrogen three times, then the mixture was stirred at 80° C. for 16 hours under nitrogen atmosphere. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (column: Unisil 3-100 C18 Ultra 150*50mm*3μm; mobile phase: [water (0.225% FA)-ACN]; B%: 45%-65%, 10 min). . Compound 213 or 3-[6-amino-1-[(2,6-difluorophenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]-2-fluoro-benzonitrile (118.51 mg, yield 30%, 98.93% purity) was obtained as a white solid. 1 H NMR (400 MHz, DMSO-d 6 )δ=8.22-8.09(m, 2H), 7.95(d, J=3.5Hz, 1H), 7.60(t, J=7.8Hz, 1H), 7.52-7.39(m, 1H), 7.19(s, 2H ), 7.13(t, J=8.0Hz, 2H), 5.45(s, 2H).

[0563] Example 1.45: Preparation of 3-(6-amino-1-(4-amino-2-fluorobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)benzonitrile (Compound 209) TIFF2023505915000122.tif33160 Reagents and conditions: (a) K 2 CO 3 , DMAc, 60 °C, 16 h; (b) Pd(PPh 3 ) 4 , K 2 CO 3 , dioxane / H 2 O, 80°C, 16 hours; (c) Fe, NH 4 Cl, EtOH / H 2 O, 80°C, 3 hours.

[0564] Step 1: Preparation of 4-chloro-1-(2-fluoro-4-nitrobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine (intermediate compound S111)

[0565] 4-chloro-1H-pyrazolo[3,4-d]pyrimidin-6-amine (5.1 g, 1 eq.) and 1-(bromomethyl)-2-fluoro-4-nitrobenzene (7 g, 1 eq.) in DMF (20 mL) equivalent) of K 2 CO 3 (8.3 g, 2 eq) was added. The mixture was stirred at 60° C. for 16 hours. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 40 g Sepa Flash® silica flash column, 0-100% ethyl acetate / petroleum ether gradient @ 40 mL / min eluent). Intermediate compound S111 or 4-chloro-1-[(2-fluoro-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-6-amine (5 g, 52% yield) was a yellow solid. obtained as 1 H NMR (400 MHz, DMSO-d 6 )δ=8.15-8.11(m, 1H), 8.08-8.06(m, 1H), 8.05-8.01(m, 1H), 7.47-7.38(m, 2H), 7.33(t, J=8.0Hz, 1H) , 5.57(s, 2H). MS: m / z=323.3 (M+1, ESI+).

[0566] Step 2: Preparation of 3-(6-amino-1-(2-fluoro-4-nitrobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)benzonitrile

[0567] (3-Cyanophenyl)boronic acid (341 mg, 1.5 eq) in dioxane (10 mL) and water (2 mL), intermediate compound S111 or 4-chloro-1-[(2-fluoro-4-nitro-phenyl)methyl ]pyrazolo[3,4-d]pyrimidin-6-amine (500mg, 1eq), Pd(PPh 3 ) 4 (179 mg, 0.1 equiv), K 2 CO 3 (428 mg, 2 eq) of the mixture was degassed and purged with nitrogen three times, then the mixture was stirred at 100° C. for 16 h under nitrogen atmosphere. The reaction mixture was concentrated under reduced pressure to remove dioxane to give a residue. The residue was purified by preparative HPLC (column: Unisil 3-100 C18 Ultra 150*50mm*3μm; mobile phase: [water (0.225% FA)-ACN]; B%: 45%-65%, 10 min). . Compound 3-[6-amino-1-[(2-fluoro-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]benzonitrile (200mg, 33% yield, 99% Purity) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ = 8.55-8.51 (m, 1H), 8.49-8.46 (m, 1H), 8.31-8.26 (m, 1H), 8.18-8.01 (m, 4H), 7.38-7.28 (m, 1H), 7.22- 7.05 (m, 2H), 5.62 (s, 2H). MS: m / z = 389.9 (M+1, ESI+).

[0568] Step 3: Preparation of 3-(6-amino-1-(4-amino-2-fluorobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)benzonitrile (Compound 209)

[0569] 3-[6-amino-1-[(2-fluoro-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]benzonitrile in ethanol (15 mL) and water (5 mL) Iron powder (143 mg, 5 eq) and NH 4 Cl (219 mg, 8 eq) was added. The mixture was stirred at 80° C. for 3 hours. The reaction mixture was concentrated under reduced pressure to remove ethanol and water to give a residue. The residue was purified by preparative HPLC (column: Unisil 3-100 C18 Ultra 150*50mm*3μm; mobile phase: [water (0.225% FA)-ACN]; B%: 30%-50%, 10 min). . Compound 209 or 3-[6-amino-1-[(4-amino-2-fluoro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]benzonitrile (36.42 mg, 19% yield) , 97.66% purity) was obtained as a pale yellow solid. 1 H NMR (400 MHz, DMSO-d 6 )δ=8.51(s, 1H), 8.49-8.44(m, 1H), 8.35(s, 1H), 8.08-8.01(m, 1H), 7.79(t, J=7.8Hz, 1H), 7.07(s , 2H), 6.88(t, J=8.5Hz, 1H), 6.36-6.22(m, 2H), 5.40(s, 2H), 5.28(s, 2H).

[0570] Example 1.46: Preparation of 3-(6-amino-1-(4-amino-2,6-difluorobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)benzonitrile (Compound 207) TIFF2023505915000123.tif59161 Reagents and conditions: (a1) NBS, AIBN, CCl 4 , 90°C, 15 hours; (a2) K 2 CO 3 , DMAc, 80 °C, 3 h; (b) Pd(dppf)Cl 2 , K 2 CO 3 , dioxane / H 2 O, 110°C, 2 hours, MW; (c) Fe, NH 4 Cl, EtOH / H 2 O, 80°C, 1 hour.

[0571] Step 1: Preparation of 4-chloro-1-[(2,6-difluoro-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-6-amine (intermediate compound S112)

[0572] NBS (3.08 g, 17.33 mmol, 1.5 eq) and AIBN (190 mg, 1.16 mmol, 0.1 eq.) was added. The mixture was then stirred at 90° C. for 15 hours. The reaction mixture was concentrated in vacuo to give a residue. DMAc (50 mL), 4-chloro-1H-pyrazolo[3,4-d]pyrimidin-6-amine (1.96 g, 11.55 mmol, 1 eq) and K 2 CO 3 (3.19 g, 23.11 mmol, 2 eq) was added. The mixture was then stirred at 80° C. for 3 hours. Water (130 mL) and ethyl acetate (130 mL) were added to the mixture and the layers were separated. The aqueous was extracted with ethyl acetate (130 mL x 2). The combined organic phases were washed with brine (150 mL x 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated in vacuo to give a residue. The residue was purified by flash silica gel chromatography (40 g Sepa Flash® silica flash column, 0-30% ethyl acetate / petroleum ether gradient @ 60 mL / min eluent). Intermediate compound S112 or 4-chloro-1-[(2,6-difluoro-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-6-amine (1.5 g, 4.26 mmol, 37% yield) yield, 96.7% purity) was obtained as a yellow solid.

[0573] Step 2: Preparation of 3-[6-amino-1-[(2,6-difluoro-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]benzonitrile

[0574] Intermediate compound S112 or 4-chloro-1-[(2,6-difluoro-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-6-amine (500mg, 1.47mmol, 1eq), (3-Cyanophenyl)boronic acid (323 mg, 2.20 mmol, 1.5 eq), K 2 CO 3 (405 mg, 2.94 mmol, 2 eq) and Pd(dppf)Cl 2 (107 mg, 146.77 μmol, 0.1 eq) was taken up in a microwave tube in dioxane (6 mL) and water (2 mL). The sealed tube was heated under microwave at 110° C. for 2 hours. Water (80 mL) and ethyl acetate (80 mL) were then added to the mixture and the layers were separated. The aqueous was extracted with ethyl acetate (80 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated in vacuo to give a residue. The residue was purified by flash silica gel chromatography (20 g SepaFlash® silica flash column, 0-100% ethyl acetate / petroleum ether gradient @ 50 mL / min eluent). Compound 3-[6-amino-1-[(2,6-difluoro-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]benzonitrile (200mg, 441.90μmol, 30% Yield, 90% purity) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 )δ=8.49(d, J=1.2Hz, 1H), 8.47-8.41(m, 1H), 8.35(s, 1H), 8.16-8.07(m, 2H), 8.06(td, J=1.3, 7.8Hz , 1H), 7.79(t, J=7.9Hz, 1H), 7.16(s, 2H), 5.55(s, 2H). MS: m / z=408.0 (M+1, ESI+).

[0575] Step 3: Preparation of 3-[6-amino-1-[(4-amino-2,6-difluoro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]benzonitrile (Compound 207)

[0576] 3-[6-amino-1-[(2,6-difluoro-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl] in ethanol (8 mL) and water (2 mL) Iron powder (137 mg, 2.45 mmol, 5 eq) and NH 4 Cl (210 mg, 3.93 mmol, 8 eq) was added. The mixture was then stirred at 80° C. for 1 hour. The reaction mixture was filtered and the filtrate was concentrated in vacuo. Water (30 mL) was then added to the mixture and then extracted with ethyl acetate (30 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated in vacuo to give a residue. The residue was purified by preparative HPLC (column: Welch Ultimate XB-CN 250*70*10μm; mobile phase: [hexane-EtOH (0.1% ammonium hydroxide)]; B%: 30%-70%, 15 min). bottom. Compound 207 or 3-[6-amino-1-[(4-amino-2,6-difluoro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]benzonitrile (62.95 mg, 163.33 μmol , 33% yield, 97.91% purity) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 )δ=8.49(t, J=1.4Hz, 1H), 8.45(td, J=1.4, 7.9Hz, 1H), 8.29(s, 1H), 8.05(td, J=1.3, 7.7Hz, 1H), 7.79(t, J=7.8Hz, 1H), 7.07(s, 2H), 6.30-6.06(m, 2H), 5.80(s, 2H), 5.25(s, 2H).

[0577] Example 1.47: 3-(6-Amino-1-(4-amino-2-fluorobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-2-fluorobenzonitrile (Compound 203) Manufacturing of TIFF2023505915000124.tif39160 Reagents and Conditions: (a) Pd(dppf)Cl 2 , K 2 CO 3 , dioxane / H 2 O, 110°C, 16 hours; (b) Fe, NH 4 Cl, EtOH / H 2 O, 80°C, 3 hours.

[0578] Step 1: Preparation of 3-(6-amino-1-(2-fluoro-4-nitrobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-2-fluorobenzonitrile

[0579] (3-Cyano-2-fluoro-phenyl)boronic acid (383 mg, 2.33 mmol, 1.5 eq), intermediate compound S111 or 4-chloro-1-[(2-fluoro) in dioxane (10 mL) and water (2 mL) -4-Nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-6-amine (500 mg, 1 eq), Pd(PPh 3 ) 4 (179 mg, 0.1 equiv), K 2 CO 3 After degassing the mixture of (428 mg, 2 eq) and purging with nitrogen three times, the mixture was stirred at 100° C. for 16 h under a nitrogen atmosphere. The reaction mixture was concentrated under reduced pressure to remove dioxane to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 12 g Sepa Flash® silica flash column, 0-80% ethyl acetate / petroleum ether gradient @ 30 mL / min eluent). Compound 3-[6-amino-1-[(2-fluoro-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]-2-fluoro-benzonitrile (300mg, 48% yield) was obtained as a yellow solid. MS: m / z = 407.9 (M+1, ESI+).

[0580] Step 2: Preparation of 3-(6-amino-1-(4-amino-2-fluorobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-2-fluorobenzonitrile (Compound 203) manufacturing

[0581] 3-[6-amino-1-[(2-fluoro-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]-2 in ethanol (15 mL) and water (5 mL) Iron powder (143 mg, 5 eq) and NH 4 Cl (219 mg, 8 eq) was added. The mixture was stirred at 80° C. for 3 hours. The reaction mixture was concentrated under reduced pressure to remove ethanol to give a residue. The residue was purified by preparative HPLC (Column: Unisil 3-100 C18 Ultra 150*50mm*3μm; mobile phase: [water (0.225% FA)-ACN]; B%: 33%-53%, 10 min). . After obtaining the target compound with 80% purity, the residue was purified by a second preparative HPLC (column: Phenomenex Gemini-NX C18 75*30mm*3μm; mobile phase: [water (0.225%FA)-ACN ]; B%: 22%-52%, 7 min). Compound 203 or 3-[6-amino-1-[(4-amino-2-fluoro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]-2-fluoro-benzonitrile (62.37mg , 31% yield, 97.40% purity) was obtained as a white solid. 1 H NMR (400 MHz, DMSO-d 6 )δ=8.21-8.10(m, 2H), 7.98(d, J=3.7Hz, 1H), 7.61(t, J=7.8Hz, 1H), 7.14(s, 2H), 6.97-6.84(m, 1H ), 6.32(s, 1H), 6.31-6.28(m, 1H), 5.42(s, 2H), 5.27(s, 2H).

[0582] Example 1.48: 3-(6-amino-1-(4-amino-2,6-difluorobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-2-fluorobenzonitrile (compound 208) manufacturing TIFF2023505915000125.tif41160 Reagents and Conditions: (a) Pd(dppf)Cl 4 , K 2 CO 3 , dioxane / H 2 O, 110°C, 15 hours. (b) Fe, NH 4 Cl, EtOH / H 2 O, 80°C, 1 hour.

[0583] Step 1: 3-[6-Amino-1-[(2,6-difluoro-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]-2-fluoro-benzonitrile manufacturing

[0584] Intermediate compound S112 or 4-chloro-1-[(2,6-difluoro-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidine-6- in water (2 mL) and dioxane (8 mL) (3-Cyano-2-fluoro-phenyl)boronic acid (300 mg, 1.82 mmol, 1.55 eq), Pd(dppf)Cl in a solution of amine (400 mg, 1.17 mmol, 1 eq) 2 (86 mg, 117.41 μmol, 0.1 equiv) and K 2 CO 3 (325 mg, 2.35 mmol, 2 eq) was added. The mixture was then stirred at 110° C. for 15 hours. The mixture was then concentrated in vacuo to give a residue which was purified by flash silica gel chromatography (12 g SepaFlash® silica flash column, 20-100% ethyl acetate / petroleum ether gradient @ 50 mL / min eluent). ). Compound 3-[6-amino-1-[(2,6-difluoro-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]-2-fluoro-benzonitrile (140mg, 322.25 μmol, 27% yield, 97.9% purity) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 )δ=8.20-8.12(m, 2H), 8.12-8.05(m, 2H), 7.99(d, J=3.6Hz, 1H), 7.60(t, J=7.8Hz, 1H), 7.22(s, 2H ), 5.54(s, 2H). MS: m / z = 426.1 (M+1, ESI+).

[0585] Step 2: 3-(6-amino-1-(4-amino-2,6-difluorobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-2-fluorobenzonitrile (compound 208 )Manufacturing of

[0586] 3-[6-amino-1-[(2,6-difluoro-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl] in ethanol (8 mL) and water (2 mL) Iron powder (92 mg, 1.65 mmol, 5 eq) and NH 4 Cl (140 mg, 2.63 mmol, 8 eq) was added. The mixture was then stirred at 80° C. for 1 hour. The reaction mixture was filtered and the filtrate was concentrated in vacuo. Water (50 mL) was added to the mixture and then extracted with ethyl acetate (30 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give a residue. The residue was subjected to preparative HPLC (column: Welch Ultimate XB-CN 250*70*10 μm; mobile phase: [hexane-EtOH (0.1% NH 3 ·H 2 O)]; B%: 35%-75%, 15 min). Compound 208 or 3-[6-amino-1-[(4-amino-2,6-difluoro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]-2-fluoro-benzonitrile ( 44.01 mg, 109.41 μmol, 33% yield, 98.28% purity) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ = 8.14 (dd, J = 6.7, 7.7Hz, 2H), 7.93 (d, J = 3.6Hz, 1H), 7.60 (t, J = 7.8Hz, 1H), 7.13 (s, 2H), 6.27- 6.07(m, 2H), 5.80(s, 2H), 5.24(s, 2H).

[0587] Example 1.49: Preparation of 4-[6-amino-1-[(2,6-difluorophenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-2-carbonitrile (Compound 234) TIFF2023505915000126.tif36161 Reagents and Conditions: (a) Pd(dppf)Cl 2 , K 2 CO 3 , dioxane / H 2 O, 80°C, 16 hours.

[0588] Intermediate compound S110 or 4-chloro-1-[(2,6-difluorophenyl)methyl]pyrazolo[3,4-d]pyrimidin-6-amine (300 mg, 1 eq), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-2-carbonitrile (279 mg, 1.2 eq), K 2 CO 3 (279 mg, 2 eq), Pd(dppf)Cl 2 (74 mg, 0.1 eq.) The mixture was degassed and purged with nitrogen three times, then the mixture was stirred at 80° C. for 16 hours under nitrogen atmosphere. The reaction mixture was concentrated under reduced pressure to remove dioxane to give a residue. The residue was purified by preparative HPLC (column: Unisil 3-100 C18 Ultra 150*50mm*3μm; mobile phase: [water (0.225% FA)-ACN]; B%: 38%-58%, 10 min). . Compound 234 or 4-[6-amino-1-[(2,6-difluorophenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-2-carbonitrile (124.39 mg, 34% yield) yield, 99.96% purity) was obtained as a white solid. 1 H NMR (400 MHz, DMSO-d 6 )δ=8.96(d, J=5.1Hz, 1H), 8.58(d, J=0.6Hz, 1H), 8.41-8.39(m, 1H), 8.39-8.36(m, 1H), 7.51-7.41(m , 1H), 7.25(s, 2H), 7.17-7.08(m, 2H), 5.47(s, 2H).

[0589] Example 1.50: Preparation of 4-(6-amino-1-(4-amino-2,6-difluorobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)picolinonitrile (Compound 226) manufacturing TIFF2023505915000127.tif38160 Reagents and Conditions: (a) Pd(dppf)Cl 2 , K 2 CO 3 , dioxane / H 2 O, 80°C, 16 hours; (b) Fe, NH 4 Cl, EtOH / H 2 O, 80°C, 2 hours.

[0590] Step 1: Preparation of 4-[6-amino-1-[(2,6-difluoro-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-2-carbonitrile

[0591] Intermediate compound S112 or 4-chloro-1-[(2,6-difluoro-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidine-6- in dioxane (10 mL) and water (2 mL) 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-2-carbonitrile (540 mg, 2.35 mmol) in a solution of the amine (400 mg, 1.17 mmol, 1 eq.) , 2 equivalents), Pd(dppf)Cl 2 (86 mg, 117.41 μmol, 0.1 equiv) and K 2 CO 3 (325 mg, 2.35 mmol, 2 eq)) was added. The mixture was then stirred at 100° C. for 15 hours. The mixture was concentrated in vacuo to give a residue. The residue was purified by flash silica gel chromatography (20 g Sepa Flash® silica flash column, 0-60% ethyl acetate / petroleum ether gradient @ 50 mL / min eluent). Compound 4-[6-amino-1-[(2,6-difluoro-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-2-carbonitrile (300mg, 625.68 μmol, 53% yield, 85% purity) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ = 8.96 (d, J = 5.1Hz, 1H), 8.58 (s, 1H), 8.43 (s, 1H), 8.38 (dd, J = 1.7, 5.1Hz, 1H), 8.09 (brd, J = 7.1 Hz, 2H), 7.28(brs, 2H), 5.56(s, 2H). MS: m / z = 409.1 (M+1, ESI+).

[0592] Step 2: 4-[6-amino-1-[(4-amino-2,6-difluoro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-2-carbonitrile (compound 226) manufacturing 4-[6-amino-1-[(2,6-difluoro-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl] in water (3 mL) and ethanol (9 mL) Iron powder (205 mg, 3.67 mmol, 5 eq) and NH 4 Cl (314 mg, 5.88 mmol, 8 eq) was added. The mixture was then stirred at 80° C. for 2 hours. The reaction mixture was filtered and the filtrate was concentrated in vacuo. Water (30 mL) was added to the mixture and extracted with ethyl acetate (30 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated in vacuo to give a residue. The residue was purified by preparative HPLC (column: Welch Ultimate XB-CN 250*70*10 μm; mobile phase: [hexane-ethanol (0.1% NH3 H2O)]; B%: 30%-70%, 15 min). bottom. Compound 226 or 4-[6-amino-1-[(4-amino-2,6-difluoro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-2-carbonitrile (70.80 mg, 178.73 μmol, 24% yield, 95.51% purity) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ = 8.96 (dd, J = 0.8, 5.1Hz, 1H), 8.58 (dd, J = 0.8, 1.6Hz, 1H), 8.46-8.24 (m, 2H), 7.19 (s, 2H), 6.29-6.08 (m, 2H), 5.80(s, 2H), 5.26(s, 2H).

[0593] Example 1.51: Preparation of 4-(6-amino-1-(4-amino-3-methylbenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)picolinonitrile (Compound 230) TIFF2023505915000128.tif36160 Reagents and Conditions: (a) Pd(dppf)Cl 2 , K 2 CO 3 , dioxane / H 2 O, 110°C, 16 hours; (b) Fe, NH 4 Cl, EtOH / H 2 O, 60°C, 3 hours.

[0594] Step 1: Preparation of 4-(6-amino-1-(3-methyl-4-nitrobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)picolinonitrile

[0595] Intermediate compound S108 or 4-chloro-1-[(3-methyl-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-6-amine ( 500 mg, 1 eq), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-2-carbonitrile (541 mg, 1.5 eq), K 2 CO 3 (433 mg, 2 eq), Pd(dppf)Cl 2 (114 mg, 0.1 eq.) of the mixture was degassed and 2 Purge the mixture three times with N 2 The mixture was stirred at 110° C. for 16 hours under atmosphere. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 12 g Sepa Flash® silica flash column, 0-100% ethyl acetate / petroleum ether gradient @ 30 mL / min eluent). Compound 4-[6-amino-1-[(3-methyl-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-2-carbonitrile (500mg, 82.49% yield) ) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ = 8.99 (dd, J = 0.7, 5.1Hz, 1H), 8.56 (s, 1H), 8.43 (dd, J = 1.7, 5.1Hz, 1H), 7.98-7.91 (m, 1H), 7.39-7.31 (m, 1H), 7.30-7.07 (m, 3H), 5.68-5.49 (m, 2H), 2.49-2.47 (m, 3H). MS: m / z = 387.1 (M+1, ESI+).

[0596] Step 2: Preparation of 4-(6-amino-1-(4-amino-3-methylbenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)picolinonitrile (Compound 230)

[0597] 4-[6-amino-1-[(3-methyl-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine- in ethanol (15 mL) and water (5 mL) Iron powder (289 mg, 5 eq) and NH 4 Cl (443 mg, 8 eq) was added. The mixture was stirred at 60° C. for 3 hours. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (column: Phenomenex Gemini-NX C18 75*30mm*3μm; mobile phase: [water (0.05% ammonium hydroxide v / v)-ACN]; B%: 15%-45% , 11.5 minutes). Compound 230 or 4-[6-amino-1-[(4-amino-3-methyl-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-2-carbonitrile (41.4 mg, 7% yield, 95.38% purity) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ = 8.97 (dd, J = 0.6, 5.1Hz, 1H), 8.60 (d, J = 0.9Hz, 1H), 8.44 (s, 1H), 8.40 (dd, J = 1.7, 5.1Hz, 1H), 7.17(s, 2H), 6.93-6.79(m, 2H), 6.52(d, J=8.1Hz, 1H), 5.24(s, 2H), 4.81(s, 2H), 1.99(s, 3H).

[0598] Example 1.52: Preparation of 6-(6-amino-1-(4-aminobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)picolinonitrile (Compound 215) TIFF2023505915000129.tif54161 Reagents and conditions: (a) NaOMe, MeOH, 25° C., 0.5 h; (b) Pd(OAc) 2 , K 2 CO 3 , Cy 3 P, dioxane, 120 °C, 16 h; (c) Fe, NH 4 Cl, EtOH / H 2 O, 60°C, 3 hours.

[0599] Step 1: Preparation of (6-cyano-2-pyridyl)sulfinyloxysodium (intermediate compound S113)

[0600] To a solution of sodium methoxide (212 mg, 1 eq) in methanol (10 mL) was added methyl 3-[(6-cyano-2-pyridyl)sulfonyl]propanoate (1 g, 1 eq). The mixture was stirred at 25° C. for 0.5 hours. The reaction mixture was concentrated under reduced pressure to remove methanol to give a residue. Intermediate compound S113 or the crude product of (6-cyano-2-pyridyl)sulfinyloxysodium (1 g, crude) was obtained as a yellow solid and used in the next step without further purification. MS: m / z=167.0 (M+1, ESI+).

[0601] Step 2: Preparation of 6-[6-amino-1-[(4-nitrophenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-2-carbonitrile

[0602] Intermediate compound S113 or 4-chloro-1-[(4-nitrophenyl)methyl]pyrazolo[3,4-d]pyrimidin-6-amine (500 mg, 1 eq), (6-cyano -2-pyridyl)sulfinyloxysodium (374 mg, 1.2 eq), palladium acetate (36 mg, 0.1 eq), Cy 3 P (92 mg, 320.2 eq), and K 2 CO 3 A mixture of (453 mg, 2 eq) was degassed and purged with nitrogen three times, then the mixture was stirred at 120° C. for 16 h under nitrogen atmosphere. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 12 g Sepa Flash® silica flash column, 70-100% ethyl acetate / petroleum ether gradient @ 35 mL / min eluent). Compound 6-[6-amino-1-[(4-nitrophenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-2-carbonitrile (200 mg, 504.92 μmol, 31% yield, 94% pure) was obtained as a white solid. 1 H NMR (400 MHz, DMSO-d 6 )δ=8.66(dd, J=1.3, 8.0Hz, 1H), 8.50(s, 1H), 8.35-8.30(m, 1H), 8.28-8.24(m, 1H), 8.20(d, J=8.9Hz , 2H), 7.41 (d, J=8.9Hz, 2H), 7.20 (s, 2H), 5.64 (s, 2H). MS: m / z = 373.1 (M+1, ESI+).

[0603] Step 3: Preparation of 6-(6-amino-1-(4-aminobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)picolinonitrile (Compound 215)

[0604] 6-[6-amino-1-[(4-nitrophenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-2-carbonitrile in water (5 mL) and ethanol (15 mL) iron powder (150 mg, 5 eq.) and NH 4 Cl (230 mg, 8 eq) was added. The mixture was stirred at 60° C. for 3 hours. The reaction mixture was concentrated under reduced pressure to remove ethanol and water to give a residue. The residue was subjected to preparative HPLC (column: Phenomenex Gemini-NX C18 75*30mm*3μm; mobile phase: [water (0.05% ammonium hydroxide v / v)-ACN]; B%: 10%-40%, 11.5 min ) to obtain the target compound with 89% purity, and the residue was subjected to preparative HPLC (column: Welch Ultimate XB-CN 250*50*10 μm; mobile phase: [hexane-EtOH (0.1% NH 3 ·H 2 O)]; B%: 20%-60%, 15 min) to give the desired compound with 91% purity. The residue was then purified by preparative HPLC (column: Phenomenex Luna C18 150*25mm*10μm; mobile phase: [water (0.225% FA)-ACN]; B%: 16%-46%, 10 min). . Compound 215 or 6-[6-amino-1-[(4-aminophenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-2-carbonitrile (21.55 mg, 11% yield, 98.25% purity) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ = 8.65 (d, J = 7.6 Hz, 1H), 8.39 (s, 1H), 8.35-8.27 (m, 1H), 8.26-8.22 (m, 1H), 7.12 (s, 2H), 6.94 (brd , J=8.3Hz, 2H), 6.48(brd, J=8.3Hz, 2H), 5.25(s, 2H), 5.03(s, 2H).

[0605] Example 1.53: 6-[6-Amino-1-[(4-amino-2-fluoro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-2-carbonitrile (Compound 219 )Manufacturing of TIFF2023505915000130.tif36160 Reagents and Conditions: (a) Pd(OAc) 2 , K 2 CO 3 , Cy 3 P, dioxane, 120 °C, 16 h; (c) Fe, NH 4 Cl, THF / H 2 O, 80°C, 4 hours.

[0606] Step 1: Preparation of 6-[6-amino-1-[(2-fluoro-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-2-carbonitrile

[0607] Intermediate compound S113 or (6-cyano-2-pyridyl)sulfinyloxysodium (495.01 mg, 2.60 mmol, 1.2 eq) in dioxane (5 mL), intermediate compound S111 or 4-chloro-1-[(2-fluoro -4-Nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-6-amine (700 mg, 2.17 mmol, 1 eq), Palladium acetate (48.70 mg, 216.93 μmol, 0.1 eq), Cy 3 P (121.67 mg, 433.86 μmol, 140.66 μL, 0.2 equiv) and K 2 CO 3 After the mixture of (599.64 mg, 4.34 mmol, 2 eq) was degassed and purged with nitrogen three times, the mixture was stirred at 120° C. for 16 h under nitrogen atmosphere. The mixture was concentrated in vacuo to give a residue. The residue was purified by flash silica gel chromatography (12 g SepaFlash® silica flash column, eluent with a 10-50% ethyl acetate / petroleum ether gradient @ 40 mL / min). Compound 6-[6-amino-1-[(2-fluoro-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-2-carbonitrile (220 mg, 503.88 μmol, 26% yield, 89.4% purity) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 )δ=8.66(dd, J=1.1, 7.9Hz, 1H), 8.49(s, 1H), 8.36-8.29(m, 1H), 8.28-8.23(m, 1H), 8.16(dd, J=2.3, 9.8Hz, 1H), 8.04(dd, J=1.8, 8.6Hz, 1H), 7.29(t, J=8.0Hz, 1H), 7.22(s, 2H), 5.64(s, 2H).

[0608] Step 2: 6-[6-Amino-1-[(4-amino-2-fluoro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-2-carbonitrile (Compound 219) Manufacturing of

[0609] 6-[6-amino-1-[(2-fluoro-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine- in THF (10 mL) and water (2 mL) Iron powder (143 mg, 2.56 mmol, 5 eq) and NH 4 Cl (219.27 mg, 4.10 mmol, 8 eq) was added. The mixture was then stirred at 80° C. for 4 hours. The reaction mixture was filtered and the filtrate was added with 50 mL of saturated NaHCO 3 An aqueous solution was added and extracted with ethyl acetate (50 mL×3). The organic layers were combined, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to give a residue. The residue was subjected to preparative HPLC (column: Welch Ultimate XB-CN 250*70*10 μm; mobile phase: [hexane-EtOH (0.1% NH 3 ·H 2 O)]; B%: 35%-75%, 15 min). Compound 219 or 6-[6-amino-1-[(4-amino-2-fluoro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-2-carbonitrile (56.69 mg, 151.63 μmol, 30% yield, 96.38% purity) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 )δ=8.65(dd, J=1.2, 8.0Hz, 1H), 8.39(s, 1H), 8.34-8.29(m, 1H), 8.26-8.22(m, 1H), 7.13(s, 2H), 6.95 -6.79(m, 1H), 6.31(dd, J=1.8, 5.4Hz, 1H), 6.28(s, 1H), 5.40(s, 2H), 5.29(s, 2H).

[0610] Example 1.54: 6-[6-amino-1-[(4-amino-2,6-difluoro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-2-carbonitrile ( Production of compound 223) TIFF2023505915000131.tif38160 Reagents and Conditions: (a) Pd(OAc) 2 , K 2 CO 3 , Cy 3 P, dioxane, 120°C, 16 hours. (c) Fe, NH 4 Cl, THF / H 2 O, 80°C, 5 hours.

[0611] Step 1: Preparation of 6-[6-amino-1-[(2,6-difluoro-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-2-carbonitrile

[0612] Intermediate compound S113 or sodium 6-cyanopyridine-2-sulfinate (530 mg, 2.79 mmol, 2 eq), intermediate compound S112 or 4-chloro-1-[(2,6-difluoro-) in dioxane (15 mL). 4-Nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-6-amine (470 mg, 1.38 mmol, 0.99 equiv), palladium acetate (31 mg, 139.36 μmol, 0.1 equiv), Cy 3 P (78 mg, 278.72 μmol, 0.2 equiv) and K 2 CO 3 After the mixture of (385 mg, 2.79 mmol, 2 eq) was degassed and purged with nitrogen three times, the mixture was stirred at 120° C. for 16 h under nitrogen atmosphere. The mixture was concentrated in vacuo to give a residue. The residue was purified by flash silica gel chromatography (20 g Sepa Flash® silica flash column, 30-60% ethyl acetate / petroleum ether gradient @ 50 mL / min eluent). Compound 6-[6-amino-1-[(2,6-difluoro-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-2-carbonitrile (180mg, 290.95 μmol, 21% yield, 66% purity) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 )δ=8.65(dd, J=1.1, 8.0Hz, 1H), 8.38(s, 1H), 8.35-8.33(m, 1H), 8.26-8.21(m, 1H), 8.12-8.06(m, 2H) , 7.22(s, 2H), 5.57(s, 2H). MS: m / z=409.0 (M+1, ESI+).

[0613] Step 2: 6-[6-amino-1-[(4-amino-2,6-difluoro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-2-carbonitrile (compound 223) manufacturing

[0614] 6-[6-amino-1-[(2,6-difluoro-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl] in THF (10 mL) and water (3 mL) Iron powder (81 mg, 1.45 mmol, 5 eq) and NH 4 Cl (124 mg, 2.33 mmol, 8 eq) was added. The mixture was then stirred at 80° C. for 5 hours. The reaction mixture was filtered and the filtrate was saturated NaHCO 3 An aqueous solution (50 mL) was added and extracted with ethyl acetate (80 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give a residue. The residue was purified by preparative HPLC (column: Welch Ultimate XB-CN 250*70*10μm; mobile phase: [hexane-EtOH (0.1% ammonium hydroxide)]; B%: 40%-80%, 10 min). bottom. Compound 223 or 6-[6-amino-1-[(4-amino-2,6-difluoro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-2-carbonitrile (24.24 mg, 60.94 μmol, 21% yield, 95.11% purity) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 )δ=8.65(dd, J=0.9, 8.0Hz, 1H), 8.35(s, 1H), 8.34-8.29(m, 1H), 8.27-8.21(m, 1H), 7.13(s, 2H), 6.18 (d, J=10.3Hz, 2H), 5.80(s, 2H), 5.27(s, 2H).

[0615] Example 1.55: Preparation of 6-(6-amino-1-(2,6-difluorobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)picolinonitrile (Compound 231) TIFF2023505915000132.tif37160 Reagents and conditions: (a) Pd(OAc) 2 , K 2 CO 3 , Cy 3 P, dioxane, 120°C, 10h, MW.

[0616] (6-Cyano-2-pyridyl)sulfinyloxysodium (231 mg, 1.2 eq) in dioxane (2 mL), intermediate compound S110 or 4-chloro-1-[(2,6-difluorophenyl)methyl]pyrazolo[3 ,4-d]pyrimidin-6-amine (300 mg, 1 eq), palladium acetate (23 mg, 0.1 eq), Cy 3 P (57 mg, 0.2 eq) and K 2 CO 3 The mixture of (280 mg, 2 eq) was degassed and purged with nitrogen three times, then the mixture was stirred under microwave conditions at 120° C. for 10 hours. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (column: Phenomenex Luna C18 150*25mm*10μm; mobile phase: [water (0.225% FA)-ACN]; B%: 37%-67%, 11 min). Compound 231 or 6-[6-amino-1-[(2,6-difluorophenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-2-carbonitrile (70.52 mg, 18% yield) yield, 95.65% purity) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 )δ=8.65(dd, J=1.0, 8.0Hz, 1H), 8.36(s, 1H), 8.33-8.27(m, 1H), 8.26-8.20(m, 1H), 7.51-7.41(m, 1H) , 7.18(s, 2H), 7.12(t, J=8.0Hz, 2H), 5.48(s, 2H).

[0617] Example 1.56: Preparation of 6-(6-amino-1-(4-amino-3-methylbenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)picolinonitrile (Compound 227) TIFF2023505915000133.tif38160 Reagents and Conditions: (a) Pd(OAc) 2 , K 2 CO 3 , Cy 3 P, dioxane, 120°C, 16 hours. (b) Fe, NH 4 Cl, EtOH / H 2 O, 60°C, 2 hours.

[0618] Step 1: Preparation of 6-[6-amino-1-[(3-methyl-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-2-carbonitrile

[0619] Intermediate compound S113 or (6-cyano-2-pyridyl)sulfinyloxysodium (356 mg, 1.2 eq) in dioxane (5 mL), intermediate compound S108 or 4-chloro-1-[(3-methyl-4-nitro -phenyl)methyl]pyrazolo[3,4-d]pyrimidin-6-amine (500 mg, 1 eq), palladium acetate (35 mg, 0.1 eq), Cy 3 P (88 mg, 0.2 eq) and K 2 CO 3 A mixture of (433 mg, 2 eq) was degassed and purged with nitrogen three times, then the mixture was stirred at 120° C. for 16 h under nitrogen atmosphere. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 24 g Sepa Flash® silica flash column, 50-80% ethyl acetate / petroleum ether gradient @ 35 mL / min eluent). Compound 6-[6-amino-1-[(3-methyl-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-2-carbonitrile (300mg, 40% yield) yield, 81% purity) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 )δ=8.66(dd, J=1.1, 7.9Hz, 1H), 8.48(s, 1H), 8.37-8.29(m, 1H), 8.28-8.22(m, 1H), 7.95(d, J=8.5Hz , 1H), 7.32 (s, 1H), 7.24-7.14 (m, 3H), 5.55 (s, 2H), 2.47 (s, 3H). MS: m / z = 387.1 (M+1, ESI+).

[0620] Step 2: Preparation of 6-(6-amino-1-(4-amino-3-methylbenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)picolinonitrile (Compound 227)

[0621] 6-[6-amino-1-[(3-methyl-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine- in water (5 mL) and ethanol (15 mL) Iron powder (225 mg, 5 eq) and NH 4 Cl (344 mg, 8 eq) was added. The mixture was stirred at 60° C. for 2 hours. The reaction mixture was concentrated under reduced pressure to remove ethanol and water to give a residue. The residue was subjected to preparative HPLC (column: Phenomenex Gemini-NX C18 75*30mm*3μm; mobile phase: [water (0.05% ammonium hydroxide v / v)-ACN]; B%: 10%-40%, 11.5 min. ) to obtain the desired compound with a purity of 88%, and the residue was repurified by preparative HPLC (column: Welch Ultimate XB-SiOH 250*50*10 μm; mobile phase: [hexane-EtOH (0.1% NH 3 ·H 2 O)]; B%: 15%-55%, 15 min), 90% pure desired compound was obtained. The residue was then purified by preparative HPLC (column: Welch Ultimate XB-SiOH 250*50*10 μm; mobile phase: [hexane-EtOH (0.1% NH 3 ·H 2 O)]; B%: 15%-55%, 15 min), yielding the desired compound in 91% purity. Finally, the residue was purified by preparative HPLC (column: Phenomenex Luna C18 150*25mm*10μm; mobile phase: [water (0.225% FA)-ACN]; B%: 21%-51%, 10 min). . Compound 227 or 6-[6-amino-1-[(4-amino-3-methyl-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-2-carbonitrile (30.69 mg, 10% yield, 98.87% purity) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ = 8.65 (dd, J = 1.1, 8.0Hz, 1H), 8.39 (s, 1H), 8.34-8.27 (m, 1H), 8.26-8.20 (m, 1H), 7.11 (s, 2H), 6.86 (s, 1H), 6.82(dd, J=1.9, 8.1Hz, 1H), 6.52(d, J=8.0Hz, 1H), 5.24(s, 2H), 4.80(s, 2H), 1.99(s, 3H).

[0622] Example 1.57: Preparation of 2-(6-amino-1-(4-aminobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)isonicotinonitrile (Compound 216) TIFF2023505915000134.tif36161 Reagents and conditions: (a) Pd(OAc) 2 , K 2 CO 3 , Cy 3 P, dioxane, 120°C, 16 hours. (b) Fe, NH 4 Cl, EtOH / H 2 O, 60°C, 2 hours.

[0623] Step 1: Preparation of 2-(6-amino-1-(4-nitrobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)isonicotinonitrile

[0624] Sodium 4-cyanopyridine-2-sulfinate (298 mg, 1.2 eq) in dioxane (5 mL), intermediate compound S3 or 4-chloro-1-[(4-nitrophenyl)methyl]pyrazolo[3,4-d ] pyrimidin-6-amine (400 mg, 1 eq), palladium acetate (29 mg, 0.1 eq), Cy 3 P (73 mg, 0.2 eq), and K 2 CO 3 A mixture of (362 mg, 2 eq) was degassed and purged with nitrogen three times, then the mixture was stirred at 120° C. for 16 h under nitrogen atmosphere. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 12 g Sepa Flash® silica flash column, 70-90% ethyl acetate / petroleum ether gradient @ 30 mL / min eluent). Compound 2-[6-amino-1-[(4-nitrophenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-4-carbonitrile (300mg, 55% yield, 89% purity ) was obtained as a yellow solid. MS: m / z = 373.1 (M+1, ESI+).

[0625] Step 2: Preparation of 2-(6-amino-1-(4-aminobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)isonicotinonitrile (Compound 216)

[0626] 2-[6-Amino-1-[(4-nitrophenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-4-carbonitrile in water (5 mL) and ethanol (15 mL) iron powder (225 mg, 5 eq) and NH 4 Cl (345 mg, 8 eq) was added. The mixture was stirred at 60° C. for 2 hours. The reaction mixture was concentrated under reduced pressure to remove ethanol and water to give a residue. The residue was subjected to preparative HPLC (column: Phenomenex Gemini-NX C18 75*30mm*3μm; mobile phase: [water (10mM NH 4 HCOs 3 )-ACN]; B%: 18%-48%, 8 min) to give the desired compound with 80% purity. The residue was then subjected to a second preparative HPLC (column: Welch Ultimate XB-SiOH 250*50*10 μm; mobile phase: [hexane-EtOH (0.1% NH 3 ·H 2 O)]; B%: 15%-55%, 15 min) to give the desired compound with 80% purity. Finally, the residue was subjected to a third preparative HPLC (column: Phenomenex Luna C18 150*25mm*10μm; mobile phase: [water (0.225% FA)-ACN]; B%: 17%-47%, 10 min). refined with Compound 216 or 2-[6-amino-1-[(4-aminophenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-4-carbonitrile (23.18 mg, 8% yield, 95.02% purity) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 )δ=9.54(d, J=2.1Hz, 1H), 9.22(d, J=2.0Hz, 1H), 8.92(t, J=2.1Hz, 1H), 8.45(s, 1H), 7.13(s, 2H), 6.96 (d, J=8.4Hz, 2H), 6.63-6.37 (m, 2H), 5.25 (s, 2H), 5.04 (s, 2H). HRMS-TOF: 343.1408.

[0627] Example 1.58: Preparation of 2-(6-amino-1-(4-amino-2-fluorobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)isonicotinonitrile (Compound 220) TIFF2023505915000135.tif36160 Reagents and Conditions: (a) Pd(OAc) 2 , K 2 CO 3 , Cy 3 P, dioxane, 120°C, 16 hours. (b) Fe, NH 4 Cl, EtOH / H 2 O, 60°C, 1 hour

[0628] Step 1: Preparation of 2-(6-amino-1-(2-fluoro-4-nitrobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)isonicotinonitrile

[0629] Sodium 4-cyanopyridine-2-sulfinate (424 mg, 1.2 eq) in dioxane (5 mL), intermediate compound S111 or 4-chloro-1-[(2-fluoro-4-nitro-phenyl)methyl]pyrazolo[ 3,4-d]pyrimidin-6-amine (600 mg, 1 eq), palladium acetate (41 mg, 0.1 eq), Cy 3 P (104 mg, 0.2 eq) and K 2 CO 3 A mixture of (513 mg, 2 eq) was degassed and purged with nitrogen three times, then the mixture was stirred at 120° C. for 16 h under nitrogen atmosphere. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 12 g Sepa Flash® silica flash column, 70-90% ethyl acetate / petroleum ether gradient @ 30 mL / min eluent). The compound 2-[6-amino-1-[(2-fluoro-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-4-carbonitrile (300 mg, 41% yield) 99% purity) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 )δ=9.13-9.06(m, 1H), 8.68(dd, J=0.9, 1.5Hz, 1H), 8.55(s, 1H), 8.16(dd, J=2.3, 9.9Hz, 1H), 8.09(dd , J=1.6, 4.9Hz, 1H), 8.03(dd, J=2.1, 8.5Hz, 1H), 7.30(t, J=8.0Hz, 1H), 7.21(s, 2H), 5.63(s, 2H) .

[0630] Step 2: Preparation of 2-(6-amino-1-(4-amino-2-fluorobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)isonicotinonitrile (Compound 220)

[0631] 2-[6-amino-1-[(2-fluoro-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine- in water (5 mL) and ethanol (15 mL) Iron powder (214 mg, 5 eq) and NH 4 Cl (328 mg, 8 eq) was added. The mixture was stirred at 60° C. for 1 hour. The reaction mixture was concentrated under reduced pressure to remove ethanol and water to give a residue. The residue was subjected to preparative HPLC (column: Welch Ultimate XB-CN 250*70*10μm; mobile phase: [Hexane-EtOH column: Welch Ultimate XB-SiOH 250*50*10μm; mobile phase: [Hexane-EtOH (0.1% NH3 H2O)]; B%: 15%-55%, 15 min (0.1% NH 3 ·H 2 O)]; B%: 30%-70%, 15 min) to give the desired compound in 90% purity after preparative HPLC, the residue was subjected to a second preparative HPLC (column: Welch Ultimate XB-CN 250*70*10 μm; mobile phase: [hexane-EtOH (0.1% aqueous ammonia)]; B%: 30%-70%, 15 minutes). Compound 220 or 2-[6-amino-1-[(4-amino-2-fluoro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-4-carbonitrile (33.67 mg, 89.81 μmol, 96.12% purity) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ = 9.08 (dd, J = 0.7, 5.0Hz, 1H), 8.68 (d, J = 1.3Hz, 1H), 8.46 (s, 1H), 8.08 (dd, J = 1.6, 5.0Hz, 1H), 7.13(s, 2H), 6.88(t, J=8.4Hz, 1H), 6.33-6.30(m, 1H), 6.29(s, 1H), 5.40(s, 2H), 5.29(s, 2H).

[0632] Example 1.59: 2-[6-Amino-1-[(4-amino-2,6-difluoro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-4-carbonitrile ( Production of compound 224) TIFF2023505915000136.tif90118 Reagents and conditions: (a) Fe, NH 4 Cl, EtOH / H 2 O, 80°C, 3 hours. (b) Pd(OAc) 2 , K 2 CO 3 , PCy3, dioxane, 120 °C, 16 h.

[0633] Step 1: Preparation of 1-(4-amino-2,6-difluorobenzyl)-4-chloro-1H-pyrazolo[3,4-d]pyrimidin-6-amine (intermediate compound S114)

[0634] Intermediate compound S112 or 4-chloro-1-[(2,6-difluoro-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidine-6- in water (3 mL) and ethanol (10 mL) Iron powder (385 mg, 6.88 mmol, 5 eq) and NH 4Cl (590 mg, 11.01 mmol, 8 eq) was added. The mixture was then stirred at 80° C. for 3 hours. The reaction mixture was filtered and the filtrate was concentrated in vacuo. Water (30 mL) was added to the mixture and extracted with ethyl acetate (30 mL×3). The combined organic layers are dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was subjected to preparative HPLC (column: Welch Ultimate XB-CN 250*70*10 μm; mobile phase: [hexane-EtOH (0.1% NH 3 ·H 2 O)]; B%: 20%-60%, 15 min). Intermediate compound S114 or 1-(4-amino-2,6-difluorobenzyl)-4-chloro-1H-pyrazolo[3,4-d]pyrimidin-6-amine (400mg, 1.03mmol, 75% yield, 88% pure) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ = 7.92 (s, 1H), 7.32 (s, 2H), 6.25-6.09 (m, 2H), 5.80 (s, 2H), 5.18 (s, 2H).

[0635] Step 2: 2-[6-amino-1-[(4-amino-2,6-difluoro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-4-carbonitrile (compound 224) manufacturing

[0636] (4-Cyano-2-pyridyl)sulfinyloxysodium (550 mg, 2.89 mmol, 2.55 equiv) in dioxane (10 mL), intermediate compound S114 or 1-[(4-amino-2,6-difluoro-phenyl)methyl ]-4-chloropyrazolo[3,4-d]pyrimidin-6-amine (400 mg, 1.13 mmol, 88% purity, 1 equiv), palladium acetate (25 mg, 113.30 μmol, 0.1 equiv), Cy 3 P (63 mg, 226.59 μmol, 73.46 μL, 0.2 equiv) and K 2 CO 3 After the mixture of (313 mg, 2.27 mmol, 2 eq) was degassed and purged with nitrogen three times, the mixture was stirred at 120° C. for 16 h under nitrogen atmosphere. The reaction mixture was filtered and the filtrate was concentrated in vacuo. The residue was purified by flash silica gel chromatography (20 g Sepa Flash® silica flash column, eluent with a 20-40% ethyl acetate / petroleum ether gradient @ 40 mL / min). Compound 224 or 2-[6-amino-1-[(4-amino-2,6-difluoro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-4-carbonitrile (70mg , 181.87 μmol, 16% yield, 98.30% purity) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 )δ=9.07(dd, J=0.8, 5.0Hz, 1H), 8.67(dd, J=0.9, 1.5Hz, 1H), 8.41(s, 1H), 8.06(dd, J=1.7, 5.0Hz, 1H ), 7.11 (s, 2H), 6.27-6.11 (m, 2H), 5.79 (s, 2H), 5.26 (s, 2H).

[0637] Example 1.60: Preparation of 2-(6-amino-1-(2,6-difluorobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)isonicotinonitrile (Compound 232) TIFF2023505915000137.tif38160 Reagents and Conditions: (a) Pd(OAc) 2 , K 2 CO 3 , Cy 3 P, dioxane, 120°C, 16 hours.

[0638] (4-Cyano-2-pyridyl)sulfinyloxysodium (232 mg, 1.2 equiv) in dioxane (5 mL), intermediate compound S110 or 4-chloro-1-[(2,6-difluorophenyl)methyl]pyrazolo[3 ,4-d]pyrimidin-6-amine (300 mg, 1 eq), palladium acetate (23 mg, 0.1 eq), Cy3P (57 mg, 0.2 eq), and K 2 CO 3 A mixture of (281 mg, 2 eq) was degassed and purged with nitrogen three times, then the mixture was stirred at 120° C. for 16 h under nitrogen atmosphere. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (column: Unisil 3-100 C18 Ultra 150*50mm*3μm; mobile phase: [water (0.225% FA)-ACN]; B%: 43%-63%, 10 min). . Compound 232 or 2-[6-amino-1-[(2,6-difluorophenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-4-carbonitrile (66.33 mg, 18% yield) yield, 99.34% purity) was obtained as a white solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ = 9.06 (d, J = 5.0 Hz, 1H), 8.67 (s, 1H), 8.44-8.38 (m, 1H), 8.09-8.03 (m, 1H), 7.51-7.39 (m, 1H), 7.22 -7.15 (m, 2H), 7.14-7.09 (m, 2H), 5.47 (s, 2H).

[0639] Example 1.61: 2-(6-Amino-1-(4-amino-3-methylbenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)isonicotinonitrile (Compound 228) TIFF2023505915000138.tif36160 Reagents and Conditions: (a) Pd(OAc) 2 , K 2 CO 3 , Cy 3 P, dioxane, 120°C, 16 hours. (b) Fe, NH 4 Cl, EtOH / H 2 O, 60°C, 2 hours.

[0640] Step 1: Preparation of 2-(6-amino-1-(3-methyl-4-nitrobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)isonicotinonitrile

[0641] (4-Cyano-2-pyridyl)sulfinyloxysodium (215 mg, 1.2 equiv) in dioxane (5 mL), intermediate compound S108 or 4-chloro-1-[(3-methyl-4-nitro-phenyl)methyl] Pyrazolo[3,4-d]pyrimidin-6-amine (300 mg, 1 eq), Palladium acetate (21 mg, 0.1 eq), Cy 3 P (52 mg, 0.2 eq) and K 2 CO 3 (260 mg, 2 eq) of the mixture was degassed and purged with nitrogen three times, then the mixture was stirred at 120° C. for 16 hours under a nitrogen atmosphere. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 24 g Sepa Flash® silica flash column, 50-80% ethyl acetate / petroleum ether gradient @ 35 mL / min eluent). Compound 2-[6-amino-1-[(3-methyl-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-4-carbonitrile (200 mg, 55% yield) ) was obtained as a yellow solid. MS: m / z = 387.1 (M+1, ESI+).

[0642] Step 2: Preparation of 2-(6-amino-1-(4-amino-3-methylbenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)isonicotinonitrile (Compound 228)

[0643] 2-[6-Amino-1-[(3-methyl-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine- in ethanol (15 mL) and water (5 mL) Iron powder (145 mg, 5 eq.) and NH 4 Cl (221 mg, 8 eq) was added. The mixture was stirred at 60° C. for 2 hours. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was subjected to preparative HPLC (column: Phenomenex Gemini-NX C18 75*30mm*3μm; mobile phase: [water (10mM NH 4 HCOs 3 )-ACN]; B%: 20%-50%, 8 min), the compound was obtained with 80% purity after preparative HPLC, the residue was purified by a second preparative HPLC (column: Shim- packC18 150*25*10 μm; mobile phase: [water (0.225% FA)-ACN]; B%: 16%-46%, 10 min). Compound 228 or 2-[6-amino-1-[(4-amino-3-methyl-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-4-carbonitrile (19.65 mg, 10% yield, 96.15% purity) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 )δ=9.08(dd, J=0.8, 4.9Hz, 1H), 8.67(dd, J=0.9, 1.6Hz, 1H), 8.45(s, 1H), 8.07(dd, J=1.6, 5.0Hz, 1H ), 7.10(s, 2H), 6.86(s, 1H), 6.82(dd, J=1.9, 8.1Hz, 1H), 6.51(d, J=8.0Hz, 1H), 5.23(s, 2H), 4.80 (s, 2H), 1.98 (s, 3H).

[0644] Example 1.62: Preparation of 5-(6-amino-1-(4-aminobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)nicotinonitrile (Compound 217) TIFF2023505915000139.tif36168 Reagents and Conditions: (a) Pd(dppf)Cl 2 , K 2 CO 3 , dioxane / H2 O, 110°C, 16 hours; (b) Fe, NH 4 Cl, THF / H 2 O, 60°C, 3 hours.

[0645] Step 1: Preparation of 5-(6-amino-1-(4-nitrobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)nicotinonitrile

[0646] (5-Cyano-3-pyridyl)boronic acid (583 mg, 1.5 eq), intermediate compound S3 or 4-chloro-1-[(4-nitrophenyl)methyl]pyrazolo in dioxane (10 mL) and water (2 mL) [3,4-d]pyrimidin-6-amine (800 mg, 1 eq), K 2 CO 3 (726 mg, 2 eq), Pd(dppf)Cl 2 (192 mg, 0.1 eq) of the mixture was degassed and purged with nitrogen three times, then the mixture was stirred at 110° C. for 16 hours under nitrogen atmosphere. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 24g Sepa Flash® silica flash column, 0-100% ethyl acetate / petroleum ether gradient @ 30 mL / min eluent). The compound 5-[6-amino-1-[(4-nitrophenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-3-carbonitrile (800 mg, 82% yield) was obtained as a yellow solid. Obtained as a solid. individual. 1 H NMR (400 MHz, DMSO-d 6 ) δ = 9.63-9.52 (m, 1H), 9.37-9.31 (m, 2H), 9.25-9.23 (m, 1H), 9.15-9.12 (m, 2H), 7.46-7.42 (m, 2H), 5.65- 5.60 (m, 2H). MS: m / z = 373.1 (M+1, ESI+).

[0647] Step 2: Preparation of 5-(6-amino-1-(4-aminobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)nicotinonitrile (Compound 217)

[0648] 5-[6-Amino-1-[(4-nitrophenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-3-carbonitrile in THF (15 mL) and water (5 mL) iron powder (224 mg, 5 eq.) and NH 4 Cl (344 mg, 8 eq) was added. The mixture was stirred at 60° C. for 3 hours. The reaction mixture was concentrated under reduced pressure to remove THF and water to give a residue. The residue was subjected to preparative HPLC (column: Phenomenex Gemini-NX C18 75*30mm*3μm; mobile phase: [water (0.05% ammonium hydroxide v / v)-ACN]; B%: 10%-40%, 11.5 min. ). Compound 217 or 5-[6-amino-1-[(4-aminophenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-3-carbonitrile (27.63 mg, 7% yield, 98.17% purity) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 )δ=9.54(d, J=2.1Hz, 1H), 9.22(d, J=2.0Hz, 1H), 8.92(t, J=2.1Hz, 1H), 8.45(s, 1H), 7.13(s, 2H), 6.96 (d, J=8.4Hz, 2H), 6.63-6.37 (m, 2H), 5.25 (s, 2H), 5.04 (s, 2H).

[0649] Example 1.63: 5-[6-Amino-1-[(4-amino-2-fluoro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-3-carbonitrile (Compound 221 )Manufacturing of TIFF2023505915000140.tif33161 Reagents and Conditions: (a) Pd(dppf)Cl 2 , K 2 CO 3 , dioxane / H 2 O, 110°C, 16 hours; (b) Fe, NH 4 Cl, EtOH / H 2 O, 60°C, 2 hours.

[0650] Step 1: Preparation of 5-(6-amino-1-(2-fluoro-4-nitrobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)nicotinonitrile

[0651] (5-Cyano-3-pyridyl)boronic acid (343 mg, 1.5 eq) in dioxane (10 mL) and water (2 mL), intermediate compound S111 or 4-chloro-1-[(2-fluoro-4-nitro- Phenyl)methyl]pyrazolo[3,4-d]pyrimidin-6-amine (500mg, 1eq), K 2 CO 3 (428 mg, 2 eq), Pd(dppf)Cl 2 (113 mg, 0.1 eq) of the mixture was degassed and purged with nitrogen three times, then the mixture was stirred at 110° C. for 16 h under nitrogen atmosphere. The reaction mixture was concentrated under reduced pressure to remove dioxane to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 12 g Sepa Flash® silica flash column, 0-80% ethyl acetate / petroleum ether gradient @ 30 mL / min eluent). Compound 5-[6-amino-1-[(2-fluoro-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-3-carbonitrile (300mg, 50% yield) ) was obtained as a yellow solid. MS: m / z=390.9 (M+1, ESI+).

[0652] Step 2: Preparation of 5-(6-amino-1-(4-amino-2-fluorobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)nicotinonitrile (Compound 221)

[0653] 5-[6-amino-1-[(2-fluoro-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine- in ethanol (15 mL) and water (5 mL) Iron powder (214 mg, 5 eq) and NH 4 Cl (328 mg, 8 eq) was added. The mixture was stirred at 60° C. for 2 hours. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by preparative HPLC (column: Phenomenex Gemini-NX C18 75*30mm*3μm; mobile phase: [water (0.05% ammonium hydroxide v / v)-ACN]; B%: 13%-43% , 11.5 minutes). Compound 221 or 5-[6-amino-1-[(4-amino-2-fluoro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-3-carbonitrile (37.61 mg, 13% yield, 94.57% purity) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 )δ=9.54(d, J=2.1Hz, 1H), 9.23(d, J=2.0Hz, 1H), 8.91(t, J=2.0Hz, 1H), 8.45(s, 1H), 7.14(s, 2H), 6.90(t, J=8.4Hz, 1H), 6.31(d, J=10.8Hz, 2H), 5.41(s, 2H), 5.29(s, 2H).

[0654] Example 1.64: 5-[6-Amino-1-[(4-amino-2,6-difluoro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-3-carbonitrile ( Production of compound 225) TIFF2023505915000141.tif39160 Reagents and Conditions: (a) Pd(dppf)Cl 2 , K 2 CO 3 , dioxane / H 2 O, 100°C, 15 hours; (b) Fe, NH 4 Cl, EtOH / H 2 O, 80°C, 2 hours.

[0655] Step 1: Preparation of 5-[6-amino-1-[(2,6-difluoro-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-3-carbonitrile

[0656] Intermediate compound S112 or 4-chloro-1-[(2,6-difluoro-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidine-6- in dioxane (10 mL) and water (2 mL) To a solution of the amine (400 mg, 1.17 mmol, 1 eq) was added (5-cyano-3-pyridyl)boronic acid (346 mg, 2.34 mmol, 2 eq), Pd(dppf)Cl 2 (86 mg, 117.00 μmol, 0.1 equiv) and K 2 CO 3 (323 mg, 2.34 mmol, 2 eq) was added. The mixture was then stirred at 100° C. for 15 hours. The mixture was concentrated in vacuo to give a residue. The residue was purified by flash silica gel chromatography (20 g Sepa Flash® silica flash column, 0-60% ethyl acetate / petroleum ether gradient @50 mL / min eluent). Compound 5-[6-amino-1-[(2,6-difluoro-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-3-carbonitrile (400mg, 852.27 μmol, 73% yield, 87% purity) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6)δ=9.51(d, J=2.0Hz, 1H), 9.21(d, J=1.9Hz, 1H), 8.89(t, J=2.1Hz, 1H), 8.44(s, 1H), 8.09(d, J=7.3Hz, 2H), 7.23(s, 2H), 5.55(s, 2H). MS: m / z=409.0 (M+1, ESI+).

[0657] Step 2: 5-[6-amino-1-[(4-amino-2,6-difluoro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-3-carbonitrile (compound 225) manufacturing

[0658] 5-[6-amino-1-[(2,6-difluoro-4-nitro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl] in water (3 mL) and ethanol (9 mL) Iron powder (274 mg, 4.90 mmol, 5 eq) and NH 4 Cl (420 mg, 7.84 mmol, 8 eq) was added. The mixture was then stirred at 80° C. for 2 hours. The reaction mixture was filtered and the filtrate was concentrated in vacuo. Water (30 mL) was then added to the mixture and then extracted with ethyl acetate (30 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to give a residue. The residue was subjected to preparative HPLC (column: Welch Ultimate XB-CN 250*70*10 μm; mobile phase: [hexane-EtOH (0.1% NH 3 ·H 2 O)]; B%: 30%-70%, 15 min) to give an impure product. The impure product was subjected to preparative HPLC (column: Welch Ultimate XB-CN 250*50*10 μm; mobile phase: [hexane-EtOH (0.1% NH 3 ·H 2 O)]; B%: 25%-65%, 15 min). Compound 225 or 5-[6-amino-1-[(4-amino-2,6-difluoro-phenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-yl]pyridine-3-carbonitrile (113.05 mg, 297.07 μmol, 30% yield, 99.42% purity) was obtained as a yellow solid. 1 H NMR (400 MHz, DMSO-d 6 )δ=9.52(d, J=2.1Hz, 1H), 9.21(d, J=1.8Hz, 1H), 8.89(t, J=2.1Hz, 1H), 8.38(s, 1H), 7.13(s, 2H), 6.18(d, J=10.1Hz, 2H), 5.25(s, 2H).

[0659] Example 1.65: Preparation of 5-(6-amino-1-(2,6-difluorobenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)nicotinonitrile (Compound 233) TIFF2023505915000142.tif39160 Reagents and Conditions: (a) Pd(dppf)Cl 2 , K 2 CO 3 , dioxane / H 2 O, 110°C, 16 hours.

[0660] Intermediate compound S110 or 4-chloro-1-[(2,6-difluorophenyl)methyl]pyrazolo[3,4-d]pyrimidin-6-amine (400 mg, 1 eq), (5-cyano-3-pyridyl)boronic acid (300 mg, 1.5 eq), K 2 CO 3 (373 mg, 2 eq), Pd(dppf)Cl 2 (99 mg, 0.1 eq.) The mixture was degassed and purged with nitrogen three times, then the mixture was ...

Claims

1. A compound of formula (Ib) or a solvate, hydrate, prodrug, and / or stereoisomer thereof, or a pharma- ceutically acceptable salt thereof: (Ib) R is H, (C 1 -C 3 ) alkyl, or substituted (C 1 -C 3 ) alkyl; Y 1 Or Y 4 is an independent CR 10 and N, Y 1 Or Y 4 At least two of the following are independently CR 10 and R 10 are each independently H, (C 1 -C 8 ) alkyl, substituted (C 1 -C 8 ) alkyl, (C 2 -C 8 ) alkenyl, substituted (C 2 -C 8 ) alkenyl, (C 2 -C 8 ) alkynyl, substituted (C 2 -C 8 ) alkynyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 8 ) alkoxy, substituted (C 1 -C 8 ) Alkoxy, -CONH 2 , substituted amide, -NH 2 , substituted amino, —CO 2 H, cyano, halogen, hydroxyl, -NO 2 , -SO 3 H, -SO 2 N.H. 2 , substituted sulfonamide, and thiol, with the proviso that Y 1 is not CH; R a and R b are each independently H, F, (C 1 -C 3 ) alkyl, and substituted (C 1 -C 3 ) alkyl, or R a and R b are attached to a ring and together with the carbon atoms to which they are attached form a cyclopropyl, or substituted cyclopropyl; A is phenyl, substituted phenyl, pyridyl, or substituted pyridyl.

2. i) A is phenyl or one, two or three R 20 phenyl substituted with R 20 are each independently (C 1 -C 8 ) alkyl, substituted (C 1 -C 8 ) alkyl, (C 2 -C 8 ) alkenyl, substituted (C 2 -C 8 ) alkenyl, (C 2 -C 8 ) alkynyl, substituted (C 2 -C 8 ) alkynyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 8 ) alkoxy, substituted (C 1 -C 8 ) Alkoxy, -CONH 2 , substituted amide, -NH 2 , substituted amino, —CO 2 H, cyano, halogen, hydroxyl, -NO 2 , -SO 3 H, -SO 2 N.H. 2 , substituted sulfonamide, and thiol, or ii) A is pyridyl or one, two or three R 20 pyridyl substituted with R 20 are each independently (C 1 -C 8 ) alkyl, substituted (C 1 -C 8 ) alkyl, (C 2 -C 8 ) alkenyl, substituted (C 2 -C 8 ) alkenyl, (C 2 -C 8 ) alkynyl, substituted (C 2 -C 8 ) alkynyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 8 ) alkoxy, substituted (C 1 -C 8 ) Alkoxy, -CONH 2 , substituted amide, -NH 2 , substituted amino, —CO 2 H, cyano, halogen, hydroxyl, -NO 2 , -SO 3 H, -SO 2 N.H. 2 , a substituted sulfonamide, and a thiol, or a solvate, hydrate, prodrug, and / or stereoisomer thereof, or a pharma- ceutically acceptable salt thereof.

3. R a and R b 10. The compound of claim 1, wherein each is H, or a solvate, hydrate, prodrug, and / or stereoisomer thereof, or a pharma- ceutically acceptable salt thereof.

4. The compound of claim 1, wherein the compound of formula (I) is of formula (IIb): or a solvate, hydrate, prodrug, and / or stereoisomer thereof, or a pharma- ceutically acceptable salt thereof: (IIb) where R 1 is (C 1 -C 8 ) alkyl, substituted (C 1 -C 8 ) alkyl, (C 2 -C 8 ) alkenyl, substituted (C 2 -C 8 ) alkenyl, (C 2 -C 8 ) alkynyl, substituted (C 2 -C 8 ) alkynyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 8 ) alkoxy, substituted (C 1 -C 8 ) Alkoxy, -CONH 2 , substituted amide, -NH 2 , substituted amino, —CO 2 H, cyano, halogen, hydroxyl, -NO 2 , -SO 3 H, -SO 2 N.H. 2 , a substituted sulfonamide, and a thiol; R 2 through R 9 are independently selected from H, (C 1 -C 8 ) alkyl, substituted (C 1 -C 8 ) alkyl, (C 2 -C 8 ) alkenyl, substituted (C 2 -C 8 ) alkenyl, (C 2 -C 8 ) alkynyl, substituted (C 2 -C 8 ) alkynyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 8 ) alkoxy, substituted (C 1 -C 8 ) alkoxy, -CONH 2 , substituted amido, -NH 2 , substituted amino, -CO 2 H, cyano, halogen, hydroxyl, -NO 2 , -SO 3 H, -SO 2 NH 2 , substituted sulfonamide, and thiol.

5. R 1 is NH 2 , F, CH 3 , and C.F. 3 and R 2 to R 9 are independently selected from H, NH 2 , F, CH 3 , and CF 3 , or a solvate, hydrate, prodrug, and / or stereoisomer thereof, or a pharma- ceutically acceptable salt thereof.

6. The compound of claim 4, wherein the compound of formula (IIb) is of formula (IIIb): (IIIb) Here, R 21 and R 22 are independently H, (C 1 -C 8 ) alkyl, substituted (C 1 -C 8 ) alkyl, SO 2 R 30 , and C.O.R. 30 is selected from R 30 (C 1 -C 8 ) alkyl, or substituted (C 1 -C 8 ) alkyl.

7. R 21 and R 22 and each is H; or a solvate, hydrate, prodrug, and / or stereoisomer thereof, or a pharma- ceutically acceptable salt thereof.

8. The method of claim 7, wherein R 1 is selected from (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 5 ) alkoxy, substituted (C 1 -C 5 ) alkoxy, halogen, and hydroxyl; R 5 , R 6 , R 8 and R 9 However, independently, H, (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 5 ) alkoxy, substituted (C 1 -C 5 7. The compound of claim 6, wherein: R is selected from alkoxy, halogen, and hydroxyl; or a solvate, hydrate, prodrug, and / or stereoisomer thereof, or a pharma- ceutically acceptable salt thereof.

9. The compound according to claim 1, wherein R 1 is selected from F, CH 3 , and CF 3 ; R 5 , R 6 , R 8 and R 9 However, independently, H, F, CH 3 , and C.F. 3 and 9. The compound of claim 8, wherein R2 to R4 are each H, or a solvate, hydrate, prodrug, and / or stereoisomer thereof, or a pharma- ceutically acceptable salt thereof.

10. R 2 Or R 4 are each H; R 1 is (C 1 -C 5 ) alkyl, substituted (C 1 -C 5 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 5 ) alkoxy, substituted (C 1 -C 5 5. The compound of claim 4, wherein: R is selected from alkoxy, halogen, and hydroxyl; or a solvate, hydrate, prodrug, and / or stereoisomer thereof, or a pharma- ceutically acceptable salt thereof.

11. The compound of claim 1, wherein the compound of formula (I) is selected from the following: or a solvate, hydrate, prodrug, and / or stereoisomer thereof, or a pharma- ceutically acceptable salt thereof:

12. A pharmaceutical composition comprising a compound according to any one of claims 1-11 or a solvate, hydrate, prodrug, and / or stereoisomer thereof, or a pharma- ceutically acceptable salt thereof, optionally comprising a pharma- ceutically acceptable excipient.

13. 1. An in vitro method of inhibiting adenosine A2A and / or A1 receptors, comprising: A sample containing adenosine A2A and / or A1 receptors is contacted with an effective amount of a compound according to any one of claims 1-11, or a solvate, hydrate, prodrug, and / or stereoisomer thereof, or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition according to claim 12, to inhibit adenosine A2A and / or A1 receptors.

14. 1. An in vitro method of antagonizing adenosine A2A and / or A1 receptors, comprising: A cell containing adenosine A2A and / or A1 receptors is contacted with an effective amount of a compound according to any one of claims 1-11, or a solvate, hydrate, prodrug, and / or stereoisomer thereof, or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition according to claim 12, to antagonize the adenosine A2A and / or A1 receptors.

15. 12. A pharmaceutical composition for treating cancer comprising a therapeutically effective amount of an A2A and / or A1 receptor antagonist compound according to any one of claims 1-11, or a solvate, hydrate, prodrug, and / or stereoisomer thereof, or a pharma- ceutically acceptable salt thereof.

16. The pharmaceutical composition of claim 15, wherein the cancer is a solid tumor cancer.

17. 16. The pharmaceutical composition of claim 15, wherein the cancer is selected from lung cancer, breast cancer, prostate cancer, ovarian cancer, solenoma, cervical cancer, bladder cancer, head and neck cancer, renal cell carcinoma, esophageal cancer, pancreatic cancer, brain cancer, liver cancer, leukemia, lymphoma, melanoma, multiple myeloma, Ewing's sarcoma, osteosarcoma, colorectal tumor, bile duct cancer, choroidal cancer, oral cancer, neuroblastoma, skin cancer, testicular cancer, stromal tumor, germ cell tumor, and thyroid cancer.

18. The pharmaceutical composition of claim 15, administered in combination with an additional active agent.

19. 20. The pharmaceutical composition of claim 18, wherein the additional active agent is selected from an anti-angiogenic agent, an anti-inflammatory agent, an immune checkpoint inhibitor, a PARP inhibitor, a chemotherapeutic agent, and an immune anti-cancer agent.

20. 19. The pharmaceutical composition of claim 18, wherein the additional active agent is an immune checkpoint inhibitor selected from a CTLA-4 inhibitor, a PD-1 inhibitor, and a PD-L1 inhibitor.

21. 21. The pharmaceutical composition of claim 20, wherein the immune checkpoint inhibitor is an antibody or an antibody fragment.

22. 12. A pharmaceutical composition for treating an inflammatory disease comprising an A2A and / or A1 receptor antagonist compound according to any one of claims 1-11, or a solvate, hydrate, prodrug, and / or stereoisomer thereof, or a pharma- ceutically acceptable salt thereof.

23. Use of an A2A and / or A1 receptor antagonist compound, or a solvate, hydrate, prodrug, and / or stereoisomer thereof, or a pharma- ceutically acceptable salt thereof, according to any one of claims 1-11, in the manufacture of a pharmaceutical composition according to any one of claims 15-22.